<!DOCTYPE html>
<html lang="en" class="nytapp-vi-interactive" xmlns:og="http://opengraphprotocol.org/schema/">
  <head>
    <title data-rh="true">Can a Vaccine for Covid-19 Be Developed in Record Time? - The New York Times</title>
    <meta data-rh="true" property="article:published" content="2020-06-09T09:00:02.000Z"/><meta data-rh="true" property="article:modified" content="2020-06-14T04:24:43.312Z"/><meta data-rh="true" http-equiv="Content-Language" content="en"/><meta data-rh="true" name="robots" content="noarchive"/><meta data-rh="true" name="articleid" content="100000007180386"/><meta data-rh="true" name="nyt_uri" content="nyt://interactive/51d8474a-dd75-5fe6-b848-ee8b8dbe0393"/><meta data-rh="true" name="pubp_event_id" content="pubp://event/e242792e103d4ae58bc2575a72916b56"/><meta data-rh="true" name="description" content="A discussion moderated by Siddhartha Mukherjee."/><meta data-rh="true" name="image" content="https://static01.graylady3jvrrxbe.onion/images/2020/06/14/magazine/14mag-roundtable/14mag-roundtable-facebookJumbo.jpg"/><meta data-rh="true" name="byl" content/><meta data-rh="true" name="thumbnail" content="https://static01.graylady3jvrrxbe.onion/images/2020/06/14/magazine/14mag-roundtable/14mag-roundtable-thumbStandard.jpg"/><meta data-rh="true" name="news_keywords" content="Clinical trial,Vaccines Immunization,Coronavirus;COVID-19,Pharmaceuticals,Coronavirus Reopenings"/><meta data-rh="true" name="pdate" content="20200609"/><meta data-rh="true" property="og:url" content="https://www.nytimes3xbfgragh.onion/interactive/2020/06/09/magazine/covid-vaccine.html"/><meta data-rh="true" property="og:type" content="article"/><meta data-rh="true" property="og:title" content="Can a Vaccine for Covid-19 Be Developed in Record Time?"/><meta data-rh="true" property="og:image" content="https://static01.graylady3jvrrxbe.onion/images/2020/06/14/magazine/14mag-roundtable/14mag-roundtable-facebookJumbo.jpg"/><meta data-rh="true" property="og:image:alt" content=""/><meta data-rh="true" property="og:description" content="A discussion moderated by Siddhartha Mukherjee."/><meta data-rh="true" property="twitter:url" content="https://www.nytimes3xbfgragh.onion/interactive/2020/06/09/magazine/covid-vaccine.html"/><meta data-rh="true" property="twitter:title" content="Can a Vaccine for Covid-19 Be Developed in Record Time?"/><meta data-rh="true" property="twitter:description" content="A discussion moderated by Siddhartha Mukherjee."/><meta data-rh="true" property="twitter:image" content="https://static01.graylady3jvrrxbe.onion/images/2020/06/14/magazine/14mag-roundtable/14mag-roundtable-videoSixteenByNineJumbo1600.jpg"/><meta data-rh="true" property="twitter:image:alt" content=""/><meta data-rh="true" property="twitter:card" content="summary_large_image"/><meta data-rh="true" property="article:section" content="Magazine"/><meta data-rh="true" property="article:tag" content="Clinical Trials"/><meta data-rh="true" property="article:tag" content="Vaccination and Immunization"/><meta data-rh="true" property="article:tag" content="Coronavirus (2019-nCoV)"/><meta data-rh="true" property="article:tag" content="Drugs (Pharmaceuticals)"/><meta data-rh="true" property="article:tag" content="Coronavirus Reopenings"/><meta data-rh="true" property="article:opinion" content="false"/><meta data-rh="true" property="article:content_tier" content="metered"/><meta data-rh="true" name="CG" content="magazine"/><meta data-rh="true" name="SCG" content=""/><meta data-rh="true" name="CN" content=""/><meta data-rh="true" name="CT" content=""/>
    <meta charset="utf-8" />
<meta http-equiv="X-UA-Compatible" content="IE=edge" />
<meta name="viewport" content="width=device-width, initial-scale=1" />
<meta property="fb:app_id" content="9869919170" />
<meta name="twitter:site" value="@nytimes" />
    
    <script>
      const override = (new URL(window.location)).searchParams.get('sentryOverride');
      if (override || Math.floor(Math.random() * 100) <= 1) {
        document.write('<script src="https://js.sentry-cdn.com/7bc8bccf5c254286a99b11c68f6bf4ce.min.js" crossorigin="anonymous">' + '<' + '/script>');
      }
    </script>
    <script>
      if (window.Sentry) {
        window.Sentry.onLoad(function() {
          window.Sentry.init({
            maxBreadcrumbs: 30,
            release: '325664c040d31f0f280d1c32af7ee1264ac506d3',
            environment: 'prd',
            ignoreErrors: [/SecurityError: Blocked a frame with origin.*/],
          });
        });
      }
    </script>
  

    <link data-rh="true" rel="alternate" hrefLang="en-US" href="https://www.nytimes3xbfgragh.onion/interactive/2020/06/09/magazine/covid-vaccine.html"/><link data-rh="true" rel="canonical" href="https://www.nytimes3xbfgragh.onion/interactive/2020/06/09/magazine/covid-vaccine.html"/>
    <link href="https://g1.graylady3jvrrxbe.onion/fonts/css/web-fonts.5810def60210a2fa7d0848f37e3fa048bb6147b1.css" rel="stylesheet" type="text/css" />
    <link rel="stylesheet" href="/vi-assets/static-assets/global-f2dfe2d3172b0c4bd44703c796af9242.css" />
    <style>[data-timezone] { display: none }</style>
    <style data-lights-css="1dv1kvn 6n7j50 1fe7a5q 1f8er69 10488qs kdur8l 1e1s8k7 15uy5yv jq1cx6 17ih8de 1d50gvk 1pv1u79 1dtr3u3 1dg16hf y8aj3r qj0ud4 i29ckm l9onyx 1vegfwe wkcogx 1sj8ssj emn6zw 11kjks6 159bbcu 1h21wu5 akb3vb 1yip8nf 1bxnhxc 1nf2dl3 133zg39 eph4ug 1uqx5yl 17jv7b4 1py22c6 10698na 1ede5it 1ho5u4o 13o0c9t 1yo489b 16ogagc l08pwh 1acmxgr 107sgp6 1jdplvu 9z2bwm 103zbxs 1iua6j5 1qg0wjs c32q7m w1nrqe 1oeie6n xuu3c2 1ncj54f 17dltfe 5it7hk 1715g16">.css-1dv1kvn{border:0;-webkit-clip:rect(0 0 0 0);clip:rect(0 0 0 0);height:1px;margin:-1px;overflow:hidden;padding:0;position:absolute;width:1px;}.css-6n7j50{display:inline;}.css-1fe7a5q{display:inline-block;height:16px;vertical-align:sub;width:16px;}.css-1f8er69{border:0;-webkit-clip:rect(0 0 0 0);clip:rect(0 0 0 0);height:1px;margin:-1px;overflow:hidden;padding:0;position:absolute;width:1px;border-radius:3px;cursor:pointer;font-family:nyt-franklin,helvetica,arial,sans-serif;-webkit-transition:ease 0.6s;transition:ease 0.6s;white-space:nowrap;vertical-align:middle;background-color:transparent;color:#000;font-size:11px;line-height:11px;font-weight:700;-webkit-letter-spacing:0.02em;-moz-letter-spacing:0.02em;-ms-letter-spacing:0.02em;letter-spacing:0.02em;padding:11px 12px 8px;background:#fff;display:inline-block;left:44px;text-transform:uppercase;-webkit-transition:none;transition:none;}.css-1f8er69:active,.css-1f8er69:focus{-webkit-clip:auto;clip:auto;overflow:visible;width:auto;height:auto;}.css-1f8er69::-moz-focus-inner{padding:0;border:0;}.css-1f8er69:-moz-focusring{outline:1px dotted;}.css-1f8er69:disabled,.css-1f8er69.disabled{opacity:0.5;cursor:default;}.css-1f8er69:active,.css-1f8er69.active{background-color:#f7f7f7;}@media (min-width:740px){.css-1f8er69:hover{background-color:#f7f7f7;}}.css-1f8er69:focus{margin-top:3px;padding:8px 8px 6px;}@media (min-width:1024px){.css-1f8er69{left:112px;}}.css-10488qs{display:none;}@media (min-width:1024px){.css-10488qs{display:inline-block;position:relative;}}.css-kdur8l::before{background-color:#fff;border-bottom:1px solid #e2e2e2;border-top:2px solid #e2e2e2;content:'';display:block;height:1px;margin-top:0;}@media (min-width:1150px){.css-kdur8l{margin:0 auto;max-width:1200px;padding:0 3% 9px;}}.NYTApp .css-kdur8l{display:none;}@media print{.css-kdur8l{display:none;}}.css-1e1s8k7{font-size:11px;text-align:center;padding-bottom:25px;}@media (min-width:1024px){.css-1e1s8k7{padding:0 3% 9px;}}.css-1e1s8k7.dockVisible{padding-bottom:45px;}@media (min-width:1024px){.css-1e1s8k7.dockVisible{padding:0 3% 45px;}}@media (min-width:1150px){.css-1e1s8k7{margin:0 auto;max-width:1200px;}}.NYTApp .css-1e1s8k7{display:none;}@media print{.css-1e1s8k7{display:none;}}.css-15uy5yv{border-top:1px solid #ebebeb;padding-top:9px;}.css-jq1cx6{color:#666;font-family:nyt-franklin,helvetica,arial,sans-serif;padding:10px 0;-webkit-text-decoration:none;text-decoration:none;white-space:nowrap;}.css-jq1cx6:hover{-webkit-text-decoration:underline;text-decoration:underline;}.css-17ih8de{box-sizing:border-box;vertical-align:top;}.css-1d50gvk{-webkit-align-self:center;-ms-flex-item-align:center;align-self:center;background-color:transparent;border:none;bottom:0.05rem;color:#666;cursor:pointer;display:-webkit-inline-box;display:-webkit-inline-flex;display:-ms-inline-flexbox;display:inline-flex;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;font-family:nyt-franklin,helvetica,arial,sans-serif;font-size:0.75rem;font-weight:500;height:25px;line-height:1rem;margin-left:2px;min-width:24px;overflow:visible;padding:0 0 4px;position:relative;text-transform:uppercase;}.css-1d50gvk:hover,.css-1d50gvk:focus{-webkit-text-decoration:none;text-decoration:none;border-color:#ccc;}.css-1pv1u79{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;background:transparent;border:1px solid #666;border-radius:4px;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:center;-webkit-justify-content:center;-ms-flex-pack:center;justify-content:center;min-width:26px;min-height:14px;padding:4px;position:relative;width:auto;}.css-1pv1u79::before{border-color:#666 transparent;border-style:solid;bottom:-7px;border-width:6px 0 0 8px;content:'';display:block;left:15px;position:absolute;width:0;}.css-1pv1u79::after{border-color:#fff transparent;border-style:solid;border-width:6px 0 0 6px;bottom:-6px;content:'';display:block;left:16px;position:absolute;width:0;}.css-1pv1u79:hover,.css-1pv1u79:focus{border-color:rgba(102,102,102,0.4);}.css-1pv1u79:hover::after,.css-1pv1u79:focus::after{border-color:#fff transparent;}.css-1pv1u79:hover::before,.css-1pv1u79:focus::before{border-color:#ccc transparent;}.css-1dtr3u3{color:#000;font-size:0.75rem;line-height:0.75rem;margin-top:auto;}.css-1dtr3u3 a{color:#000;}.css-1dg16hf{background-color:#567b95;border:1px solid #326891;border-radius:3px;color:white;display:block;font-family:nyt-franklin,helvetica,arial,sans-serif;font-size:0.8125rem;font-weight:600;-webkit-letter-spacing:0.05em;-moz-letter-spacing:0.05em;-ms-letter-spacing:0.05em;letter-spacing:0.05em;line-height:1.5rem;margin-left:auto;margin-right:auto;padding:5px 0;text-transform:uppercase;-webkit-transition:background-color 0.6s ease;transition:background-color 0.6s ease;width:100%;}.css-1dg16hf:active,.css-1dg16hf:focus,.css-1dg16hf:hover{background-color:#326891;}@media print{.css-1dg16hf{display:none;}}.css-y8aj3r{padding:0;}.css-qj0ud4{color:#999;display:inline;margin-right:16px;padding:10px 0;width:100%;}.css-qj0ud4 a{-webkit-text-decoration:none;text-decoration:none;}@media (max-width:659px){.css-qj0ud4.email-share-item,.css-qj0ud4.more-share-item{display:none;}}.css-qj0ud4:last-of-type{margin-right:0;}.css-i29ckm{width:calc(100% - 40px);max-width:600px;margin:1.5rem auto 2rem;}@media (min-width:1440px){.css-i29ckm{width:600px;max-width:600px;}}@media (min-width:600px){.css-i29ckm{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:justify;-webkit-justify-content:space-between;-ms-flex-pack:justify;justify-content:space-between;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;}}@media (max-width:600px){.css-i29ckm .facebook,.css-i29ckm .twitter,.css-i29ckm .email{display:inline-block;}}.css-l9onyx{color:#ccc;font-family:nyt-franklin,helvetica,arial,sans-serif;font-size:0.5625rem;font-weight:300;-webkit-letter-spacing:0.05rem;-moz-letter-spacing:0.05rem;-ms-letter-spacing:0.05rem;letter-spacing:0.05rem;line-height:0.5625rem;margin-bottom:9px;text-align:center;text-transform:uppercase;}.css-1vegfwe{width:calc(100% - 40px);max-width:600px;margin-left:20px;margin-bottom:1.375rem;color:#333;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:start;-webkit-justify-content:start;-ms-flex-pack:start;justify-content:start;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;text-align:left;}.css-1vegfwe .e16638kd0{font-size:0.8125rem;line-height:1.125rem;}.css-1vegfwe .e1n4ps4i0{font-weight:600;font-size:0.875rem;line-height:1.125rem;}.css-1vegfwe .e1n4ps4i0 span{white-space:nowrap;display:inline;}@media (min-width:740px){.css-1vegfwe{max-width:720px;margin-left:auto;margin-bottom:1.5rem;text-align:center;}}@media (min-width:600px){.css-1vegfwe{margin-left:auto;margin-right:auto;-webkit-flex-direction:row;-ms-flex-direction:row;flex-direction:row;}}.css-wkcogx{margin:0 auto 1.375rem;text-align:left;width:calc(100% - 40px);max-width:600px;margin-left:20px;margin-right:20px;}@media (min-width:600px){.css-wkcogx{margin-left:auto;margin-right:auto;}}@media (min-width:740px){.css-wkcogx{text-align:center;margin-bottom:1.5rem;}}.css-1sj8ssj{color:#000;display:inline-block;font-weight:700;font-size:1.875rem;line-height:2.125rem;padding-left:2px;padding-right:2px;}.css-1sj8ssj span{color:#333;font-weight:500;font-size:1.5rem;line-height:1.8125rem;}.css-1sj8ssj a:focus{outline:0;}.css-emn6zw{color:#567b95;display:none;font-family:nyt-cheltenham,georgia,'times new roman',times,serif;line-height:1.18rem;margin-top:5px;-webkit-text-decoration:none;text-decoration:none;}.css-emn6zw:hover{-webkit-text-decoration:underline;text-decoration:underline;}.css-11kjks6{background-color:#fff;box-shadow:3px 0 12px 3px rgba(0,0,0,0.25);font-family:nyt-franklin,helvetica,arial,sans-serif;height:100%;overflow:hidden;position:fixed;right:0;top:0;width:100%;z-index:1000000109;visibility:hidden;-webkit-transform:translateX(110%);-ms-transform:translateX(110%);transform:translateX(110%);-webkit-transition:-webkit-transform 300ms ease,visibility 300ms;-webkit-transition:transform 300ms ease,visibility 300ms;transition:transform 300ms ease,visibility 300ms;}@media print{.css-11kjks6{display:none;}}@media (min-width:600px){.css-11kjks6{width:530px;}}.css-159bbcu{background-color:#fff;display:block;height:15px;right:16px;position:absolute;top:16px;width:15px;z-index:3;}@media (max-width:600px){.css-159bbcu{right:15px;}}.css-1h21wu5{height:100%;overflow-y:scroll;width:100%;-webkit-overflow-scrolling:touch;}.css-akb3vb{padding:40px 0;position:relative;box-sizing:border-box;height:100%;}.css-1yip8nf{padding:0 40px;z-index:0;}@media (max-width:600px){.css-1yip8nf{padding:0 20px;}}.css-1bxnhxc{margin-bottom:10px;position:-webkit-sticky;position:sticky;top:0;z-index:2;}@media (min-width:600px){.css-1bxnhxc{padding:0 40px;}}@media (min-width:1024px){.css-1nf2dl3{position:relative;border-bottom:none;position:inherit;width:inherit;z-index:inherit;}}.css-133zg39{background:transparent;border-bottom:1px solid #e2e2e2;height:36px;padding:8px 15px 3px;position:relative;background:transparent;border-bottom:none;max-width:100%;top:-7px;}@media (min-width:740px){.css-133zg39{background:transparent;padding:10px 15px 6px;}}@media (min-width:1024px){.css-133zg39{background:transparent;border-bottom:0;padding:4px 15px 2px;}}@media (min-width:1024px){.css-133zg39{margin:0 auto;max-width:1605px;max-width:100%;}}.css-eph4ug{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:space-around;-webkit-justify-content:space-around;-ms-flex-pack:space-around;justify-content:space-around;left:10px;position:absolute;}@media print{.css-eph4ug{display:none;}}.css-1uqx5yl{border-radius:3px;cursor:pointer;font-family:nyt-franklin,helvetica,arial,sans-serif;-webkit-transition:ease 0.6s;transition:ease 0.6s;white-space:nowrap;vertical-align:middle;background-color:transparent;color:#000;font-size:11px;line-height:11px;font-weight:700;-webkit-letter-spacing:0.02em;-moz-letter-spacing:0.02em;-ms-letter-spacing:0.02em;letter-spacing:0.02em;padding:11px 12px 8px;border:0;padding:8px 9px;text-transform:uppercase;}.css-1uqx5yl.hidden{opacity:0;visibility:hidden;}.css-1uqx5yl.hidden:focus{opacity:1;}.css-1uqx5yl::-moz-focus-inner{padding:0;border:0;}.css-1uqx5yl:-moz-focusring{outline:1px dotted;}.css-1uqx5yl:disabled,.css-1uqx5yl.disabled{opacity:0.5;cursor:default;}.css-1uqx5yl:active,.css-1uqx5yl.active{background-color:#f7f7f7;}@media (min-width:740px){.css-1uqx5yl:hover{background-color:#f7f7f7;}}@media (min-width:1024px){.css-1uqx5yl{display:none;}}.css-17jv7b4{border-radius:3px;cursor:pointer;font-family:nyt-franklin,helvetica,arial,sans-serif;-webkit-transition:ease 0.6s;transition:ease 0.6s;white-space:nowrap;vertical-align:middle;background-color:transparent;color:#000;font-size:11px;line-height:11px;font-weight:700;-webkit-letter-spacing:0.02em;-moz-letter-spacing:0.02em;-ms-letter-spacing:0.02em;letter-spacing:0.02em;padding:11px 12px 8px;display:none;padding:8px 9px 9px;}.css-17jv7b4::-moz-focus-inner{padding:0;border:0;}.css-17jv7b4:-moz-focusring{outline:1px dotted;}.css-17jv7b4:disabled,.css-17jv7b4.disabled{opacity:0.5;cursor:default;}.css-17jv7b4:active,.css-17jv7b4.active{background-color:#f7f7f7;}@media (min-width:740px){.css-17jv7b4:hover{background-color:#f7f7f7;}}@media (min-width:1024px){.css-17jv7b4{border:0;display:inline-block;margin-right:8px;}.css-17jv7b4:hover{background-color:rgba(0,0,0,0.3);}}.css-1py22c6{border-radius:3px;cursor:pointer;font-family:nyt-franklin,helvetica,arial,sans-serif;-webkit-transition:ease 0.6s;transition:ease 0.6s;white-space:nowrap;vertical-align:middle;background-color:transparent;color:#000;font-size:11px;line-height:11px;font-weight:700;-webkit-letter-spacing:0.02em;-moz-letter-spacing:0.02em;-ms-letter-spacing:0.02em;letter-spacing:0.02em;padding:11px 12px 8px;border:0;}.css-1py22c6::-moz-focus-inner{padding:0;border:0;}.css-1py22c6:-moz-focusring{outline:1px dotted;}.css-1py22c6:disabled,.css-1py22c6.disabled{opacity:0.5;cursor:default;}.css-1py22c6:active,.css-1py22c6.active{background-color:#f7f7f7;}@media (min-width:740px){.css-1py22c6:hover{background-color:#f7f7f7;}}.css-1py22c6.activeSearchButton{background-color:#f7f7f7;background-color:rgba(0,0,0,0.3);}.css-1py22c6:hover{background-color:rgba(0,0,0,0.3);}@media (min-width:1024px){.css-1py22c6{padding:8px 9px 9px;}}.css-10698na{text-align:center;}@media (min-width:740px){.css-10698na{padding-top:0;}}@media print{.css-10698na a[href]::after{content:'';}.css-10698na svg{fill:black;}}.css-1ede5it{background-color:#f7f7f7;border-bottom:1px solid #f3f3f3;border-top:1px solid #f3f3f3;margin:37px auto;padding-bottom:30px;padding-top:12px;text-align:center;margin-top:60px;}@media (min-width:740px){.css-1ede5it{margin:43px auto;}}@media print{.css-1ede5it{display:none;}}@media (min-width:740px){.css-1ede5it{margin-bottom:0;margin-top:0;}}.css-1ho5u4o{list-style:none;margin:0 0 15px;padding:0;}@media (min-width:600px){.css-1ho5u4o{display:inline-block;}}.css-13o0c9t{list-style:none;line-height:8px;margin:0 0 35px;padding:0;}@media (min-width:600px){.css-13o0c9t{display:inline-block;}}.css-1yo489b{display:inline-block;line-height:20px;padding:0 10px;}.css-1yo489b:first-child{border-left:none;}.css-1yo489b.desktop{display:none;}@media (min-width:740px){.css-1yo489b.smartphone{display:none;}.css-1yo489b.desktop{display:inline-block;}}.css-16ogagc{background:transparent;display:inline-block;height:20px;width:20px;background-color:#eee;border:1px #eee solid;border-radius:100%;padding:5px;width:27px;height:27px;}.css-16ogagc.hidden{opacity:0;visibility:hidden;}.css-16ogagc.hidden:focus{opacity:1;}.css-16ogagc:hover{background-color:#fff;border:1px solid #ccc;}.css-l08pwh{width:100%;margin:0 auto;height:auto;}.css-1acmxgr{display:inline-block;height:15px;vertical-align:middle;width:15px;background-color:#eee;border:1px #eee solid;border-radius:100%;padding:5px;width:15px;height:15px;}.css-1acmxgr:hover{background-color:#fff;border:1px solid #ccc;}.css-107sgp6{display:inline-block;height:15px;vertical-align:middle;width:15px;bottom:5px;position:relative;width:15px;height:15px;bottom:4px;}.css-1jdplvu{display:block;width:170px;height:14px;margin:10px auto 0;}@media (min-width:375px){.css-1jdplvu{width:220px;height:19px;margin:9px auto 0;}}@media (min-width:740px){.css-1jdplvu{width:264px;height:23px;margin:7px auto 0;}}@media (min-width:1024px){.css-1jdplvu{width:305px;height:27px;margin:6px auto;}}.css-9z2bwm{color:#999;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-family:nyt-franklin,helvetica,arial,sans-serif;font-size:17px;margin-bottom:5px;height:32px;}@media print{.css-9z2bwm{display:none;}}.css-9z2bwm li.fb-share-item,.css-9z2bwm li.twitter-share-item,.css-9z2bwm li.email-share-item{display:inline;}@media (min-width:740px){.css-9z2bwm{-webkit-box-pack:center;-webkit-justify-content:center;-ms-flex-pack:center;justify-content:center;}}@media (min-width:740px){.css-103zbxs{margin-left:auto;margin-right:auto;}}.css-103zbxs .last-byline{padding-right:10px;}.css-1iua6j5{color:#999;display:inline;margin-right:16px;padding:10px 0;width:100%;}.css-1iua6j5 a{-webkit-text-decoration:none;text-decoration:none;}@media (max-width:659px){.css-1iua6j5.email-share-item,.css-1iua6j5.more-share-item{display:none;}}.css-1iua6j5:last-of-type{margin-right:0;}.css-1iua6j5.fb-share-item,.css-1iua6j5.twitter-share-item,.css-1iua6j5.email-share-item{display:inline;}@media (max-width:659px){.css-1iua6j5.email-share-item,.css-1iua6j5.more-share-item{display:inline;}}.css-1qg0wjs{border:0;-webkit-clip:rect(0 0 0 0);clip:rect(0 0 0 0);height:1px;margin:-1px;overflow:hidden;padding:0;position:absolute;width:1px;font-family:nyt-franklin,helvetica,arial,sans-serif;font-size:0.875rem;line-height:1.25rem;font-weight:700;text-transform:uppercase;-webkit-letter-spacing:0.05em;-moz-letter-spacing:0.05em;-ms-letter-spacing:0.05em;letter-spacing:0.05em;top:50px;right:125px;}.css-1qg0wjs:active,.css-1qg0wjs:focus{-webkit-clip:auto;clip:auto;overflow:visible;width:auto;height:auto;}.css-c32q7m{margin-top:10px;color:#333;font-size:0.875rem;font-weight:500;line-height:1.125rem;margin-bottom:12px;margin-top:15px;}.css-c32q7m a{color:#326891;font-family:nyt-franklin,helvetica,arial,sans-serif;-webkit-text-decoration:none;text-decoration:none;}.css-c32q7m a:hover{-webkit-text-decoration:underline;text-decoration:underline;}@media (min-width:740px){.css-c32q7m{line-height:1.25rem;}}.css-w1nrqe{color:#999;display:inline;margin-right:16px;padding:10px 0;width:100%;position:relative;right:3px;}.css-w1nrqe a{-webkit-text-decoration:none;text-decoration:none;}@media (max-width:659px){.css-w1nrqe.email-share-item,.css-w1nrqe.more-share-item{display:none;}}.css-w1nrqe:last-of-type{margin-right:0;}.NYTApp .css-w1nrqe{display:none;}.css-1oeie6n{color:#999;display:inline;margin-right:16px;padding:10px 0;width:100%;width:calc(100% - 40px);max-width:600px;margin:1.5rem auto 2rem;width:calc(100% - 40px);max-width:600px;padding:0 1rem 0 0;}.css-1oeie6n a{-webkit-text-decoration:none;text-decoration:none;}@media (max-width:659px){.css-1oeie6n.email-share-item,.css-1oeie6n.more-share-item{display:none;}}.css-1oeie6n:last-of-type{margin-right:0;}@media (min-width:1440px){.css-1oeie6n{width:600px;max-width:600px;}}@media (min-width:600px){.css-1oeie6n{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:justify;-webkit-justify-content:space-between;-ms-flex-pack:justify;justify-content:space-between;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;}}@media (max-width:600px){.css-1oeie6n .facebook,.css-1oeie6n .twitter,.css-1oeie6n .email{display:inline-block;}}@media (min-width:600px){.css-1oeie6n{width:330px;}}.NYTApp .css-1oeie6n{display:none;}.css-xuu3c2{position:absolute;top:6px;width:100%;z-index:1000000000;}@media print{.css-xuu3c2{display:none;}}.NYTApp .css-xuu3c2{display:none;}.css-1ncj54f{margin-bottom:0.78125rem;margin-top:0;font-family:nyt-imperial,georgia,'times new roman',times,serif;font-size:1.125rem;line-height:1.5625rem;width:calc(100% - 40px);max-width:600px;margin-left:20px;margin-right:20px;}@media (min-width:740px){.css-1ncj54f{margin-bottom:0.9375rem;margin-top:0;}}.css-1ncj54f .css-1g7m0tk{-webkit-text-decoration:underline;text-decoration:underline;}.css-1ncj54f .css-1g7m0tk:hover,.css-1ncj54f .css-1g7m0tk:focus{-webkit-text-decoration:none;text-decoration:none;}@media (min-width:740px){.css-1ncj54f{font-size:1.25rem;line-height:1.875rem;}}@media (min-width:600px){.css-1ncj54f{margin-left:auto;margin-right:auto;}}@media (min-width:1024px){.css-1ncj54f{width:600px;}}.css-17dltfe{margin-top:1.5625rem;padding-top:60px;}@media (min-width:740px){.css-17dltfe{margin-top:3.75rem;}}.css-17dltfe .e6idgb70{color:#121212;font-weight:700;line-height:0.75rem;margin-bottom:1.25rem;margin-top:0;}@media print{.css-17dltfe .e6idgb70{margin-left:0;margin-right:0;width:100%;max-width:100%;}}.css-17dltfe .e1h9rw200{margin-bottom:1rem;}@media (min-width:740px){.css-17dltfe .e1h9rw200{position:relative;}}.css-17dltfe .ezdmqqa0{margin-bottom:3px;}@media (min-width:600px){.css-17dltfe .ezdmqqa0{margin-bottom:0;}}.css-17dltfe .e1wiw3jv0{color:#333;}.css-17dltfe .e16638kd0{display:inline-block;}.css-17dltfe .e12qa4dv0{margin-bottom:20px;color:#121212;}@media print{.css-17dltfe .e12qa4dv0{margin-left:0;margin-right:0;width:100%;max-width:100%;}}@media (min-width:740px){.css-17dltfe .e12qa4dv0{text-align:left;}}@media (min-width:600px){.css-17dltfe{margin-top:45px;}}.NYTApp .css-17dltfe{margin-top:55px;}.css-17dltfe .e6idgb70{font-size:0.75rem;line-height:0.875rem;color:#121212;margin-top:20px;margin-bottom:10px;text-align:center;width:calc(100% - 40px);max-width:600px;margin-left:20px;margin-right:20px;}@media (min-width:600px){.css-17dltfe .e6idgb70{font-size:0.875rem;line-height:1.125rem;margin-top:35px;}}@media (min-width:600px){.css-17dltfe .e6idgb70{margin-left:auto;margin-right:auto;}}@media (min-width:1024px){.css-17dltfe .e6idgb70{width:600px;}}@media (min-width:1440px){.css-17dltfe .e6idgb70{width:600px;max-width:600px;}}.css-17dltfe .e1h9rw200{font-size:1.8125rem;line-height:2.0625rem;margin-bottom:1.125rem;text-align:left;width:calc(100% - 40px);max-width:600px;margin-left:20px;margin-right:20px;}@media (min-width:600px){.css-17dltfe .e1h9rw200{margin-left:auto;margin-right:auto;}}@media (min-width:740px){.css-17dltfe .e1h9rw200{width:720px;max-width:720px;font-size:2.5rem;line-height:2.75rem;text-align:center;margin-bottom:1.25rem;}}.css-17dltfe .e16638kd0{text-transform:capitalize;}.css-17dltfe .e16638kd0 span:last-of-type{margin-right:0;}@media (min-width:600px){.css-17dltfe .e16638kd0{margin-top:0;}}@media (min-width:740px){.css-17dltfe .e16638kd0{margin-right:auto;}}.css-5it7hk{color:#121212;font-family:nyt-magslab;font-weight:700;font-style:normal;font-size:2.9375rem;line-height:3.0625rem;text-align:left;}@media (min-width:740px){.css-5it7hk{font-size:3.375rem;line-height:3.25rem;}}.css-1715g16{font-family:nyt-franklin,helvetica,arial,sans-serif;font-weight:500;color:#333;margin-bottom:1rem;font-size:0.8125rem;line-height:1rem;font-family:nyt-magsans,helvetica,arial,sans-serif;font-weight:500;color:#444;}html.DarkTheme .css-1715g16{color:#ccc;}</style>
    
    

    
    <script type="text/javascript">
      // 29.328kB
      window.viHeadScriptSize = 29.328;
      window.NYTD = {};
      window.vi = window.vi || {};
      window.vi.pageType = { type: '', edge: 'vi-interactive-minimal'};
      (function () { var _f=function(e){window.vi=window.vi||{},window.vi.env=Object.freeze(e)};;_f.apply(null, [{"JKIDD_PATH":"https://a.nytimes3xbfgragh.onion/svc/nyt/data-layer","ET2_URL":"https://a.et.nytimes3xbfgragh.onion","ALS_URL":"https://als-svc.nytimes3xbfgragh.onion","WEDDINGS_PATH":"https://content.api.nytimes3xbfgragh.onion","GDPR_PATH":"https://us-central1-nyt-dsra-prd.cloudfunctions.net/datagov-dsr-formhandler","RECAPTCHA_SITEKEY":"6LevSGcUAAAAAF-7fVZF05VTRiXvBDAY4vBSPaTF","ABRA_ET_URL":"//et.nytimes3xbfgragh.onion","NODE_ENV":"production","EXPERIMENTAL_ROUTE_PREFIX":"","ENVIRONMENT":"prd","RELEASE":"325664c040d31f0f280d1c32af7ee1264ac506d3","AUTH_HOST":"https://myaccount.nytimes3xbfgragh.onion","SWG_PUBLICATION_ID":"nytimes3xbfgragh.onion","GQL_FETCH_TIMEOUT":"4000","GOOGLE_CLIENT_ID":"1005640118348-amh5tgkq641oru4fbhr3psm3gt2tcc94.apps.googleusercontent.com","STORY_SURROGATE_CONTROL":"max-age=300, stale-if-error=259200, stale-while-revalidate=259200"}]); })();;

try {
 
  var marks = ['first-paint', 'first-contentful-paint', 'userBtnRender', 'appRenderTime'];

  var observer = new window.PerformanceObserver(function(list) {
    var entries = list.getEntries();
    for (var i = 0; i < entries.length; i += 1) {
      var entry = entries[i];
      if (marks.indexOf(entry.name) > -1) {
        var performance = {};
        performance[entry.name] = Math.round(entry.duration || entry.startTime);
        (window.dataLayer = window.dataLayer || []).push({
          event: 'performance',
          pageview: {
            performance: performance,
          },
        });
      }
    }
  });
 
  observer.observe({ entryTypes: ['mark', 'measure', 'paint'] });
} catch(e) {};
!function(c,e){var s,p,d,u,g,l=[],
_="object"==typeof c.navigator&&"string"==typeof c.navigator.userAgent&&/iP(ad|hone|od)/.test(
c.navigator.userAgent),f="object"==typeof c.navigator&&c.navigator.sendBeacon,
v=f?_?"xhr_ios":"beacon":"xhr";function y(){var e,t,n=c.crypto||c.msCrypto;if(n)t=n.getRandomValues(
new Uint8Array(18));else for(t=[];t.length<18;)t.push(256*Math.random()^255&(e=e||+new Date)),
e=Math.floor(e/256);return btoa(String.fromCharCode.apply(String,t)).replace(/\+/g,"-").replace(
/\//g,"_")}if(c.nyt_et)try{console.warn("et2 snippet should only load once per page")}catch(e
){}else c.nyt_et=function(){var e,t,n,i,o={pv_id:"",ctx_id:""},r=arguments;function a(o){l.length&&(
function(e,t,n){if("beacon"===v||f&&o)return c.navigator.sendBeacon(e,t)
;var i="undefined"!=typeof XMLHttpRequest?new XMLHttpRequest:new ActiveXObject("Microsoft.XMLHTTP")
;i.open("POST",e),i.withCredentials=!0,i.setRequestHeader("Accept","*/*"),
"string"==typeof t?i.setRequestHeader("Content-Type","text/plain;charset=UTF-8"
):"[object Blob]"==={}.toString.call(t)&&t.type&&i.setRequestHeader("Content-Type",t.type);try{
i.send(t)}catch(e){}}(s+"/track",JSON.stringify(l)),l.length=0,clearTimeout(g),g=null)}if(
"string"==typeof r[0]&&/init/.test(r[0])&&(o=function(e,t){var n="",i="";if(
"string"==typeof e&&"init"==e&&"object"==typeof t&&"string"==typeof t.pv_id_override&&"string"==typeof t.ctx_id_override
)if(24<=t.pv_id_override.length&&24<=t.ctx_id_override.length)n=t.pv_id_override,
i=t.ctx_id_override;else try{console.warn("override id(s) must be >= 24 chars long")}catch(e){}
return{pv_id:n,ctx_id:i}}(r[0],r[3]),d=o.pv_id||y(),"init"==r[0]&&!p)){if(p=o.ctx_id||y(),
"string"!=typeof r[1]||!/^http/.test(r[1]))throw new Error("init must include an et host url");if(
s=String(r[1]).replace(/\/$/,""),"string"!=typeof r[2])throw new Error(
"init must include a source app name");u=r[2]}r[r.length-1]&&"object"==typeof r[r.length-1]&&(
e=r[r.length-1]),e||/init/.test(r[0])?e&&!e.subject&&console.warn(
"event data {} must include a subject"):console.warn(
"when invoked without 'init' or 'pageinit', nyt_et() must include a event data"),s&&e&&e.subject&&(
t=e.subject,delete e.subject,i="page_exit"==t||"ob_click"==(e.eventData||{}).type,
n="page"==t||"page_soft"==t?d:y(),l.push({context_id:p,pageview_id:d,event_id:n,client_lib:"v1.1.1",
sourceApp:u,subject:t,how:i&&_&&f?"beacon_ios":v,client_ts:+new Date,data:JSON.parse(JSON.stringify(
e))}),"send"==r[0]||n==d||i?a(i):g||(g=setTimeout(a,5500)))},c.nyt_et.get_pageview_id=function(){
return d},c.nyt_et.get_context_id=function(){return p}}(window);
;
  (function initWebUnifiedTracking(root) {
  var _root;

  root = root || (typeof window !== 'undefined' ? window : undefined);
  var UnifiedTracking = ((_root = root) === null || _root === void 0 ? void 0 : _root.UnifiedTracking) || {};

  if (!root) {
    return UnifiedTracking;
  }

  root.UnifiedTracking = UnifiedTracking;

  UnifiedTracking.sendAnalytic = function sendAnalytic(eventName, dataBlob) {
    root.dataLayer = root.dataLayer || [];

    if (Array.isArray(root.dataLayer)) {
      // Don't use a spread operator here for babel reasons
      dataBlob.event = dataBlob.event || eventName;
      root.dataLayer.push(dataBlob);
    }

    return Promise.resolve({
      success: true
    });
  };

  return UnifiedTracking;
})(window);
;!function(r){var n,t;r=r||self,n=r.Abra,(t=r.Abra=function(){"use strict";var r=Array.isArray,n=function(r,n,t){return r(t,n).reduce((function(r,n){return parseFloat(r)+parseFloat(n)}),0)},t=function(r,n,t){var e=r(t,n);return e[0]/e[1]},e=function(r,n,t){var e=r(t,n);return e[0]%e[1]},u=function(r,n,t){return r(t,n).reduce((function(r,n){return parseFloat(r)*parseFloat(n)}),1)},o=function(r,n,t){var e=r(t,n),u=e[0],o=e[1];return void 0===o?-u:u-o};function i(n){return!(r(n)&&0===n.length||!n)}var a=function(r,n,t){for(var e,u=0;u<t.length;u++)if(!i(e=r(t[u],n)))return e;return e},f=function(r,n,t){var e;for(e=0;e<t.length-1;e+=2)if(i(r(t[e],n)))return r(t[e+1],n);return t.length===e+1?r(t[e],n):null},c=function(r,n,t){return!i(r(t,n)[0])},l=function(r,n,t){for(var e,u=0;u<t.length;u++)if(i(e=r(t[u],n)))return e;return e},v=function(r,n,t){var e=r(t,n);return e[0]===e[1]},s=function(r,n,t){var e=r(t,n);return e[0]!==e[1]},d=function(r,n,t){var e=r(t,n),u=e[0],o=e[1];return!(!o||void 0===o.indexOf)&&-1!==o.indexOf(u)},h=function(r,n,t){var e=r(t,n);return e[0]>e[1]},g=function(r,n,t){var e=r(t,n);return e[0]>=e[1]},p=function(r,n,t){var e=r(t,n),u=e[0],o=e[1],i=e[2];return void 0===i?u<o:u<o&&o<i},b=function(r,n,t){var e=r(t,n),u=e[0],o=e[1],i=e[2];return void 0===i?u<=o:u<=o&&o<=i},w=function(r,n,t){var e=t[0],u=t[1],o=t.slice(2),i=r(e,n);if(!i)return null;if(0===o.length)return null;if(1===o.length)return r(o[0],n);if(4294967295===o[0])return r(o[1],n);for(var a=function(r){var n,t,e,u,o,i=[],a=[t=1732584193,e=4023233417,~t,~e,3285377520],f=[],c=unescape(encodeURI(r))+"Â€",l=c.length;for(f[r=--l/4+2|15]=8*l;~l;)f[l>>2]|=c.charCodeAt(l)<<8*~l--;for(n=l=0;n<r;n+=16){for(t=a;l<80;t=[t[4]+(i[l]=l<16?~~f[n+l]:2*c|c<0)+1518500249+[e&u|~e&o,c=341275144+(e^u^o),882459459+(e&u|e&o|u&o),c+1535694389][l++/5>>2]+((c=t[0])<<5|c>>>27),c,e<<30|e>>>2,u,o])c=i[l-3]^i[l-8]^i[l-14]^i[l-16],e=t[1],u=t[2],o=t[3];for(l=5;l;)a[--l]+=t[l]}return a[0]>>>0}(i+" "+r(u,n));o.length>1;){var f=o.splice(0,2),c=f[0],l=f[1];if(a<=r(c,n))return r(l,n)}return 0===o.length?null:r(o[0],n)},m=function(r,n,t){var e=t[0],u=t[1],o=r(e,n);return null==o?null:new RegExp(u).test(o)},y=function(r,n,t){var e=r(t,n),u=e[0],o=e[1];if(!u)return n;for(var i=n,a=String(u).split("."),f=0;f<a.length&&(i=i[a[f]]);f++);if(null==i){if(!o){var c=new Error("Abra missing input: "+u);throw c.missingInput=u,c}i=o}return null!=i?i:null};return function(i,k,A,O){void 0===i&&(i={}),void 0===k&&(k={}),void 0===A&&(A={}),void 0===O&&(O=!1);var j=function(){var r={},n=function(n){if(n)for(var t,e=decodeURIComponent(n[1]),u=/(?:^|,)([^,=]+)=([^,]+)/g;t=u.exec(e);){var o=t,i=o[1],a=o[2];r[i]=a}};n(document.cookie.match(/(?:^|;) *abra-overrides=([^;]+)/)),n(window.location.search.match(/(?:\?|&)abra-overrides=([^&]+)/));var t=/(?:^|;) *abra-nuke=true(?:;|$)/.test(document.cookie)||/(?:\?|&)abra-nuke=true(?:&|$)/.test(window.location.search);return[r,t]}(),x=j[0],E=j[1];Object.keys(A).forEach((function(r){x[r]=A[r]}));var F,C=O||E,I=(F={var:y,if:f,"===":v,"!==":s,and:a,or:l,"!":c,">":h,">=":g,"<":p,"<=":b,"+":n,"-":o,"*":u,"/":t,"%":e,in:d,abtest_partition:w,regex_match:m,ref:function(r,n,t){var e=r(t,n)[0];return R(e)}},function n(t,e){if(e||(e={}),r(t))return t.map((function(r){return n(r,e)}));if(!function(n){return"object"==typeof n&&null!==n&&!r(n)&&1===Object.keys(n).length}(t))return t;var u=function(r){return Object.keys(r)[0]}(t),o=t[u];r(o)||(o=[o]);var i=F[u];if(!i)throw new Error("Unrecognized operation "+u);return i(n,e,o)}),R=function(r){if(!r)return null;var n=x[r];if(void 0===n){if(!C){if(Object.prototype.hasOwnProperty.call(x,r))throw new Error("circular logic");x[r]=void 0,n=I(i[r],k)}void 0===n&&(n=null),x[r]=n}return n};return R}}()).noConflict=function(){return r.Abra=n,t}}(this);
;(function () { var NYTD="undefined"!=typeof window&&window.NYTD?window.NYTD:{};function setupTimeZone(){var e='[data-timezone][data-timezone~="'+(new Date).getHours()+'"] { display: block }',t=document.createElement("style");t.innerHTML=e,document.head.appendChild(t)}function userAgentIndicatesApp(){var e=window.navigator.userAgent||window.navigator.vendor||window.opera,t=-1!==e.indexOf("nyt_android"),n=-1!==e.indexOf("nytios");return t||n}function addNYTAppClass(){userAgentIndicatesApp()&&document.documentElement.classList.add("NYTApp")}function setupPageViewId(){NYTD.PageViewId={},NYTD.PageViewId.update=function(){return"undefined"!=typeof nyt_et&&"function"==typeof window.nyt_et.get_pageview_id?(window.nyt_et("pageinit"),NYTD.PageViewId.current=window.nyt_et.get_pageview_id()):NYTD.PageViewId.current="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx".replace(/[xy]/g,function(e){var t=16*Math.random()|0;return("x"===e?t:3&t|8).toString(16)}),NYTD.PageViewId.current}}var _f=function(){try{document.domain="nytimes3xbfgragh.onion"}catch(e){}window.swgUserInfoXhrObject=new XMLHttpRequest,setupPageViewId(),setupTimeZone(),addNYTAppClass(),window.nyt_et&&"function"==typeof window.nyt_et&&window.nyt_et("init",vi.env.ET2_URL,"nyt-vi",{subject:"page",canonicalUrl:(document.querySelector("link[rel=canonical]")||{}).href,articleId:(document.querySelector("meta[name=articleid]")||{}).content,nyt_uri:(document.querySelector("meta[name=nyt_uri]")||{}).content,pubpEventId:(document.querySelector("meta[name=pubp_event_id]")||{}).content,url:location.href,referrer:document.referrer||void 0,client_tz_offset:(new Date).getTimezoneOffset()}),"undefined"!=typeof nyt_et&&"function"==typeof window.nyt_et.get_pageview_id?NYTD.PageViewId.current=window.nyt_et.get_pageview_id():NYTD.PageViewId.update()};;_f.apply(null, []); })();;(function () { var NYTD="undefined"!=typeof window&&window.NYTD?window.NYTD:{};var _f=function(a){window.Abra&&"function"==typeof window.Abra&&(NYTD.Abra=function(t){var r=(t.document.cookie.match(/(?:^|;) *nyt-a=([^;]*)/)||[])[1],e=[];function n(a){return n.getAbraSync(a).variant}return t.dataLayer=t.dataLayer||[],n.config=a.abraConfig||{},n.reportedAllocations={},n.reportedExposures={},n.getAbraSync=function(a){var e=null,o=!1;try{e=t.Abra(n.config,{agent_id:r})(a),o=!0}catch(a){}return{variant:e,allocated:o}},n.reportExposure=function(a){var r=n.getAbraSync(a).variant;void 0!==n.reportedExposures[a]&&r===n.reportedExposures[a]||(n.reportedExposures[a]=r,t.dataLayer.push({event:"ab-expose",abtest:{test:a,variant:r||"0"}}))},Object.keys(n.config).forEach(function(a){var t=n.getAbraSync(a);t.allocated&&(n.reportedAllocations[a]=t.variant,e.push({test:a,variant:t.variant}))}),t.dataLayer.push({event:"ab-alloc",abtest:{batch:e}}),n}(this))};;_f.apply(null, [{"abraConfig":{"ACCT_CancelTheCancel":{"abtest_partition":[{"var":"regi_id"},"MKT_CancelTheCancel",2147483647,"0_control",4294967295,"1_reactivatebutton"]},"dfp_1p_ver":{"abtest_partition":[{"var":"agent_id"},"dfp_1p_ver",1431512599,"0_control",2863025199,"1_bk",4294537798,"2_fp"]},"dfp_1p2":{"abtest_partition":[{"var":"agent_id"},"dfp_1p2",1431512599,"0_control",2863025199,"1_bk",4294537798,"2_fp"]},"DFP_delayedAd_0820":{"abtest_partition":[{"var":"agent_id"},"DFP_delayedAd_0820"]},"dfp_MWTest":{"abtest_partition":[{"var":"agent_id"},"dfp_MWTest",42949672,"0_control",85899345,"1_vendorA",128849018,"2_vendorB"]},"FREEX_Regi_Bundle_Sale":{"abtest_partition":[{"var":"agent_id"},"FREEX_Regi_Bundle_Sale",4294967295,"0_Sale"]},"FREEX_Time_Bound_Pricing":{"abtest_partition":[{"var":"agent_id"},"FREEX_Time_Bound_Pricing",4294967295,"4_sale_today"]},"MKT_dfp_KMB":{"abtest_partition":[{"var":"agent_id"},"MKT_dfp_KMB",644245093,"0_control",4294967295,"1_test"]},"ON_WelcomeBlock_CK_0720":{"abtest_partition":[{"var":"agent_id"},"ON_WelcomeBlock_CK_0720",858993458,"0_control",1717986917,"1_CK_nobutton",2576980377,"2_CK_button",3435973836,"3_Takeover_nobutton",4294967295,"4_Takeover_button"]},"styln_climate_keepup":{"if":[{"and":[{"===":[{"ref":"styln-climate"},"1_Show"]},{"===":[{"ref":"STYLN_pharmacy_components"},"show"]}]},{"abtest_partition":[{"var":"agent_id"},"styln_climate_keepup",1073741823,"0_control",4294967295,"1_variant"]}]},"STYLN_coronavirus_economy_menu":{"if":[{"and":[{"===":[{"ref":"STYLN_pharmacy_components"},"show"]}]},{"abtest_partition":[{"var":"agent_id"},"STYLN_coronavirus_economy_menu",3221225471,"0_control_normal_menu",4294967295,"1_economy_menu"]}]},"styln_coronavirus_reopening_keepup":{"abtest_partition":[{"var":"agent_id"},"styln_coronavirus_reopening_keepup",2147483647,"0_control_hide_reopening_keepup",4294967295,"1_reopening_keepup"]},"styln-ada-at-30":{"if":[{"and":[{"===":[{"ref":"STYLN_pharmacy_components"},"show"]}]},{"abtest_partition":[{"var":"agent_id"},"styln-ada-at-30",214748364,"0_Control",4294967295,"1_Show"]}]},"styln-beirut":{"if":[{"and":[{"===":[{"ref":"STYLN_pharmacy_components"},"show"]}]},{"abtest_partition":[{"var":"agent_id"},"styln-beirut",214748364,"0_Control",4294967295,"1_Show"]}]},"styln-california-wildfires":{"if":[{"and":[{"===":[{"ref":"STYLN_pharmacy_components"},"show"]}]},{"abtest_partition":[{"var":"agent_id"},"styln-california-wildfires",214748364,"0_Control",4294967295,"1_Show"]}]},"styln-climate":{"if":[{"and":[{"===":[{"ref":"STYLN_pharmacy_components"},"show"]}]},{"abtest_partition":[{"var":"agent_id"},"styln-climate",214748364,"0_Control",4294967295,"1_Show"]}]},"styln-coronavirus-es":{"if":[{"and":[{"===":[{"ref":"STYLN_pharmacy_components"},"show"]}]},{"abtest_partition":[{"var":"agent_id"},"styln-coronavirus-es",214748364,"0_Control",4294967295,"1_Show"]}]},"styln-coronavirus-schools-reopening":{"if":[{"and":[{"===":[{"ref":"STYLN_pharmacy_components"},"show"]},{"===":[{"ref":"styln-coronavirus"},"1_Show"]}]},{"abtest_partition":[{"var":"agent_id"},"styln-coronavirus-schools-reopening",214748364,"0_Control",4294967295,"1_Show"]}]},"styln-coronavirus":{"if":[{"and":[{"===":[{"ref":"STYLN_pharmacy_components"},"show"]}]},{"abtest_partition":[{"var":"agent_id"},"styln-coronavirus",214748364,"0_Control",4294967295,"1_Show"]}]},"styln-elections-2020":{"if":[{"and":[{"===":[{"ref":"STYLN_pharmacy_components"},"show"]}]},{"abtest_partition":[{"var":"agent_id"},"styln-elections-2020",214748364,"0_Control",4294967295,"1_Show"]}]},"styln-george-floyd":{"if":[{"and":[{"===":[{"ref":"STYLN_pharmacy_components"},"show"]}]},{"abtest_partition":[{"var":"agent_id"},"styln-george-floyd",214748364,"0_Control",4294967295,"1_Show"]}]},"styln-hong-kong":{"if":[{"and":[{"===":[{"ref":"STYLN_pharmacy_components"},"show"]}]},{"abtest_partition":[{"var":"agent_id"},"styln-hong-kong",214748364,"0_Control",4294967295,"1_Show"]}]},"styln-hurricanes":{"if":[{"and":[{"===":[{"ref":"STYLN_pharmacy_components"},"show"]}]},{"abtest_partition":[{"var":"agent_id"},"styln-hurricanes",214748364,"0_Control",4294967295,"1_Show"]}]},"styln-isaias-storm":{"if":[{"and":[{"===":[{"ref":"STYLN_pharmacy_components"},"show"]}]},{"abtest_partition":[{"var":"agent_id"},"styln-isaias-storm",214748364,"0_Control",4294967295,"1_Show"]}]},"styln-juneteenth":{"if":[{"and":[{"===":[{"ref":"STYLN_pharmacy_components"},"show"]}]},{"abtest_partition":[{"var":"agent_id"},"styln-juneteenth",214748364,"0_Control",4294967295,"1_Show"]}]},"styln-kobe":{"if":[{"and":[{"===":[{"ref":"STYLN_pharmacy_components"},"show"]}]},{"abtest_partition":[{"var":"agent_id"},"styln-kobe",214748364,"0_Control",4294967295,"1_Show"]}]},"styln-mars":{"if":[{"and":[{"===":[{"ref":"STYLN_pharmacy_components"},"show"]}]},{"abtest_partition":[{"var":"agent_id"},"styln-mars",214748364,"0_Control",4294967295,"1_Show"]}]},"styln-scroll-into-homepage":{"abtest_partition":[{"var":"agent_id"},"styln-scroll-into-homepage",42949672,"0_Control",85899345,"1_Variant"]},"styln-sports-reopening":{"if":[{"and":[{"===":[{"ref":"STYLN_pharmacy_components"},"show"]}]},{"abtest_partition":[{"var":"agent_id"},"styln-sports-reopening",214748364,"0_Control",4294967295,"1_Show"]}]},"styln-suffrage-at-100":{"if":[{"and":[{"===":[{"ref":"STYLN_pharmacy_components"},"show"]}]},{"abtest_partition":[{"var":"agent_id"},"styln-suffrage-at-100",214748364,"0_Control",4294967295,"1_Show"]}]},"dfp_adslot4v2":{"abtest_partition":[{"var":"agent_id"},"dfp_adslot4v2",4294967295,"1_external"]},"DFP_als_home":{"abtest_partition":[{"var":"agent_id"},"DFP_als_home",4294967295,"1_als"]},"DFP_als":{"abtest_partition":[{"var":"agent_id"},"DFP_als",4294967295,"1_als"]},"DFP_amzn":{"abtest_partition":[{"var":"agent_id"},"DFP_amzn",42949672,"0_control",429496729,"0_control",472446402,"1_amzn_fast_fetch",515396075,"2_adslot_priority",901943131,"2_adslot_priority",944892804,"3_no_mnet"]},"dfp_messaging_flexframe_ctr":{"abtest_partition":[{"var":"agent_id"},"dfp_messaging_flexframe_ctr",322122546,"2_noheadnosummary",644245093,"1_msgInv_noCTA",4294967295,"0_control"]},"DFP_mt":{"abtest_partition":[{"var":"agent_id"},"DFP_mt",1932735282,"0_control",3865470565,"1_mt",4294967295,"2_hdt"]},"HOME_timesExclusive":{"abtest_partition":[{"var":"agent_id"},"HOME_timesExclusive",2147483647,"0_control",4294967295,"1_variant"]},"INBOX_individualpage_redesign":{"abtest_partition":[{"var":"agent_id"},"INBOX_individualpage_redesign",4294967295,"0_control"]},"MAPS_algorithmicOnboardingInterestCollection_0820":{"abtest_partition":[{"var":"agent_id"},"MAPS_algorithmicOnboardingInterestCollection_0820",2147483647,null,2860448218,"0_control",3577707757,"1_algo_before_newsletters",4294967295,"2_algo_after_newsletters"]},"MC_DFP_topbar_bar_anon_1019":{"abtest_partition":[{"var":"agent_id"},"MC_DFP_topbar_bar_anon_1019",4294967295,"0_control"]},"MC_DFP_topbar_bar_regi_1019":{"abtest_partition":[{"var":"agent_id"},"MC_DFP_topbar_bar_regi_1019",4294967295,"0_control"]},"MKT_dfp_hd_paywall_zip":{"abtest_partition":[{"var":"agent_id"},"MKT_dfp_hd_paywall_zip",2147483647,"0_control",4294967295,"1_zip"]},"MKT_dfp_intl_pricing_low_conv":{"abtest_partition":[{"var":"agent_id"},"MKT_dfp_intl_pricing_low_conv",1431655764,"0_control",2863311530,"1_25cents",4294967295,"2_50cents"]},"MKT_dfp_intl_pricing_med_conv":{"abtest_partition":[{"var":"agent_id"},"MKT_dfp_intl_pricing_med_conv",1431655764,"0_control",2863311530,"1_50cents",4294967295,"2_75cents"]},"MKT_DFP_ods":{"abtest_partition":[{"var":"agent_id"},"MKT_DFP_ods",214748364,"0_control",2147483647,"1_test",4294967295,"2_test"]},"MKT_first_party_data_survey_regi_dock":{"abtest_partition":[{"var":"agent_id"},"MKT_first_party_data_survey_regi_dock",4209067949,"0_control",4252017622,"1_survey",4294967295,"0_control"]},"MKT_first_party_data_survey_regi_inline":{"abtest_partition":[{"var":"agent_id"},"MKT_first_party_data_survey_regi_inline",4080218930,"0_control",4294967295,"1_survey"]},"MKT_first_party_data_survey_subs_dock":{"abtest_partition":[{"var":"agent_id"},"MKT_first_party_data_survey_subs_dock",3435973836,"0_control",3478923509,"1_survey",4294967295,"0_control"]},"MKT_first_party_data_survey_subs_inline":{"abtest_partition":[{"var":"agent_id"},"MKT_first_party_data_survey_subs_inline",4080218930,"0_control",4294967295,"1_survey"]},"MKT_first_party_data_survey":{"abtest_partition":[{"var":"agent_id"},"MKT_first_party_data_survey",3865470565,"0_control",4294967295,"1_survey"]},"MKT_intl_price_exp":{"abtest_partition":[{"var":"agent_id"},"MKT_intl_price_exp",2147483647,"0_control",4294967295,"1_monthly_exp"]},"MKT_not_ready_to_sub_survey":{"abtest_partition":[{"var":"agent_id"},"MKT_not_ready_to_sub_survey",3865470565,"0_control",4294967295,"1_survey"]},"MKT_timeout_pw_0520":{"abtest_partition":[{"var":"agent_id"},"MKT_timeout_pw_0520",4294967295,"1_noreauth"]},"MKT_timeout_pw_intl_0620":{"abtest_partition":[{"var":"agent_id"},"MKT_timeout_pw_intl_0620",4294967295,"1_noreauth"]},"SA_Referral_DFP_April2020_Test":{"abtest_partition":[{"var":"agent_id"},"SA_Referral_DFP_April2020_Test",2147483647,"1_yellow_evergreen",4294967295,"2_yellow_moment"]},"SA_Referral_iframe_0520":{"abtest_partition":[{"var":"agent_id"},"SA_Referral_iframe_0520",4294967295,"1_useiframe"]},"SEARCH_FACET_DROPDOWN":{"abtest_partition":[{"var":"agent_id"},"SEARCH_FACET_DROPDOWN",2147483647,"0_FACET_MULTI_SELECT",4294967295,"1_DYNAMIC_FACET_SELECT"]},"STORY_intentional_links_v1":{"abtest_partition":[{"var":"agent_id"},"STORY_intentional_links_v1",4294967295,"0_control"]},"STORY_topical_recirc":{"abtest_partition":[{"var":"agent_id"},"STORY_topical_recirc",2147483647,"0_control",4294967295,"1_variant"]},"STYLN_coronavirus_briefing_alerts":{"abtest_partition":[{"var":"agent_id"},"STYLN_coronavirus_briefing_alerts",1073741823,"control",3221225471,"variant",3578996247,"control",4294967295,"variant"]},"STYLN_daily_question_block":{"abtest_partition":[{"var":"agent_id"},"STYLN_daily_question_block",644245093,"0_control",1288490188,"1_variant"]},"STYLN_elections_alerts":{"abtest_partition":[{"var":"agent_id"},"STYLN_elections_alerts",1073741823,"0_control",2147483647,"1_elections_alerts"]},"STYLN_elections_notifications":{"abtest_partition":[{"var":"agent_id"},"STYLN_elections_notifications",214748364,"0_control",4294967295,"1_elections_notifications"]},"STYLN_embedded_hub":{"abtest_partition":[{"var":"agent_id"},"STYLN_embedded_hub",3865470565,"0_control",4080218930,"1_modal",4294967295,"2_footer"]},"STYLN_feedback_form":{"abtest_partition":[{"var":"agent_id"},"STYLN_feedback_form",3006477106,"0_control_feedback_form",4294967295,"1_feedback_form"]},"STYLN_fr_recirc_quantity_desktop":{"abtest_partition":[{"var":"agent_id"},"STYLN_fr_recirc_quantity_desktop",1073741823,"0_control_fr_recirc_quantity_desktop",2147483647,"1_fr_recirc_quantity_desktop",3221225471,"2_fr_recirc_quantity_desktop",4294967295,"3_fr_recirc_quantity_desktop"]},"STYLN_fr_storylines_recirc":{"abtest_partition":[{"var":"agent_id"},"STYLN_fr_storylines_recirc",42949672,"0_control",429496729,null,472446402,"1_variant",858993458,null]},"STYLN_homepage_service_module":{"abtest_partition":[{"var":"agent_id"},"STYLN_homepage_service_module",85899345,"show",171798691,"hide"]},"STYLN_lb_newposts":{"abtest_partition":[{"var":"agent_id"},"STYLN_lb_newposts",4080218930,"0_control",4294967295,"1_lb_newposts"]},"STYLN_live_conventions_push":{"abtest_partition":[{"var":"agent_id"},"STYLN_live_conventions_push",429496729,"0_hide",1503238553,"1_show",1687492650,"0_hide",2147483647,"1_show"]},"STYLN_live_covid_markets_push":{"abtest_partition":[{"var":"agent_id"},"STYLN_live_covid_markets_push",429496729,"0_hide",1503238553,"1_show"]},"STYLN_live_newupdates":{"abtest_partition":[{"var":"agent_id"},"STYLN_live_newupdates",214748364,"control",4294967295,"variant"]},"STYLN_live_updates":{"abtest_partition":[{"var":"agent_id"},"STYLN_live_updates",214748364,"0_control",429496729,"2_live_updates",4294967295,"1_live_updates"]},"STYLN_liveblog_email":{"abtest_partition":[{"var":"agent_id"},"STYLN_liveblog_email",2147483647,"0_control",4294967295,"1_signup"]},"STYLN_pharmacy_components":{"abtest_partition":[{"var":"agent_id"},"STYLN_pharmacy_components",4080218930,"show",4294967295,"hide"]},"STYLN_remove_relatedlinks":{"abtest_partition":[{"var":"agent_id"},"STYLN_remove_relatedlinks",4252017622,"0_control_STYLN_remove_relatedlinks",4294967295,"1_remove_relatedlinks"]},"vi-ads-et":{"abtest_partition":[{"var":"agent_id"},"vi-ads-et",257698037,"2_remainder"]}}}]); })();;(function () { var _f=function(e){var r=function(){var r=e.url;try{r+=window.location.search.slice(1).split("&").reduce(function(e,r){return"ip-override"===r.split("=")[0]?"?"+r:e},"")}catch(e){console.warn(e)}var n=new XMLHttpRequest;for(var t in n.withCredentials=!0,n.open("POST",r,!0),n.setRequestHeader("Content-Type","application/json"),e.headers)n.setRequestHeader(t,e.headers[t]);return n.send(e.body),n};window.userXhrObject=r(),window.userXhrRefresh=function(){return window.userXhrObject=r(),window.userXhrObject}};;_f.apply(null, [{"url":"https://samizdat-graphql.nytimes3xbfgragh.onion/graphql/v2","body":"{\"operationName\":\"UserQuery\",\"variables\":{},\"query\":\"   query UserQuery {     user {       __typename       profile {         displayName         email       }       userInfo {         regiId         entitlements         demographics {           emailSubscriptions           wat           bundleSubscriptions {             bundle             inGrace             promotion             source           }         }       }       subscriptionDetails {         graceStartDate         graceEndDate         isFreeTrial         hasQueuedSub         startDate         endDate         status         entitlements       }     }   } \"}","headers":{"nyt-app-type":"project-vi","nyt-app-version":"0.0.5","nyt-token":"MIIBIjANBgkqhkiG9w0BAQEFAAOCAQ8AMIIBCgKCAQEAs+/oUCTBmD/cLdmcecrnBMHiU/pxQCn2DDyaPKUOXxi4p0uUSZQzsuq1pJ1m5z1i0YGPd1U1OeGHAChWtqoxC7bFMCXcwnE1oyui9G1uobgpm1GdhtwkR7ta7akVTcsF8zxiXx7DNXIPd2nIJFH83rmkZueKrC4JVaNzjvD+Z03piLn5bHWU6+w+rA+kyJtGgZNTXKyPh6EC6o5N+rknNMG5+CdTq35p8f99WjFawSvYgP9V64kgckbTbtdJ6YhVP58TnuYgr12urtwnIqWP9KSJ1e5vmgf3tunMqWNm6+AnsqNj8mCLdCuc5cEB74CwUeQcP2HQQmbCddBy2y0mEwIDAQAB"}}]); })();;(function () { var registry=window._interactiveRegistry={};function getId(t){for(;(t=t.parentElement)&&!t.matches("[data-sourceid].interactive-body"););return t?t.getAttribute("data-sourceid"):null}window.registerInteractive=function(t){var e={_subs:{cleanup:[],remount:[]},id:t,on:function(t,r){return this._subs[t].push(r),e}};registry[t]=e},window.getInteractiveBridge=function(t){var e="string"==typeof t?t:getId(t);return registry[e]}; })();;(function () { function swgDataLayer(e){return!!window.dataLayer&&((window.dataLayer=window.dataLayer||[]).push({event:"impression",module:e}),!0)}function checkSwgOptOut(){if(!window.localStorage)return!1;var e=window.localStorage.getItem("nyt-swgOptOut");if(!e)return!1;var t=parseInt(e,10);return((new Date).getTime()-t)/864e5<1||(window.localStorage.removeItem("nyt-swgOptOut"),!1)}function swgDeferredAccount(e,t){return e.completeDeferredAccountCreation({entitlements:t,consent:!1}).then(function(e){var t=vi.env.AUTH_HOST+"/svc/account/auth/v1/swg-dal-web",n=e.purchaseData.raw.data?e.purchaseData.raw.data:e.purchaseData.raw,o=JSON.parse(n),a={package_name:o.packageName,product_id:o.productId,purchase_token:o.purchaseToken,google_id_token:e.userData.idToken,google_user_email:e.userData.email,google_user_id:e.userData.id,google_user_name:e.userData.name},r=new XMLHttpRequest;r.withCredentials=!0,r.open("POST",t,!0),r.setRequestHeader("Content-Type","application/json"),r.send(JSON.stringify(a)),r.onload=function(){200===r.status?(swgDataLayer({name:"swg",context:"Deferred",label:"Seamless Signin",region:"swg-modal"}),e.complete().then(function(){window.location.reload(!0)})):(e.complete(),window.location=encodeURI(vi.env.AUTH_HOST+"/get-started/swg-link?redirect="+window.location.href))}}).catch(function(){return!!window.localStorage&&(!window.localStorage.getItem("nyt-swgOptOut")&&(window.localStorage.setItem("nyt-swgOptOut",(new Date).getTime()),!0))}),!0}function hasLogoutCookie(){var e=document.cookie.match("(^|;) ?nyt-auth-action=([^;]*)(;|$)")||null;return e&&"logout"===e[2]}function loginWithGoogle(){return"undefined"!=typeof window&&(-1===document.cookie.indexOf("NYT-S")&&(!0!==checkSwgOptOut()&&(!!window.SWG&&((window.SWG=window.SWG||[]).push(function(e){return e.init(vi.env.SWG_PUBLICATION_ID),!0!==hasLogoutCookie()&&(e.getEntitlements().then(function(t){if(void 0===t||!t.raw)return!1;window.SwGEntitlement=!0;var n={entitlements_token:t.raw};return window.swgUserInfoXhrObject.withCredentials=!0,window.swgUserInfoXhrObject.open("POST",vi.env.AUTH_HOST+"/svc/account/auth/v1/login-swg-web",!0),window.swgUserInfoXhrObject.setRequestHeader("Content-Type","application/json"),window.swgUserInfoXhrObject.send(JSON.stringify(n)),window.swgUserInfoXhrObject.onload=function(){switch(window.swgUserInfoXhrObject.status){case 200:return swgDataLayer({name:"swg",context:"Seamless",label:"Seamless Signin",region:"login"}),window.location.reload(!0),!0;case 412:return swgDeferredAccount(e,t);default:return!1}},t}).catch(function(){return!1}),!0)}),!0))))}var _f=function(){if(window.swgUserInfoXhrObject.checkSwgResponse=!1,window.SwGEntitlement=!1,-1===document.cookie.indexOf("NYT-S")){var e=document.createElement("script");e.src="https://news.google.com/swg/js/v1/swg.js",e.setAttribute("subscriptions-control","manual"),e.setAttribute("async",!0),e.onload=function(){loginWithGoogle()},document.getElementsByTagName("head")[0].appendChild(e)}};;_f.apply(null, []); })();
    </script>
    <script>!function(e){function t(t){for(var n,a,i=t[0],l=t[1],f=t[2],c=0,s=[];c<i.length;c++)a=i[c],Object.prototype.hasOwnProperty.call(o,a)&&o[a]&&s.push(o[a][0]),o[a]=0;for(n in l)Object.prototype.hasOwnProperty.call(l,n)&&(e[n]=l[n]);for(p&&p(t);s.length;)s.shift()();return u.push.apply(u,f||[]),r()}function r(){for(var e,t=0;t<u.length;t++){for(var r=u[t],n=!0,i=1;i<r.length;i++){var l=r[i];0!==o[l]&&(n=!1)}n&&(u.splice(t--,1),e=a(a.s=r[0]))}return e}var n={},o={54:0},u=[];function a(t){if(n[t])return n[t].exports;var r=n[t]={i:t,l:!1,exports:{}};return e[t].call(r.exports,r,r.exports,a),r.l=!0,r.exports}a.m=e,a.c=n,a.d=function(e,t,r){a.o(e,t)||Object.defineProperty(e,t,{enumerable:!0,get:r})},a.r=function(e){"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},a.t=function(e,t){if(1&t&&(e=a(e)),8&t)return e;if(4&t&&"object"==typeof e&&e&&e.__esModule)return e;var r=Object.create(null);if(a.r(r),Object.defineProperty(r,"default",{enumerable:!0,value:e}),2&t&&"string"!=typeof e)for(var n in e)a.d(r,n,function(t){return e[t]}.bind(null,n));return r},a.n=function(e){var t=e&&e.__esModule?function(){return e.default}:function(){return e};return a.d(t,"a",t),t},a.o=function(e,t){return Object.prototype.hasOwnProperty.call(e,t)},a.p="/vi-assets/static-assets/";var i=window.webpackJsonp=window.webpackJsonp||[],l=i.push.bind(i);i.push=t,i=i.slice();for(var f=0;f<i.length;f++)t(i[f]);var p=l;r()}([]);
//# sourceMappingURL=runtime~adslot-cf656654d46f9fe3f35c.js.map</script>
    <script async src="/vi-assets/static-assets/adslot-6dd19106cc066b3272a7.js"></script>
    <script data-rh="true" type="application/ld+json">{"@context":"http://schema.org","@type":"NewsArticle","description":"A discussion moderated by Siddhartha Mukherjee.","image":[{"@context":"http://schema.org","@type":"ImageObject","url":"https://static01.graylady3jvrrxbe.onion/images/2020/06/14/magazine/14mag-roundtable/14mag-roundtable-videoSixteenByNineJumbo1600.jpg","height":900,"width":1600},{"@context":"http://schema.org","@type":"ImageObject","url":"https://static01.graylady3jvrrxbe.onion/images/2020/06/14/magazine/14mag-roundtable/14mag-roundtable-superJumbo-v2.jpg","height":2047,"width":2048},{"@context":"http://schema.org","@type":"ImageObject","url":"https://static01.graylady3jvrrxbe.onion/images/2020/06/14/magazine/14mag-roundtable/14mag-roundtable-mediumSquareAt3X-v2.jpg","height":1799,"width":1800}],"mainEntityOfPage":"https://www.nytimes3xbfgragh.onion/interactive/2020/06/09/magazine/covid-vaccine.html","url":"https://www.nytimes3xbfgragh.onion/interactive/2020/06/09/magazine/covid-vaccine.html","inLanguage":"en-US","author":{"@id":"https://www.nytimes3xbfgragh.onion/#publisher"},"dateModified":"2020-06-14T04:24:43.312Z","datePublished":"2020-06-09T09:00:02.000Z","headline":"Can a Vaccine for Covid-19 Be Developed in Record Time?","publisher":{"@id":"https://www.nytimes3xbfgragh.onion/#publisher"},"copyrightHolder":{"@id":"https://www.nytimes3xbfgragh.onion/#publisher"},"sourceOrganization":{"@id":"https://www.nytimes3xbfgragh.onion/#publisher"},"copyrightYear":2020,"isAccessibleForFree":false,"hasPart":{"@type":"WebPageElement","isAccessibleForFree":false,"cssSelector":".meteredContent"},"isPartOf":{"@type":["CreativeWork","Product"],"name":"The New York Times","productID":"nytimes3xbfgragh.onion:basic"}}</script><script data-rh="true" type="application/ld+json">{"@context":"http://schema.org","@type":"NewsMediaOrganization","name":"The New York Times","logo":{"@context":"http://schema.org","@type":"ImageObject","url":"https://static01.graylady3jvrrxbe.onion/images/misc/NYT_logo_rss_250x40.png","height":40,"width":250},"url":"https://www.nytimes3xbfgragh.onion/","@id":"https://www.nytimes3xbfgragh.onion/#publisher","diversityPolicy":"https://www.nytco.com/diversity-and-inclusion-at-the-new-york-times/","ethicsPolicy":"https://www.nytco.com/who-we-are/culture/standards-and-ethics/","masthead":"https://www.nytimes3xbfgragh.onion/interactive/2019/admin/the-new-york-times-masthead.html","foundingDate":"1851-09-18","sameAs":"https://en.wikipedia.org/wiki/The_New_York_Times"}</script>

    
    
    <script id="adslot-config">
      var AdSlot4=function(){"use strict";function E(n,o,e){var i=document.getElementsByTagName("head")[0],t=document.createElement("script");o&&(t.onload=o),e&&(t.onerror=e),t.src=n,t.async=!0,i.appendChild(t)}function Y(n){var o=document.cookie.match(new RegExp("".concat(n,"=([^;]+)")));return o?o[1]:""}var n={adConfigPosition:5,full:"f",restrictedDataProcessing:"r",nonPersonalized:"n",collapsed:"c",adLuce:"a",socrates:"s"};function k(){return(Y("nyt-purr")[n.adConfigPosition]||"")===n.full}var a=[{id:"dfp-ad-top",sizes:{large:[[728,90],[970,90],[970,250]],medium:[[728,90],[300,250]],small:[[300,250],[300,420]]}},{id:"top",sizes:{large:[[728,90],[970,90],[970,250]],medium:[[728,90],[300,250]],small:[[300,250],[300,420]]}}];return function(){var _=window.AdSlot4||{};_.cmd=_.cmd||[];var T=!1;if(_.loadScripts)return _;var e,t=window.innerWidth;function d(i){_.events.subscribe({name:"AdDefined",scope:"all",callback:function(n){var e,o=[-1];n.sizes.forEach(function(n){n[0]<t&&n[0]>o[0]&&(o=[n])}),o[0][1]&&window.apstag.fetchBids({slots:[{slotID:n.truePosition||n.id,slotName:"".concat(n.truePosition||n.id,"_").concat(i,"_web"),sizes:(e=o[0][1],Array.isArray(e)?[[300,250],[728,90],[970,90],[970,250]].filter(function(o){return e.some(function(n){return n[0]===o[0]&&n[1]===o[1]})}):(console.warn("filterSizes() did not receive an array"),[]))}]},function(){window.googletag.cmd.push(function(){window.apstag.setDisplayBids()})})}})}function z(n,o){"art, oak"!==n&&"art,oak"!==n||(n="art"),_.cmd.push(function(){var i,t;o&&window.apstag.fetchBids({slots:(i=e,t=n,a.reduce(function(n,o){var e={slotID:o.id,slotName:"".concat(o.id,"_").concat(t,"_web"),sizes:o.sizes[i]};return n.push(e),n},[]))},function(){window.googletag.cmd.push(function(){window.apstag.setDisplayBids()})}),d(n)})}function N(){"undefined"!=typeof window&&window.document&&window.document.createElement&&(window.grumi={key:"b3960cc6-bfd2-4adc-910c-6e917e8a6a0e"});E("//rumcdn.geoedge.be/b3960cc6-bfd2-4adc-910c-6e917e8a6a0e/grumi-ip.js",function(){},function(){console.error("failed to load geo edge script in ad experience ab test")})}return t<=600?e="small":t<=740?e="medium":740<t&&(e="large"),_.loadScripts=function(n){var o,e,i,t,d,a,c,r=n||{},s=r.loadMnet,u=void 0===s||s,w=r.loadAmazon,l=void 0===w||w,p=r.setFastFetch,f=void 0!==p&&p,m=r.loadBait,g=void 0===m||m,v=r.section,h=void 0===v?"none":v,y=r.pageViewId,b=void 0===y?"":y,B=r.pageType,A=void 0===B?"":B,x=r.mwtVariant,D=void 0===x?"":x;T||("1"!==Y("nyt-gdpr")&&(o=document.referrer||"",!((e=/([a-zA-Z0-9_\-.]+)(@|%40)([a-zA-Z0-9_\-.]+).([a-zA-Z]{2,5})/).test(o)||e.test(window.location.href)))&&k()&&("2_vendorB"===D?(N(),window.NYTD&&window.NYTD.Abra&&window.NYTD.Abra.reportExposure("dfp_MWTest")):"1_vendorA"===D?(E("//d1ow86vuqua8fi.cloudfront.net/script.js",function(){},function(){console.error("failed to load clean io script in ad experience ab test")}),window.NYTD&&window.NYTD.Abra&&window.NYTD.Abra.reportExposure("dfp_MWTest")):"0_control"===D&&window.NYTD.Abra.reportExposure("dfp_MWTest"),!u||window.advBidxc&&window.advBidxc.isLoaded||(a=b,c="8CU2553YN",window.innerWidth<740&&(c="8CULO58R6"),E("https://contextual.media.net/bidexchange.js?cid=".concat(c,"&dn=").concat("www.nytimes3xbfgragh.onion","&https=1"),function(){window.advBidxc&&window.advBidxc.isLoaded||console.warn("Media.net not loading properly")},function(){_.cmd.push(function(){_.events.publish({name:"BidderError",value:{type:"Mnet"}})})}),window.advBidxc=window.advBidxc||{},window.advBidxc.renderAd=function(){},window.advBidxc.startTime=(new Date).getTime(),window.advBidxc.customerId={mediaNetCID:c},window.advBidxc.misc={isGptDisabled:1},a&&(window.advBidxc.misc.keywords=a)),l&&!window.apstag&&(i=h,t=A,d=f,function(e,i){function n(n,o){i[e]._Q.push([n,o])}i[e]||(i[e]={init:function(){n("i",arguments)},fetchBids:function(){n("f",arguments)},setDisplayBids:function(){},targetingKeys:function(){return[]},_Q:[]})}("apstag",window),E("//c.amazon-adsystem.com/aax2/apstag.js",function(){window.apstag||console.warn("A9 not loading properly")},function(){_.cmd.push(function(){_.events.publish({name:"BidderError",value:{type:"A9"}})})}),window.apstag.init({pubID:"3030",adServer:"googletag",params:{si_section:i}}),z(t,d))),g&&E("https://nytimes3xbfgragh.onion/ads/google/adsbygoogle.js",function(){},function(){_.cmd.push(function(){_.events.publish({name:"AdEmpty",value:{type:"AdBlockOn"}})})}),T=!0)},window.AdSlot4=_}()}();
      AdSlot4.loadScripts({
        loadMnet: window.NYTD.Abra('medianet_interactive_toggle') !== '1_block',
        loadAmazon: window.NYTD.Abra('amazon_interactive_toggle') !== '1_block',
        section: 'magazine',
        pageType: 'int',
        pageViewId: window.NYTD.PageViewId.current,
      });
      (function () { var _f=function(e){var o=performance.navigation&&1===performance.navigation.type;function n(){return window.matchMedia("(max-width: 739px)").matches}function r(e){var r,t,i,d,a,w,p=function(){var e=window.userXhrObject&&""!==window.userXhrObject.responseText&&JSON.parse(window.userXhrObject.responseText).data||null,o=null;return e&&e.user&&e.user.userInfo&&(o=e.user.userInfo.demographics),o}();return p&&(t=e,d=(r=p)&&r.emailSubscriptions,(a=r&&r.bundleSubscriptions)&&t&&(d&&d.length&&(t.em=d.toString().toLowerCase()),r.wat&&(t.wat=r.wat.toLowerCase()),a&&a.length&&a[0].bundle&&((i=a[0]).source&&(t.subsrc=i.source.toLowerCase()),i.promotion&&(t.subprm=i.promotion),i.in_grace&&(t.grace=i.in_grace.toString()))),e=t),n()?(e.prop="mnyt",e.plat="mweb",e.ver="mvi"):(e.prop="nyt",e.plat="web",e.ver="vi"),"/es/"===window.location.pathname.substring(0,4)&&(e.prop="esnyt",e.edn="es",n()&&(e.prop="mesnyt")),"hp"===e.typ&&(document.referrer&&(e.topref=document.referrer),o&&(e.refresh="manual")),e.abra_dfp=(w=window.NYTD&&window.NYTD.Abra)&&w.config?Object.keys(w.config).reduce(function(e,o){const n=o.toLowerCase(),r=w.getAbraSync&&w.getAbraSync(o)||{};if((n.indexOf("dfp")>-1||o.indexOf("redbird")>-1)&&r.variant){var t=n+"_"+r.variant.toLowerCase();e.push(t)}return e},[]):"",e.page_view_id=window.NYTD.PageViewId&&window.NYTD.PageViewId.current,e.sov=function(){const e=(Math.floor(4*Math.random())+1).toString();return window.sov?window.sov:(window.sov=e,window.sov)}(),e}var t=e||{},i=t.adTargeting||{},d=t.adUnitPath||"/29390238/nyt/homepage",a=t.offset||400,w=t.hideTopAd||n(),p=t.lockdownAds||!1,s=t.sizeMapping||{top:[[970,["fluid",[728,90],[970,90],[970,250],[1605,300]]],[728,["fluid",[728,90],[1605,300]]],[0,[]]],fp1:[[0,[[195,250],[215,270]]]],fp2:[[0,[[195,250],[215,270]]]],fp3:[[0,[[195,250],[215,270]]]],feat1:[[0,["fluid"]]],feat2:[[0,["fluid"]]],feat3:[[0,["fluid"]]],feat4:[[0,["fluid"]]],interstitial:[[0,[[1,1],[640,480]]]],mktg:[[1020,[300,250]],[0,[]]],pencil:[[728,[[336,46]],[0,[]]]],pp_edpick:[[0,["fluid"]]],pp_morein:[[0,["fluid"],[210,218]]],ribbon:[[0,["fluid"]]],sponsor:[[765,[150,50]],[0,[320,25]]],supplemental:[[1020,[[300,250],[300,600]]],[0,[]]],chat:[[0,[[300,250],[300,420]]]],column:[[0,[[300,250],[300,420]]]],default:[[970,["fluid",[728,90],[970,90],[970,250],[1605,300]]],[728,["fluid",[728,90],[300,250],[1605,300]]],[0,["fluid",[300,250],[300,420]]]]},u=t.dfpToggleName||"dfp_home_toggle",f=t.lazyApi||{};window.AdSlot4=window.AdSlot4||{},window.AdSlot4.cmd=window.AdSlot4.cmd||[],window.AdSlot4.cmd.push(function(){var e,o,n;window.AdSlot4.init({adTargeting:r(i),adUnitPath:d,sizeMapping:s,offset:a,haltDFP:"1_block"===window.NYTD.Abra(u),hideTopAd:w,lockdownAds:p,lazyApi:(e=f,o=e&&e.fetch&&e.render?e:{},n=window.NYTD&&window.NYTD.Abra&&window.NYTD.Abra("dfp_lazy5"),n&&e[n]&&(o=e[n],window.NYTD.Abra.reportExposure("dfp_lazy5")),o)}),window.NYTD.Abra.reportExposure("dfp_adslot4v2")})};;_f.apply(null, [{"adTargeting":{"vp":"small","als_test":"1599799778608","prop":"mnyt","plat":"mweb","edn":"us","brandsensitive":"true","des":"clinicaltrials,vaccinationandimmunization,coronavirus2019ncov,drugspharmaceuticals,coronavirusreopenings","coll":"thenewyorktimesmagazine,health","artlen":"short","ledemedsz":"none","template":"interactive","typ":"int","section":"magazine","si_section":"magazine","id":"100000007180386","pt":"nt13,nt17,nt19,nt20,nt5,nt7,pt15","gscat":"neg_citi_aa,neg_ibmtest,neg_capitalone,neg_chanel,neg_virus,gs_health,neg_bofa,neg_ibm,neg_fcli,gs_health_misc,gs_covid19,neg_mastercard,gs_science,neg_hearts,gs_science_misc,gv_safe,gs_t","mt":"MT5","ver":"mvi","sov":"2","test":"projectvi","ref":"","refdom":"","abra_dfp":"","gpt-beta":"vqwdtftx"},"adUnitPath":"/29390238/nyt/magazine","dfpToggleName":"dfp_interactive_toggle"}]); })();
    </script>
  
  <script id="als-svc">
    (function () {
      if (!window.NYTD || !window.NYTD.Abra) {
        return;
      }
      var alsVariant = window.NYTD.Abra('DFP_als');
      if (alsVariant != null && alsVariant.match(/(0_control|1_als)/)) {
        window.NYTD.Abra.reportExposure('DFP_als');
      }
      if (window.NYTD.Abra('DFP_als') === '1_als') {
    (function () { var _f=function(e){let t=()=>{var e=new Date,t=e.getFullYear();return e.getMonth()<9&&(t+="0"),t+=e.getMonth()+1,e.getDate()<10&&(t+="0"),t+=e.getDate(),e.getHours()<10&&(t+="0"),t+=e.getHours(),e.getMinutes()<10&&(t+="0"),t+=e.getMinutes(),e.getSeconds()<10&&(t+="0"),t+e.getSeconds()};window.googletag=window.googletag||{},googletag.cmd=googletag.cmd||[];let a=new URLSearchParams(location.search).get("alice_rules_test");var n,o=new XMLHttpRequest,l=window.vi.env.ALS_URL,i=document.querySelector('[name="nyt_uri"]');if("/"===location.pathname){var s=encodeURIComponent("https://www.nytimes3xbfgragh.onion/pages/index.html");n="uri="+s}else if(void 0===i||""===i||null===i){var r=e||location.protocol+"//"+location.hostname+location.pathname;n="url="+encodeURIComponent(r)}else{s=encodeURIComponent(i.content);n="uri="+s}var d=document.querySelector('[name="template"]'),g=document.querySelector('[name="prop"]'),c=document.querySelector('[name="plat"]'),u=null==d||null==d.content?"":d.content,m=null==g||null==g.content?"nyt":g.content,w=null==c||null==c.content?"web":c.content;window.innerWidth<740&&(m="mnyt",w="mweb");var _=window.localStorage.getItem("als_test_clientside"),p=null;window.googletag.cmd.push(function(){var e=_&&0!==_.length?_:"empty_empty_empty_empty_empty_"+t(),a=p||e;googletag.pubads().setTargeting("als_test_clientside",a)});var b=window.localStorage.getItem("mktg"),v=null;window.googletag.cmd.push(function(){var e=v||b;e&&googletag.pubads().setTargeting("mktg",e)});var f=window.localStorage.getItem("bt"),y=null;window.googletag.cmd.push(function(){var e=y||f;e&&googletag.pubads().setTargeting("bt",e)});var h=window.localStorage.getItem("sub"),U=null;window.googletag.cmd.push(function(){var e=U||h;e&&googletag.pubads().setTargeting("sub",e)}),n=null==a?n:n+"&alice_rules_test="+a,o.open("GET",l+"/als?"+n+"&typ="+u+"&prop="+m+"&plat="+w,!0),o.withCredentials=!0,o.send(),o.onerror=function(){var e="reqfailed_reqfailed_reqfailed_reqfailed_reqfailed_"+t();p=e,window.googletag.cmd.push(function(){googletag.pubads().setTargeting("als_test_clientside",e)});var a={event:"impression",module:{name:"alice-timing",context:"script-load",label:"alice-error-reqfail-"+n}};(window.dataLayer=window.dataLayer||[]).push(a)},o.onreadystatechange=function(){if(4===o.readyState)if(200===o.status){var e=new Date,a=JSON.parse(o.responseText);p=a.als_test_clientside&&0!==a.als_test_clientside.length?a.als_test_clientside:"bou_bou_bou_bou_bou_"+t(),void 0!==a.User&&(void 0!==a.User.mktg&&(v=a.User.mktg,window.localStorage.setItem("mktg",a.User.mktg)),void 0!==a.User.bt&&(y=a.User.bt,window.localStorage.setItem("bt",a.User.bt)),void 0!==a.User.sub&&(U=a.User.sub,window.localStorage.setItem("sub",a.User.sub))),window.googletag.cmd.push(function(){if(a.als_test_clientside&&0!==a.als_test_clientside.length){var n=(new Date).getTime()-e.getTime()+"_server_server_server_server_20200326152254";googletag.pubads().setTargeting("als_test_clientside",n),window.localStorage.setItem("als_test_clientside","ls-"+a.als_test_clientside)}else{var o=void 0===a.als_test_clientside?"undefined_undefined_undefined_undefined_undefined_"+t():"blank_blank_blank_blank_blank_"+t();googletag.pubads().setTargeting("als_test_clientside",o);var l={event:"impression",module:{name:"alice-timing",context:"script-load",label:"alice-error-test-client-undefined"}};(window.dataLayer=window.dataLayer||[]).push(l)}if(void 0!==a.User){if(v)googletag.pubads().setTargeting("mktg",v);else{l={event:"impression",module:{name:"alice-timing",context:"script-load",label:"alice-error-mktg-undefined"}};(window.dataLayer=window.dataLayer||[]).push(l)}if(y)googletag.pubads().setTargeting("bt",y);else{l={event:"impression",module:{name:"alice-timing",context:"script-load",label:"alice-error-bt-undefined"}};(window.dataLayer=window.dataLayer||[]).push(l)}if(U)googletag.pubads().setTargeting("sub",U);else{l={event:"impression",module:{name:"alice-timing",context:"script-load",label:"alice-error-sub-undefined"}};(window.dataLayer=window.dataLayer||[]).push(l)}(a.User.lucidC1||a.User.lucidC2||a.User.lucidC3||a.User.lucidC4||a.User.lucidC5)&&dataLayer.push({event:"lucidtest",c1_val:a.User.lucidC1,c2_val:a.User.lucidC2,c3_val:a.User.lucidC3,c4_val:a.User.lucidC4,c5_val:a.User.lucidC5})}else{l={event:"impression",module:{name:"alice-timing",context:"script-load",label:"alice-error-user-undefined"}};(window.dataLayer=window.dataLayer||[]).push(l)}})}else{o.responseText.substring(0,40);var l="error_error_"+o.status+"_error_error_"+t();window.googletag.cmd.push(function(){googletag.pubads().setTargeting("als_test_clientside",l)});var i={event:"impression",module:{name:"alice-timing",context:"script-load",label:"alice-error-ajaxreq-"+o.status+"-"+n}};(window.dataLayer=window.dataLayer||[]).push(i)}}};;_f.apply(null, []); })();
  }
    }());
  </script>
  
  </head>
  <body>
    <div id="app"><div id="standalone-header"><div class="interactive-masthead NYTAppHideMasthead css-xuu3c2 e1suatyy0"><header class="css-1nf2dl3 e1suatyy1"><section class="css-133zg39 e1suatyy2"><div class="css-eph4ug er09x8g0"><div class="css-6n7j50"><button aria-haspopup="true" aria-expanded="false" aria-label="Sections Navigation &amp; Search" class="er09x8g1 css-1uqx5yl" data-testid="nav-button" type="button"><svg class="css-1fe7a5q" viewBox="0 0 16 16"><rect x="1" y="3" fill="#fff" width="14" height="2"></rect><rect x="1" y="7" fill="#fff" width="14" height="2"></rect><rect x="1" y="11" fill="#fff" width="14" height="2"></rect></svg></button></div><button id="desktop-sections-button" data-testid="desktop-section-button" aria-label="Sections Navigation" class="css-17jv7b4 er09x8g2"><span class="css-1dv1kvn">Sections</span><svg class="css-1fe7a5q" viewBox="0 0 16 16"><rect x="1" y="3" fill="#fff" width="14" height="2"></rect><rect x="1" y="7" fill="#fff" width="14" height="2"></rect><rect x="1" y="11" fill="#fff" width="14" height="2"></rect></svg></button><div class="css-10488qs"><button class="css-1py22c6 ewfai8r0" data-test-id="search-button"><span class="css-1dv1kvn">SEARCH</span><svg class="css-1fe7a5q" viewBox="0 0 16 16"><path fill="#fff" d="M11.3,9.2C11.7,8.4,12,7.5,12,6.5C12,3.5,9.5,1,6.5,1S1,3.5,1,6.5S3.5,12,6.5,12c1,0,1.9-0.3,2.7-0.7l3.3,3.3c0.3,0.3,0.7,0.4,1.1,0.4s0.8-0.1,1.1-0.4c0.6-0.6,0.6-1.5,0-2.1L11.3,9.2zM6.5,10.3c-2.1,0-3.8-1.7-3.8-3.8c0-2.1,1.7-3.8,3.8-3.8c2.1,0,3.8,1.7,3.8,3.8C10.3,8.6,8.6,10.3,6.5,10.3z"></path></svg></button></div><a class="css-1f8er69" href="#site-content">Skip to content</a><a class="css-1f8er69" href="#site-index">Skip to site index</a></div><div class="css-10698na e1huz5gh0"><a href="/section/magazine" aria-label="New York Times Magazine Logo, link to Magazine section" class="css-1jdplvu e1huz5gh2"><svg viewBox="0 0 260 23" fill="#fff"><path d="M13 2.6C13 .7 11.1.1 9.6.2v.4c.9.1 1.6.3 1.6.8 0 .4-.2.8-1 .8-.7 0-2-.4-3-.7C6 1.1 4.7.7 3.8.7 2 .7.6 1.9.6 3.5c0 1.4.9 2 1.4 2.2l.2-.3c-.3-.2-.5-.4-.5-.9 0-.4.4-1 1.2-1 .5 0 .9.1 1.5.2s1.2.3 2 .5c1.2.4 2.3.7 3.3.8v2.6L8.4 8.7V9l1.3 1.1v3.7c-.7.4-1.4.5-2.2.5C6.2 14.2 4.9 14 4 13l3.7-1.8V5.1L3 7.1c.5-1 1.2-1.9 2.2-2.5L5 4.3c-2.6.7-5 3-5 6.1 0 3.6 3 6.2 6.6 6.2 3.9 0 6.2-2.8 6.2-5.9h-.4c-.6 1.1-1.3 2.2-2.3 2.7V9.9l1.4-1.1v-.1l-1.4-1.1V4.9c1.4.2 2.9-.6 2.9-2.3m-8.1 9.6l-1.2.6c-.7-.8-1-2-1-3.4 0-.6 0-1.2.2-1.6l2.1-1-.1 5.4zm18.4-4.8l-.8.6-2.4-2-2.6 1.9V.7h-.4l-3.4 2.4v.3c.5.2 1 .3 1 1.1V14l-1.4.9.3.4.8-.5 2.2 1.9 2.6-1.8-.3-.4-.6.5-.8-.8v-6l.9-.6L19.9 9v5c0 3.3-.9 4-2.3 4.5v.5c2.7.1 5-.9 5-5.2V8.3l.9-.7-.2-.2zm8.7 5.5l-2.3 1.8-2.5-1.7v-.9l4.5-2.8v-.1L29.6 6l-5 2.6v5.6l-1 .7.3.4 1-.7 3.1 2.3 4.3-3.5-.3-.5zm-4.8-1.3V7.7l.4-.1 1.8 2.6-2.2 1.4zm22.5-9.7c0-.3-.1-.7-.2-1h-.3c-.3.8-.6 1.1-1.3 1.1-.8 0-1.2-.5-1.6-.9h-.4l-2.6 3 .3.3.8-.9c.3.2.5.4.9.6.3.2.8.3 1.2.3v6.9l-5.2-8.7c-.4-.6-1-1.7-2.4-1.7-1.6 0-2.8 1.2-2.6 3.3l.4.1c.1-.6.4-1.1.9-1.1s.8.3 1 .7v2.8c-1.6 0-2.6.9-2.6 2.2 0 .7.4 1.8 1.5 2l.1-.3c-.2-.2-.3-.3-.3-.5 0-.4.5-.7 1-.7h.3v3.5c-1.8 0-3.2 1-3.2 2.8 0 1.8 1.5 2.7 3.1 2.6l.1-.4c-1-.1-1.4-.6-1.4-1.1 0-.7.5-1 1.1-1 .7 0 1.2.4 1.7.9l2.7-3-.3-.3-.7.8c-.8-.7-1.6-1.2-2.6-1.3V4.5l7.2 12.2h.8V4.4c1.3.1 2.6-.8 2.6-2.5m6.7 11l-2.3 1.8-2.5-1.7v-.9l4.5-2.8v-.1L54 6l-5 2.6v5.6l-1 .7.3.4 1-.7 3.1 2.3 4.3-3.5-.3-.5zm-4.8-1.3V7.7l.4-.1 1.8 2.6-2.2 1.4zm20.3-4.5l-.8.5L69.2 6l-2 1.8.9.8v6.2l-.4.2-1.9-1.1V8.5l.9-.6L64.5 6l-2.2 1.8.9.8v6.2l-.3.1-2-1.4V8.6c0-1.2-.6-1.6-1.3-2.1-.7-.4-.9-.8-.9-1.4 0-.7.7-.9.9-.9l-.1-.4c-1 0-2.7.9-2.7 2.5 0 .9.4 1.2.9 1.7.5.4.9.9.9 1.6v4.8l-1 .8.3.4.9-.6 2.6 2 2.3-1.5 2.5 1.5 4.8-3V8.3l1.2-.9-.3-.3zm16.9-4.6l-.8.6-2.2-1.9-2.9 2.4V1.4h-.5v14.2c-.3 0-.8-.2-1.4-.3V3.4c0-.9-.7-2.1-2.3-2.1-1.8 0-2.9 1.4-2.9 2.6h.5c.1-.6.5-1 .9-1 .6 0 .9.3.9 1.5v3.3c-1.5.1-2.6 1-2.6 2.3 0 .9.4 1.7 1.4 1.9l.1-.4c-.4-.2-.5-.4-.5-.6 0-.5.5-.7 1.1-.7h.4v5.4c-1.3.5-1.9 1.4-1.9 2.6 0 1.5 1.2 2.6 3 2.6 1.2 0 2.3-.2 3.4-.5.9-.2 2.3-.4 2.8-.4.7 0 1 .3 1 .8 0 .6-.3.8-.7.9l.1.4c1.5-.3 2.4-1.2 2.4-2.6s-1.3-2.1-2.8-2.1c-.8 0-2.5.2-3.6.5-1.2.3-2.5.4-2.8.4-.7 0-1.4-.4-1.4-1.2 0-.8.8-1.4 2.3-1.4.9 0 1.7.2 2.7.4 1 .2 1.9.5 2.9.5 1.3 0 2.6-.5 2.6-2.4V3.6l.9-.8-.1-.3zm-3.7 5c-.3.3-.6.5-1.1.5-.6 0-.9-.2-1.1-.5V4l.9-.7 1.3 1v3.2zm0 2.7c-.3-.2-.5-.4-1.1-.4-.6 0-.9.2-1.1.4V8.1c.1.2.5.4 1.1.4.5 0 .9-.2 1.1-.4v2.1zm0 3.8c0 .8-.5 1.6-1.4 1.6-.2 0-.7 0-.9-.1v-4.9c.2-.2.6-.4 1.1-.4.5 0 .9.2 1.1.4V14zm12.6-5.8l-3-2.3L90 8.6v5.5l-1 .7.3.4.9-.6 2.9 2.1 4.6-2.8V8.2zm-5 5.3v-6l2.4 1.6v6l-2.4-1.6zM106.5 6c-.3.3-.5.5-.9.5s-.9-.2-1-.5h-.2l-1.5 1.7-1.6-1.7-2.8 2 .3.4.8-.5.8.8V14l-1.4.9.3.4.8-.5 2.3 1.9 3.1-2.1-.3-.4-.9.6-1.1-.9V8c.7.7 1.3.9 1.9.9 1.2 0 1.9-1.5 2-2.9h-.6zm11.3 8.3l-.9.6-4.1-6.1.2-.4c.4.3.9.7 1.9.7 1.1 0 2.2-1.2 2.4-3h-.4c-.4.5-.7.8-1.3.8-.4 0-1-.3-1.4-.8h-.2l-3.1 4.8 4.1 6 3.2-2.1-.4-.5zm-5.8.3l-.7.5-.8-.8V.7h-.4l-3.4 2.4v.3c.5.2 1 .3 1 1.1V14l-1.4.9.3.4.8-.5 2.2 1.9 2.6-1.8-.2-.3zm21.8-12c0-1.9-1.9-2.5-3.4-2.4v.4c.9.1 1.6.3 1.6.8 0 .4-.2.8-1 .8-.7 0-2-.4-3-.7-1.1-.4-2.4-.8-3.3-.8-1.8 0-3.2 1.1-3.2 2.7 0 1.4.9 2 1.4 2.2l.2-.3c-.3-.2-.5-.4-.5-.9 0-.4.4-1 1.2-1 .5 0 .9.1 1.5.2s1.2.3 2 .5c1.2.4 2.3.7 3.3.8v2.6l-1.3 1.1v.3l1.3 1.1v3.7c-.7.4-1.4.5-2.2.5-1.3 0-2.6-.3-3.6-1.2l3.7-1.8V5.1l-4.6 2c.5-1 1.2-1.9 2.2-2.5l-.2-.3c-2.6.7-5 3-5 6.1 0 3.6 3 6.2 6.6 6.2 3.9 0 6.2-2.8 6.2-5.9h-.4c-.6 1.1-1.3 2.2-2.3 2.7V9.9l1.4-1.1v-.1L131 7.6V4.9c1.4.2 2.8-.6 2.8-2.3m-8.1 9.6l-1.2.6c-.7-.8-1-2-1-3.4 0-.6 0-1.2.2-1.6l2.2-.9-.2 5.3zm11.4-10.7h-.1l-1.9 1.7v.2l1.7 1.8h.2l1.9-1.7v-.2l-1.8-1.8zm3 12.8l-.9.6-.7-.7V7.9L136.9 6 134 7.9l.3.4.8-.5.7.9v5.5l-1.3.9.3.4.7-.5 2 1.8 3-2.1-.4-.4zm15.8 0l-.8.6-.8-.8V8.6l.9-.7-.2-.4-.9.6-2.3-2-2.6 1.9-2.2-1.9-2.7 1.8-1.6-1.8-2.9 2 .3.4.8-.5.8.9v5.5l-.8.7 2.4 1.9 2-1.8-.9-.8V8.5l.9-.5 1.4 1.3v5.2l-.8.7L148 17l2.2-1.8-.9-.8V8.6l.8-.5 1.5 1.3v5.1l-.7.7 2.1 1.9 3-2.1-.1-.7zm8.1-1.4l-2.3 1.8-2.5-1.7v-.9l4.5-2.8v-.1L161.6 6l-5 2.6v5.8l3.3 2.4 4.3-3.5-.2-.4zm-4.7-1.3V7.7l.4-.1 1.8 2.6-2.2 1.4zm13.2-.3l-1.9-1.4c1.1-1 1.7-2.5 1.7-3.3V6h-.3c-.2.5-.6.9-1.2.9-.7 0-1.1-.4-1.5-.9L165 8.5v3l1.6 1.3c-1.5 1.3-2 2.1-2 3 0 .9.6 1.6 1.3 1.9l.2-.3c-.2-.2-.4-.3-.4-.6s.3-.8.9-.8c.9 0 1.4.6 1.7.9l4.1-2.5v-3.1zm-1.4-2.7c-.6 1-2 2-2.6 2.4l-.9-.9V7.2c.4 1 1.2 1.7 2.4 1.7.3 0 .8-.1 1.1-.3m-1.3 6.9c-.5-1.1-1.4-1.8-2.6-1.8-.4 0-.9.2-1.4.5.4-.7 1.7-1.8 2.8-2.5l1.1.9.1 2.9zM183.1.8c-.3.3-.6.6-1 .6-.5 0-.9-.1-1.2-.2-.6-.2-1.1-.4-1.6-.4-.8 0-2.2.5-2.9 2.6l.4.2c.2-.4.5-.9 1.2-.9.4 0 .9.1 1.2.2.3.1.9.2 1.2.2 1.2 0 2.4-1.3 3.1-2.1l-.4-.2zm14.1 13.3l-.8.6-1-.9V4.1l1.1-.9-.2-.2-.9.6-2.8-2.5-2.3 1.4V1.3h-.5v1.4l-1.2.8-2.9-2.4-4.1 2.6c-.8.5-2.6 1.8-2.6 3.3v.2c-1.6.1-2.5.9-2.5 2.3 0 .6.2.9.3 1.2h.4v-.2c0-.6.3-1 1.2-1h.7V11c0 1-.1 1.8-1 2l.1.4c2.5-.4 3.6-1.2 3.6-3.1V5.4c0-.9.6-1.5 1.2-2.1v7.8c0 2-.9 2.5-1.8 2.6-.9.2-1.7.1-2.6.5-.8.3-1.5.9-1.5 2.2 0 1.7 1.2 2.4 2.5 2.4v-.5c-.6 0-1.1-.2-1.1-.8 0-.5.3-.8 1-.9.6-.1 1.2-.1 1.9-.3.9-.2 2.2-1.1 2.2-2.7v-3c.2-.2.6-.4 1.1-.4.5 0 .9.2 1.1.4V14l-1.3.9.2.3.7-.5 2.4 2 3.5-2.6-.3-.3-.6.4v-3.6c.2-.2.6-.4 1.1-.4.5 0 .9.2 1.1.4v3.3l-1.2.9.2.3.7-.5 2.3 2 3-2.5h-.4zm-4.7-6.6c-.3.3-.7.4-1.1.4-.6 0-.9-.2-1.1-.4V3.2l2.2 1.8v2.5zm0 2.7c-.3-.2-.6-.4-1.1-.4-.6 0-.9.2-1.1.4V8.1c.2.2.6.4 1.1.4.5 0 .9-.2 1.1-.4v2.1zm-2.8 4.3l-1.2-.9V3.9l1.2-.8v11.4zm-4-7c-.3.3-.7.4-1.1.4-.6 0-.9-.2-1.1-.4V3.3l2.3 1.6v2.6zm0 2.7c-.3-.2-.6-.4-1.1-.4-.6 0-.9.2-1.1.4V8.1c.2.2.6.4 1.1.4.5 0 .9-.2 1.1-.4v2.1zm21.5 4.2l-.9.6-1-1V8.6l1-.7-.2-.4-.9.6-3.1-2-2.3 1.2c-.8.4-1.3.9-1.3 1.8s.9 1.4 1.8 1.9c-1.2.7-2.5 1.6-2.5 3 0 1.7 1.6 2.6 2.8 2.8l2.2-1.6 1.6 1.6 2.9-2-.1-.4zm-4.4-3.2c-1.5-.4-3.7-1-3.7-2.3 0-.8.6-1.1 1-1.3l2.6 1.6v2zm0 3.7c-.1 0-.4.1-.6.1-1 0-1.9-1.2-1.9-2.6 0-.5.1-.9.4-1.3.7.3 1.7.6 2.1.7v3.1zm13.5-7.5l-.8.6-2.8-2.1-4.7 2.7v6l3 2.1 2-1.4c0 1 .7 1.7.7 2.3 0 .4-.4.8-.8.9-.7-.6-1.5-1.1-2.7-1.1-1.6 0-2.6 1-3.2 2.3l.3.2c.5-.3.8-.6 1.3-.6.8 0 1.6.4 2.4 1.2 0 0 1.7-1.2 2.8-2 .6-.4 1.2-.8 1.7-1 .4-.3.8-.7.8-1.1 0-.4-.1-.8-.3-1-.1-.4-.3-.8-.3-1.6V8.4l1-.7-.4-.3zm-5.8 5.9V7.4l2.4 1.6v5.8l-2.4-1.5zm15.8 1.1l-.9.6-1-1V8.6l1-.7-.2-.4-.9.6-3.1-2-2.2 1.2c-.8.4-1.3.9-1.3 1.8s.9 1.4 1.8 1.9c-1.2.7-2.5 1.6-2.5 3 0 1.7 1.6 2.6 2.8 2.8l2.2-1.6 1.6 1.6 2.9-2-.2-.4zm-4.5-3.2c-1.5-.4-3.7-1-3.7-2.3 0-.8.6-1.1 1-1.3l2.6 1.6v2zm0 3.7c-.1 0-.4.1-.6.1-1 0-1.9-1.2-1.9-2.6 0-.5.1-.9.4-1.3.7.3 1.7.6 2.1.7v3.1zm12.8-1.2l-.6.7c-.9-.5-2.3-.8-2.9-.8-.9 0-1.9.1-2.5.3h-.1c.4-.6 1-1.2 1.4-1.7h2.2l1.7-2-.3-.3-.6.6H231c1.5-1.4 2.7-2.6 3.5-4.1l-.2-.3c-.9.5-1.6.8-2.8.8-1.2 0-2.6-.5-3.2-.8h-.2l-1.6 3 .4.2.5-.8c.6.3 1.6.6 2.6.6.6 0 1.4-.1 2-.3l-1.5 1.6h-2l-1.7 2 .3.3.6-.6h1.7c-1.6 1.7-2.6 2.8-3 4.4l.2.2c.8-.7 1.8-.9 3-.9 1 0 2.4.5 3 .8h.1l2.2-2.7-.3-.2zm3.2-12.2h-.2l-1.9 1.7v.2l1.7 1.8h.2l1.9-1.7v-.2l-1.7-1.8zm2.8 12.8l-.9.6-.7-.7V7.9L237.4 6l-2.8 1.9.3.4.8-.5.7.9v5.5l-1.3.9.3.4.7-.5 2 1.8 3-2.1-.5-.4zm11 0l-.8.6-.9-.8V8.6l.9-.7-.3-.4-.9.6-2.3-2-2.3 1.8-1.6-1.8-2.9 2 .3.4.8-.5.8.9v5.5l-.8.7L244 17l2-1.8-.9-.8V8.5l.9-.5 1.5 1.3v5.1l-.7.7 2.1 1.9 3.1-2.1-.4-.6zm8.2-1.4l-2.3 1.8L255 13v-.9l4.5-2.8v-.1L257.4 6l-5 2.6v5.8l3.3 2.4 4.3-3.5-.2-.4zm-4.7-1.3V7.7l.4-.1 1.8 2.6-2.2 1.4z"></path></svg></a></div></section></header></div><div class="css-11kjks6" role="region" aria-label="comments panel" tabindex="-1"><button type="button" class="css-159bbcu" aria-label="close comments panel"><svg class="" viewBox="0 0 12 12" stroke="#666" stroke-width="1" stroke-linecap="round" style="opacity:0.95"><line x1="11" y1="1" x2="1" y2="11"></line><line x1="1" y1="1" x2="11" y2="11"></line></svg></button><div class="css-1h21wu5"><div class="css-akb3vb"><div><div class="css-1yip8nf"><header><h2 class="css-1sj8ssj"><a href="#commentsContainer" tabindex="-1" aria-label="Comments Panel">Comments </a></h2><a class="css-emn6zw" href="">Can a Vaccine for Covid-19 Be Developed in Record Time?</a><a href="" class="css-1qg0wjs" tabindex="0">Skip to Comments</a></header><div class="css-c32q7m">The comments section is closed.
      To submit a letter to the editor for publication, write to
      <a href="mailto:letters@NYTimes.com">letters@NYTimes.com</a>.</div></div><div class="css-1bxnhxc"></div><div class="css-1yip8nf"></div></div></div></div></div></div><main id="site-content"><article id="interactive" class="interactive"><header id="interactive-header" class="dish interactive-header css-17dltfe e1n4ps4i1"><h1 id="interactive-heading" class="interactive-heading css-5it7hk e1h9rw200" itemProp="headline" data-test-id="headline">Can a Vaccine for Covid-19 Be Developed in Record Time?</h1><div class="css-1vegfwe interactive-byline-container"><div class="interactive-byline css-103zbxs"><time class="interactive-timestamp css-1715g16 e16638kd0" dateTime="2020-06-09T05:00:02-04:00">June 9, 2020</time></div></div><div id="interactive-standalone-sharetools" class="css-wkcogx"><div class=""><div role="toolbar" aria-label="Social Media Share buttons, Save button, and Comments Panel with current comment count" class="interactive-sharetools css-9z2bwm" data-testid="share-tools"><ul class="css-y8aj3r"><li class="css-qj0ud4 fb-share-item"><a href="https://www.facebookcorewwwi.onion/dialog/feed?app_id=9869919170&amp;link=https%3A%2F%2Fwww.nytimes3xbfgragh.onion%2Finteractive%2F2020%2F06%2F09%2Fmagazine%2Fcovid-vaccine.html%3Fsmid%3Dfb-share&amp;name=Can%20a%20Vaccine%20for%20Covid-19%20Be%20Developed%20in%20Record%20Time%3F&amp;redirect_uri=https%3A%2F%2Fwww.facebookcorewwwi.onion%2F" target="_blank" rel="noopener noreferrer" aria-label="Share on Facebook"><svg class="css-1acmxgr" viewBox="0 0 7 15" width="7" height="15"><path fill-rule="evenodd" clip-rule="evenodd" d="M4.775 14.163V7.08h1.923l.255-2.441H4.775l.004-1.222c0-.636.06-.977.958-.977H6.94V0H5.016c-2.31 0-3.123 1.184-3.123 3.175V4.64H.453v2.44h1.44v7.083h2.882z" fill="#000"></path></svg></a></li><li class="css-qj0ud4 twitter-share-item"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.nytimes3xbfgragh.onion%2Finteractive%2F2020%2F06%2F09%2Fmagazine%2Fcovid-vaccine.html%3Fsmid%3Dtw-share&amp;text=Can%20a%20Vaccine%20for%20Covid-19%20Be%20Developed%20in%20Record%20Time%3F" target="_blank" rel="noopener noreferrer" aria-label="Share on Twitter"><svg viewBox="0 0 13 10" class="css-1acmxgr" width="13" height="10"><path fill-rule="evenodd" clip-rule="evenodd" d="M5.987 2.772l.025.425-.429-.052c-1.562-.2-2.927-.876-4.086-2.011L.93.571.784.987c-.309.927-.111 1.906.533 2.565.343.364.266.416-.327.2-.206-.07-.386-.122-.403-.096-.06.06.146.85.309 1.161.223.434.678.858 1.176 1.11l.42.199-.497.009c-.481 0-.498.008-.447.19.172.564.85 1.162 1.606 1.422l.532.182-.464.277a4.833 4.833 0 0 1-2.3.641c-.387.009-.704.044-.704.07 0 .086 1.047.572 1.657.762 1.828.564 4 .32 5.631-.641 1.159-.685 2.318-2.045 2.859-3.363.292-.702.583-1.984.583-2.6 0-.398.026-.45.507-.927.283-.277.55-.58.6-.667.087-.165.078-.165-.36-.018-.73.26-.832.226-.472-.164.266-.278.584-.78.584-.928 0-.026-.129.018-.275.096a4.79 4.79 0 0 1-.755.294l-.464.148-.42-.286C9.66.467 9.335.293 9.163.24 8.725.12 8.055.137 7.66.276c-1.074.39-1.752 1.395-1.674 2.496z" fill="#000"></path></svg></a></li><li class="css-qj0ud4 email-share-item"><a href="mailto:?subject=nytimes3xbfgragh.onion%3A%20Can%20a%20Vaccine%20for%20Covid-19%20Be%20Developed%20in%20Record%20Time%3F&amp;body=From%20The%20New%20York%20Times%3A%0A%0ACan%20a%20Vaccine%20for%20Covid-19%20Be%20Developed%20in%20Record%20Time%3F%0A%0AA%20discussion%20moderated%20by%20Siddhartha%20Mukherjee.%0A%0Ahttps%3A%2F%2Fwww.nytimes3xbfgragh.onion%2Finteractive%2F2020%2F06%2F09%2Fmagazine%2Fcovid-vaccine.html%3Fsmid%3Dem-share" target="_blank" rel="noopener noreferrer" aria-label="Email"><svg viewBox="0 0 15 9" class="css-1acmxgr" width="15" height="9"><path fill-rule="evenodd" clip-rule="evenodd" d="M.906 8.418V0L5.64 4.76.906 8.419zm13 0L9.174 4.761 13.906 0v8.418zM7.407 6.539l-1.13-1.137L.907 9h13l-5.37-3.598-1.13 1.137zM1.297 0h12.22l-6.11 5.095L1.297 0z" fill="#000"></path></svg></a></li><li class="css-qj0ud4 more-share-item"><div class="css-6n7j50"><button aria-haspopup="true" aria-expanded="false" aria-label="More sharing options ..." class="css-16ogagc" data-testid="" type="button"><svg class="css-107sgp6" viewBox="0 0 16 13" width="16" height="13"><path fill-rule="evenodd" clip-rule="evenodd" d="M15.406 5.359L8.978 0v3.215C3.82 3.215.406 8.107.406 12.66 1.653 9.133 4.29 7.517 8.978 7.517v3.2l6.428-5.358z" fill="#000"></path></svg></button></div></li><li class="css-w1nrqe"><button type="button" class="css-1d50gvk" aria-label="147 comments. Click to read and post comments." id="comments-speech-bubble-top"><i class="css-1pv1u79"><span class="css-1dtr3u3">147</span></i></button></li></ul></div></div></div><p id="interactive-leadin" data-testid="interactive-leadin" class="interactive-leadin css-1ncj54f evys1bk0">A discussion moderated by Siddhartha Mukherjee.</p></header><section id="covid-vaccine" data-id="100000007180386" class="css-l08pwh interactive-minimal interactive-content interactive-size-medium"><div class="css-17ih8de interactive-body"><!--

======================================================

THIS IS A GENERATED TEMPLATE FILE. DO NOT EDIT.

======================================================

-->
<!-- this is generated from src/style.css -->
<link id="nytg-rendered-css" href="https://static01.graylady3jvrrxbe.onion/newsgraphics/2020/06/04/2020-magtechdesign/a4fdae938d97ed501d80d0405d6760d098697e64/style.css" rel="stylesheet">


  <div class="rad-article" data-slug="14mag-roundtable">
    <div class="rad-cover headline-image-topper">
  <header id="rad-interactive-header" class="rad-interactive-header rad-hed-color-black">
  <div class="rad-cover-main">
    
<figure class="media photo full_bleed" data-id="100000007179782"  data-slug="14mag-roundtable">
  <div class="rad-media-wrapper">
    <div class="image" style="height: 0; padding-bottom: 100%">

      <img class="rad-lazy"
        src='data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7'
        data-pattern='https://static01.graylady3jvrrxbe.onion/images/2020/06/14/magazine/14mag-roundtable/{{file}}'
        data-widths='{"master":[{"size":495,"filename":"14mag-roundtable-master495-v2.jpg"},{"size":675,"filename":"14mag-roundtable-master675-v2.jpg"},{"size":1024,"filename":"14mag-roundtable-jumbo-v2.jpg"},{"size":2048,"filename":"14mag-roundtable-superJumbo-v2.jpg"}],"square":[{"size":150,"filename":"14mag-roundtable-thumbLarge.jpg"},{"size":320,"filename":"14mag-roundtable-square320-v2.jpg"},{"size":640,"filename":"14mag-roundtable-square640-v2.jpg"}],"threeTwo":[{"size":190,"filename":"14mag-roundtable-thumbWide.jpg"},{"size":225,"filename":"14mag-roundtable-mediumThreeByTwo225.jpg"},{"size":768,"filename":"14mag-roundtable-videoLarge.jpg"}],"twoThree":[{"size":735,"filename":"14mag-roundtable-verticalTwoByThree735-v2.jpg"}]}'
        data-master-ratio='1'
        data-mobile-square='false'
        data-mobile-vert='false'
        itemprop="url"/>
    </div>

  </div>

  <div class="rad-caption">
  <div class="rad-caption-wrapper">
    <span class="rad-caption-text"></span>
    <span class="rad-credit" itemprop="copyrightHolder">Photo illustration by Mike McQuade</span>
  </div>
</div>


</figure>

    <div class="rad-head-wrap">

      <h1 itemProp="headline" class="rad-headline">Can a Vaccine for Covid-19 Be Developed in Record Time?</h1>
      <p class="rad-summary">A discussion moderated by Siddhartha Mukherjee.</p>
      <div class="rad-byline-wrap">
        <p class="rad-byline" itemProp="author creator" itemscope="" itemType="http://schema.org/Person" itemID="">
          <span class="g-byline-name" itemProp="name"></span>
          <!-- TODO MULTI CONTRIB BYLINES [By ... Photos by ...] -->
        </p>
      <time class="rad-datetime">June 9, 2020</time>
      <div class="rad-date-share"></div>




        <!-- THIS NEEDS WORK
        
          <time class="rad-datetime">Published  June 9, 2020</time>
          <time class="rad-datetime">Updated June 11, 2020</time>
         -->



        <button class="rad-share">
          <span>SHARE</span>
          <svg version="1.1" id="Layer_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 40 40" xml:space="preserve">
            <style type="text/css">
              .st0{fill:#333333;}
            </style>
            <path class="st0" d="M30.5,19.4l-9-7.5v4.5c-7.2,0-12,6.8-12,13.2c1.7-4.9,5.4-7.2,12-7.2v4.5L30.5,19.4z"/>
          </svg>
        </button>
      </div>
  </div>


    
  </div>

</header>

</div>

<div class="rad-story-body">
  
    

    <p class="paragraph">In the history of medicine, rarely has a vaccine been developed in less than five years. Among the fastest to be <a href="https://www.nytimes3xbfgragh.onion/2013/05/07/health/maurice-hilleman-mmr-vaccines-forgotten-hero.html">developed was the current mumps vaccine</a>, which was isolated from the throat washings of a child named Jeryl Lynn in 1963. Over the next months, the virus was systematically â€œweakenedâ€ in the lab by her father, a biomedical scientist named Maurice Hilleman. Such a weakened or attenuated virus stimulates an immune response but does not cause the disease; the immune response protects against future infections with the actual virus. Human trials were carried out over the next two years, and the vaccine was licensed by Merck in December 1967.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph">Antiviral drugs, too, have generally taken decades to develop; effective combinations of them take even longer. The first cases of AIDS were described in the early 1980s; it took more than a decade to develop and validate the highly effective triple drug cocktails that are now the mainstay of therapy. We are still continuing to develop new classes of medicines against H.I.V., and notably, there is no vaccine for that disease. And yet the oft-cited target for creating a vaccine against SARS-CoV-2, the virus that causes Covid-19, is 12 months, 18 at the outside.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph">Pulling that off is arguably the most important scientific undertaking in generations. The Times assembled (virtually, of course) a round table to help us understand the maddening complexity of the challenge and the extraordinary collaboration it has already inspired. The group included a virologist; a vaccine scientist; an immunologist and oncologist; a biotech scientist and inventor; and a former head of the Food and Drug Administration.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    
    <h4 class="header">The Panelists</h4>

    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph paragraph-detail"><strong>Siddhartha Mukherjee</strong> is an associate professor of medicine at Columbia University and a cancer physician and researcher. He is the author of â€œThe Emperor of All Maladies: A Biography of Cancer,â€ which was the winner of the 2011 Pulitzer Prize in general nonfiction, and â€œThe Gene: An Intimate History.â€ He was recently appointed to Gov. Andrew Cuomoâ€™s blue-ribbon commission to reimagine New York.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph paragraph-detail"><strong>Dan Barouch</strong> is the director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston and a professor of medicine at Harvard Medical School.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph paragraph-detail"><strong>Margaret (Peggy) Hamburg</strong> is the foreign secretary of the National Academy of Medicine. She was commissioner of the Food and Drug Administration from 2009 to 2015.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph paragraph-detail"><strong>Susan R. Weiss</strong> is a professor and vice-chairwoman of the Department of Microbiology at the University of Pennsylvania and a co-director of the Penn Center for Research on Coronaviruses and Other Emerging Pathogens.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph paragraph-detail"><strong>George Yancopoulos</strong> is co-founder, president and chief scientific officer of Regeneron.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    
    
    
    
    
    
    
    
<figure class="media photo large" data-id="100000007179785"  data-slug="14mag-roundtable-04">
  <div class="rad-media-wrapper">
    <div class="image" style="height: 0; padding-bottom: 120%">

      <img class="rad-lazy"
        src='data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7'
        data-pattern='https://static01.graylady3jvrrxbe.onion/images/2020/06/14/magazine/14mag-roundtable-04/{{file}}'
        data-widths='{"master":[{"size":495,"filename":"14mag-roundtable-04-master495.jpg"},{"size":675,"filename":"14mag-roundtable-04-master675.jpg"},{"size":854,"filename":"14mag-roundtable-04-jumbo.jpg"},{"size":1707,"filename":"14mag-roundtable-04-superJumbo.jpg"}],"square":[{"size":150,"filename":"14mag-roundtable-04-thumbLarge.jpg"},{"size":320,"filename":"14mag-roundtable-04-square320.jpg"},{"size":640,"filename":"14mag-roundtable-04-square640.jpg"}],"threeTwo":[{"size":190,"filename":"14mag-roundtable-04-thumbWide.jpg"},{"size":225,"filename":"14mag-roundtable-04-mediumThreeByTwo225.jpg"},{"size":768,"filename":"14mag-roundtable-04-videoLarge.jpg"}],"twoThree":[{"size":735,"filename":"14mag-roundtable-04-verticalTwoByThree735.jpg"}]}'
        data-master-ratio='1.2'
        data-mobile-square='false'
        data-mobile-vert='false'
        itemprop="url"/>
    </div>

  </div>

  <div class="rad-caption">
  <div class="rad-caption-wrapper">
    <span class="rad-caption-text"></span>
    <span class="rad-credit" itemprop="copyrightHolder">Photo illustration by Mike McQuade</span>
  </div>
</div>


</figure>

    
    
    
    
    
    
  
    <div class="g-ad rad-ad-wrapper">
	<div data-slot-id="mid17" class="place-ad" data-position="mid"></div>
</div>


    
    <h4 class="header">What It Takes to Find a Vaccine</h4>

    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>George Yancopoulos</strong>: Most people donâ€™t realize that successfully inventing and developing any new drug or vaccine is quantifiably among the hardest things that human beings try to do. This is reflected in the numbers. Although there are thousands of major medical institutions and thousands of biotech and biopharma companies that collectively involve millions of researchers and hundreds of billions of dollars invested per year â€” and all are working on new vaccines and medicines â€” the vast majority of efforts fail, with the F.D.A. only approving 20 to 50 new medicines a year. And each of the rare success stories usually occurs over many years, often a decade or two.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Peggy Hamburg</strong>: So with Covid-19, we are moving at record speed, in terms of the history of vaccine development.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Siddhartha Mukherjee</strong>: Can you put a number down for how quickly we can get an effective vaccine developed? Is the 12-to-18-month time frame weâ€™ve been hearing realistic?</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Dan Barouch</strong>: The hope is that it will be within a year, but that is not in any way guaranteed. That projection will be refined as time goes on â€” and a year assumes that everything goes smoothly from this point forward. Thatâ€™s never been done before. And safety cannot be compromised.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Hamburg</strong>: Realistically, the 12 to 18 months that most people have been saying would be a pretty good marker but still optimistic.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Susan R. Weiss</strong>: Iâ€™d agree.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Mukherjee</strong>: To think about whether thereâ€™s any way to make this process go faster, letâ€™s start by talking about how the search for a vaccine usually happens. Dan, what is the general principle of what a vaccine is and how it works?</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Barouch</strong>: The goal of a vaccine is to raise an immune response against a virus or a bacterium. Later, when a vaccinated person is exposed to the actual virus or bacterium, the immune system will then block or rapidly control the pathogen so that the person doesnâ€™t get sick. The immune cells that make antibodies are called B cells. Once theyâ€™ve been triggered by a vaccine to raise an immune response, some of these B cells can last for years and are always standing ready to make antibodies against the pathogen when it is encountered, thereby protecting against the disease for a prolonged period of time.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Hamburg</strong>: Under normal conditions, drug-and-vaccine development begins with â€œpreclinicalâ€ work â€” basic science â€” to identify the nature of the disease in question.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    <div class="g-ad rad-ad-wrapper">
	<div data-slot-id="mid18" class="place-ad" data-position="mid"></div>
</div>


    <p class="paragraph"><strong>Weiss</strong>: In virology labs like mine, we try to identify the viral proteins that a vaccine might target, usually the protein that recognizes and attaches to the host-cell receptor. All coronaviruses have a so-called spike protein, which is what gives the virus its corona-like morphology, the â€œcrownlike shape,â€ as can be visualized in an electron microscope. To invade a cell, the spike protein attaches to a receptor â€” another protein, usually â€” on the cellâ€™s outer membrane. This eventually results in the genetic material of the virus, in this case, an RNA protein complex, being internalized in the cell. And once that happens, replication can begin and a person can get sick. If you can identify the viral protein that interacts with the cellular receptor, then you can try to create a vaccine. This spike protein represents a particularly attractive candidate for a vaccine, because it is a protein that most prominently sticks outside of the surface of the virus, and so itâ€™s the part of the virus that is most visible to the immune system.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Mukherjee</strong>: So what are the different approaches that you can take to finding vaccines?</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Barouch</strong>: A tried-and-true vaccine approach is a whole inactivated virus vaccine â€” thatâ€™s when you grow up the actual virus in the laboratory, for example in cells or in eggs, and then â€œinactivateâ€ it with chemicals or another method to make it unable to infect cells but still able to elicit an immune response. A company in China, Sinovac Biotech, currently has an inactivated SARS-CoV-2 vaccine in clinical trials. The pros are that thereâ€™s a long clinical history of multiple vaccines that have been successful in that regard, such as the inactivated polio vaccine and the inactivated flu vaccine. The cons are that there are always some safety considerations around proving that the virus has been fully inactivated. If the virus is not fully inactivated, the danger is that it might actually cause the disease.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph">Because of those issues, many groups are working on approaches that are called gene-based vaccines. Gene-based vaccines, such as DNA vaccines and RNA vaccines, do not consist of the entire virus particle. Rather, these vaccines use just a small fraction â€” sometimes even just one gene â€” from the virus.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph">That still leaves the question of how to get that gene into human cells. A vector-based vaccine uses a delivery vehicle â€” one example would be a recombinant adenovirus, a â€œharmless virusâ€ carrier, like a common-cold virus â€” to deliver the protein into a personâ€™s cells. For instance, you can take the spike-protein DNA from SARS-CoV-2 and â€œstitchâ€ it into the DNA of the harmless cold virus using genetic-engineering techniques. The virus delivers the spike-protein DNA into cells, but it cannot replicate in cells, so itâ€™s a safe delivery system. Still other approaches use purified proteins, such as the spike protein itself, as vaccines.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Yancopoulos</strong>: This gene-based approach was used in the case of Ebola. Scientists figured out that the protein the virus used to invade human cells is one thatâ€™s called the GP protein. They were able to make a very successful vaccine. They actually stitched in the GP protein, using genetic-engineering techniques, into a benign virus. When this virus infected cells, it made the GP protein, and the body recognized that protein as â€œforeignâ€ and made antibodies against it.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Mukherjee</strong>: There is also the idea of ditching the â€œharmlessâ€ virus altogether and just using a snippet of a viral gene, by itself, as an inoculum. As soon as the sequence of the SARS-CoV-2 genome became available in January, it became possible to design such a viral-gene snippet. Through reasons that we still donâ€™t fully understand, the bodyâ€™s own cells take up that viral gene, even without a carrier, and produce viral protein from it. Why and how cells take up this so-called naked DNA or RNA is still being worked out, but the viral protein is recognized as â€œforeignâ€ because it has never been seen by the body, and the host raises antibodies against it. And because it is not carried by any virus, this kind of vaccine can be easier to manufacture initially, although scaling up the manufacture may be tough. This is the approach that Moderna is taking to try and make a vaccine. In Modernaâ€™s case, it involves using RNA as the inoculum.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph">But what is the track record so far of a real human vaccine for a real human disease using these genetic techniques?</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Barouch</strong>: Currently there are no approved DNA vaccines or RNA vaccines. Some of them have been tested in small, early-phase clinical trials, for safety and ability to induce an immune response. However, they have not previously been tested in large-scale efficacy trials or mass produced or approved for clinical use.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Mukherjee</strong>: Yes, so we have to be very careful with these vaccines. The data discussed by Moderna in May would suggest that their vaccine can elicit antibodies in humans. It did so in eight patients. But whether that is protective against SARS-CoV-2, and how long the protection lasts, is an open question. More so, because elderly people need particular protection, and we need to understand how much of this vaccine, or ones like it, are eliciting long-term immunity in the elderly, where the immune system might be already somewhat attenuated in its response.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    <div class="g-ad rad-ad-wrapper">
	<div data-slot-id="mid19" class="place-ad" data-position="mid"></div>
</div>


    <p class="paragraph">Once you have a vaccine that you want to test, then you begin animal studies. What animals are coronavirus vaccines and drugs being tested on? And how do scientists know which ones to use?</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Weiss</strong>: An ideal animal model is one that reproduces the human disease as closely as possible â€” in which, for example, clinical signs resembling symptoms in humans are observed, virus replication is observed in similar organs, immune response mirrors that in humans and so on. In addition, an animal model is often used to demonstrate whether a virus can be transmitted from an infected to an uninfected animal. Scientists use animal models to understand how the virus causes disease. They are also useful to determine whether a vaccine will be successful to prevent infection or a drug will be able to reduce or eliminate the disease. With Covid-19, thereâ€™s currently a hamster model that looks like it works pretty well to mimic the disease and also some promising research with mice, ferrets and also nonhuman primates. None of these models are perfect, but each one of them tells us something about the immune response and may be useful for testing of vaccine efficacy as well as for antiviral therapies.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Mukherjee</strong>: Dan, you have been working with the monkey model and a genetically engineered vaccine. Can you tell us more about it?</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Barouch</strong>: Weâ€™re collaborating with Johnson & Johnson in the development of a SARS-CoV-2 vaccine. This vaccine involves a recombinant adenovirus vector â€” a common-cold virus thatâ€™s been altered to make it harmless â€” to shuttle the spike protein into cells. That is an efficient way of inducing potent immune responses to a pathogen and elicits durable immune responses as well.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph">There are two key scientific questions related to vaccine development that are crucial. First, is there evidence that natural immunity induced by infection protects against a subsequent encounter with the virus? And then, of course, there is the question of which vaccines to test and how effective any of these will be. We have just published some preliminary answers to these questions in the animal model in monkeys.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph">In the first experiment, we infected nine monkeys with SARS-CoV-2 in the nose and in the lungs. All the animals developed a viral pneumonia, which was similar to human disease, except the monkey disease was mild and all animals recovered. Thirty-five days later, we re-exposed the animals a second time to the virus â€” and found that all the animals were protected. There was no virus or very low levels of the virus in the lungs. This is an important question because, historically, it has proved much easier to develop vaccines when there is natural protective immunity against the virus. For H.I.V., for instance, there is no natural protective immunity, and thatâ€™s part of the reason that H.I.V. vaccines have been so hard to develop.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph">In the second study, we developed a series of prototype vaccines. These were â€œnaked DNAâ€ vaccines â€” ones without any delivery vehicles. These are not the vaccines that we are planning to take into the clinic, but rather these prototype DNA vaccines can teach us a lot about the immune responses needed to protect against this virus. We used six different versions of the spike-protein gene â€” some encoding the full protein, some with smaller pieces. Twenty-five monkeys received these vaccines and 10 received just saline as a control. Each monkey received two vaccine shots. Six weeks after the first shot, they were exposed to the virus, and we found that vaccinated animals were protected from SARS-CoV-2. Eight of the 25 animals had no virus detected after exposure, and the remaining animals showed low levels of the virus. Most important, the level of antibodies induced by the vaccine correlated with the level of protection, and this biomarker may therefore be useful for monitoring vaccine studies moving forward. The full-length spike protein appeared to work the best.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph">The implications of these two studies are that both natural immunity and vaccine-induced immunity can exist in primates and that the amount of antibody may serve as a useful marker for vaccine effectiveness. But of course, these are animal studies, and we will need to study these questions in humans.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Mukherjee</strong>: So what happens next in terms of making a real vaccine out of these data?</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Barouch</strong>: DNA encoding the full-length spike protein has been stitched into the common-cold virus vector as a more efficient way of transporting the spike-protein DNA into cells. Thatâ€™s the basis of the vaccine we are developing with J.&â€‰J.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    <div class="g-ad rad-ad-wrapper">
	<div data-slot-id="mid20" class="place-ad" data-position="mid"></div>
</div>


    <p class="paragraph"><strong>Mukherjee</strong>: In addition to the J.&â€‰J. and Moderna vaccines, there are several other programs. One is the Oxford program. What do we know about that one?</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Barouch</strong>: The Oxford vaccine is based on a chimpanzee common-cold virus, and it also encodes the spike protein. Early data shows that in monkeys, the vaccine was able to reduce the amount of virus in the lung but not in the nose, following exposure to SARS-CoV-2. This vaccine has already started early human testing, but we are still waiting for definitive data. Several vaccines are also in clinical trials in China, including Sinovacâ€™s inactivated-virus vaccine and another vaccine based on a human common-cold virus.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    
    
    
    
    
    
    
    
<figure class="media photo large" data-id="100000007179783"  data-slug="14mag-roundtable-02">
  <div class="rad-media-wrapper">
    <div class="image" style="height: 0; padding-bottom: 125.05050505050505%">

      <img class="rad-lazy"
        src='data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7'
        data-pattern='https://static01.graylady3jvrrxbe.onion/images/2020/06/14/magazine/14mag-roundtable-02/{{file}}'
        data-widths='{"master":[{"size":495,"filename":"14mag-roundtable-02-master495.jpg"},{"size":675,"filename":"14mag-roundtable-02-master675.jpg"},{"size":820,"filename":"14mag-roundtable-02-jumbo.jpg"},{"size":1639,"filename":"14mag-roundtable-02-superJumbo.jpg"}],"square":[{"size":150,"filename":"14mag-roundtable-02-thumbLarge.jpg"},{"size":320,"filename":"14mag-roundtable-02-square320.jpg"},{"size":640,"filename":"14mag-roundtable-02-square640.jpg"}],"threeTwo":[{"size":190,"filename":"14mag-roundtable-02-thumbWide.jpg"},{"size":225,"filename":"14mag-roundtable-02-mediumThreeByTwo225.jpg"},{"size":768,"filename":"14mag-roundtable-02-videoLarge.jpg"}],"twoThree":[{"size":735,"filename":"14mag-roundtable-02-verticalTwoByThree735.jpg"}]}'
        data-master-ratio='1.2505050505050506'
        data-mobile-square='false'
        data-mobile-vert='false'
        itemprop="url"/>
    </div>

  </div>

  <div class="rad-caption">
  <div class="rad-caption-wrapper">
    <span class="rad-caption-text"></span>
    <span class="rad-credit" itemprop="copyrightHolder">Photo illustration by Mike McQuade</span>
  </div>
</div>


</figure>

    
    
    
    
    
    
  
    

    
    <h4 class="header">Getting From a Discovery to a Cure</h4>

    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Mukherjee</strong>: Once you know the vaccine you want to test, what happens next?</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Barouch</strong>: Vaccine development for a new pathogen traditionally takes many years or even decades. The process includes small-scale manufacturing; Phase 1, Phase 2 and Phase 3 clinical trials; and then regulatory approval and large-scale manufacturing. For SARS-CoV-2, the goal is to compress these timelines considerably without compromising safety, which is absolutely critical for any vaccine that will be given to large numbers of individuals.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Hamburg</strong>: And there are a lot of hurdles that come up along the way. Sometimes developers have a good idea but canâ€™t translate it into a viable vaccine. Or you wind up with unexpected side effects in early human studies. Worse, you can find safety or efficacy problems further along, or you find that you canâ€™t reliably scale up manufacturing or you run into problems with regulatory authorities.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Mukherjee</strong>: Walk us through what happens with human testing.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Yancopoulos</strong>: The first human trials are called Phase 1 trials and consist of small â€œsafety trialsâ€ exploring increasing doses of the drug, to prove you can get into an effective level of the drug without obvious harm. This usually takes from a few months to a year or two. If you are satisfied that the Phase 1 trial has established that an effective level of the drug does not cause obvious harm (albeit in the small number of patients in Phase 1), you then proceed in the next stage of trials, Phase 2, that further establish safety in larger patient numbers while also demonstrating that your drug has some beneficial effect.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph">For example, Phase 2 might show that a drug lowers â€œbad cholesterol.â€ But it doesnâ€™t necessarily mean that it prevents heart attacks. Only when you do very large, well-controlled Phase 3 studies can you prove that lowering the â€œbad cholesterolâ€ also can prevent heart attacks and save lives. For example, for the heart-disease drug Praluent that my company developed, we could show that it effectively lowered â€œbad cholesterolâ€ in Phase 2 trials of a couple hundred patients, but the Phase 3 trial that was required to show it prevented heart attacks and improved survival involved about 20,000 patients and about five years.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    <div class="g-ad rad-ad-wrapper">
	<div data-slot-id="mid21" class="place-ad" data-position="mid"></div>
</div>


    <p class="paragraph"><strong>Mukherjee</strong>: In what you just described, the Phase 1 alone can be up to two years. How could we accelerate the whole process?</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Hamburg</strong>: Well, we canâ€™t abandon the rigor of the science. And we certainly canâ€™t abandon the ethics of how we do studies either. But what we can do is, frankly, ask developers to take more risks themselves. Vaccine development can be costly and success uncertain. As compared to a drug that someone may take every day, the return on investment versus risk of failed development is pretty high for vaccines. Because vaccines are often viewed as a public good, protecting both people and communities, there can be considerable pressure on companies to restrict price on vaccines, so a company rarely has a â€œblockbusterâ€ vaccine the way that a cancer treatment, ulcer drug or cholesterol-lowering drug can be. Also, there are liability issues because you are giving a vaccine to a healthy person to protect them from disease rather than treating an existing problem. So the trade-off of development risk and benefit often does not favor vaccines. In order to manage those risks, trials of different vaccine candidates tend to be done one step at a time.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Barouch</strong>: For Covid-19, developers are talking about performing as many steps in parallel as possible, as opposed to sequentially. For example, multiple vaccine manufacturers are willing to take enormous financial risks â€” planning for large-scale manufacturing up front, even before knowing whether the vaccine works or not.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph">There might be a half dozen vaccines that will get to the Phase 3 stage. How do we select which ones go forward? Do we prioritize vaccines that are similar to ones that have been tested previously in humans and that have shown safety and potency? Or do we turn to vaccines that can be mass produced quickly and safely? Ultimately, the prioritization is a complicated process that involves many decisions. The F.D.A. has to be involved, as well as governments and regulatory agencies and stakeholders around the world. There are questions about safety, efficacy, manufacturability and scalability that must be tackled.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Hamburg</strong>: Obviously weâ€™re looking for ones that work in the early trials. But we donâ€™t just need a vaccine that works; we need one that can be reliably scaled up to manufacture in very large volumes. Ideally, it would be one that doesnâ€™t require multiple doses to be effective, certainly not beyond, say, a two-dose regimen. And ideally it wouldnâ€™t require refrigerated storage, so it can be made more available in resource-poor settings. So, there are characteristics of a vaccine in addition to safety and efficacy that are going to matter.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Mukherjee</strong>: Are there other ways to speed up the process? Typically in Phase 3 trials, youâ€™d go out into the field and give, say, 15,000 people the vaccine youâ€™re testing and 15,000 people a placebo. And then you wait and see how many of those with the vaccine came down with the disease versus the numbers who were given the placebo. But of course, that takes a long time. Youâ€™d need to wait months or years to watch this natural experiment. One ethically fraught possibility that some experts have floated is the use of so-called â€œchallengeâ€ trials, in which young, healthy people are given a vaccine and then deliberately exposed to the virus. This would only happen once the safety of the vaccine was established and there was some hint that there is an immune response. But what are the ethical concerns about accelerating a vaccine process?</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Barouch</strong>: For certain pathogens, it has been considered ethical to perform human-challenge studies but typically only for pathogens for which there is a highly effective treatment. For example, for malaria there is a very widely and effectively used human-challenge model in which vaccines or other interventions can be tested. Human volunteers can be inoculated with malaria and then, if they develop the disease, can be treated rapidly so that they donâ€™t actually get sick.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Mukherjee</strong>: Why canâ€™t we do this for Covid-19?</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Barouch</strong>: The dilemma for Covid-19 is that there currently is no curative therapy. So, if a volunteer in a potential human-challenge study gets severely ill, there may not be a way to cure that person. In fact, far from it: The drugs in our armamentarium are not perfect, and so we would have no guarantee that we could â€œrescueâ€ a person who got severely ill.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Weiss</strong>: Iâ€™m not an ethicist, but my gut feeling is that challenge trials are too dangerous. Young people can get quite sick and die from Covid-19.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    <div class="g-ad rad-ad-wrapper">
	<div data-slot-id="mid22" class="place-ad" data-position="mid"></div>
</div>


    <p class="paragraph"><strong>Mukherjee</strong>: If we could develop a drug or an antibody that would be able to mitigate the disease, we would still need to think about the ethical concerns of a human challenge. Thereâ€™s also the question of who â€œvolunteersâ€ for such a challenge. Thereâ€™s been a whole history â€” extremely fraught â€” where minorities were used as experimental subjects without their understanding or consent. How do we ensure that the volunteers understand the consent? How do we ensure that they are not given perverse incentives? A young person might believe that if they get vaccinated and challenged, then they have an â€œimmunity passportâ€ against the disease. But what if, in fact, they fall sick and we have no effective therapy. The question of a challenge experiment therefore requires both deep ethical thinking â€” who, what, how many â€” and scientific thinking: Is there a strategy to â€œrescueâ€ a patient if the challenge resulted in a real disease.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Hamburg</strong>: Thereâ€™s also the question of how much a challenge trial on young healthy patients will even tell us what we need to know. If we do a study using these lowest-risk patients, will that give us adequate information about the value of the vaccine in the elderly populations, who in many ways are the most important target for this vaccine?</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Barouch</strong>: Absolutely. The problem for human-challenge studies, beyond the ethical questions, is that a controlled human-challenge experiment doesnâ€™t necessarily translate to showing how a vaccine would actually perform in the real world. Participants in any such challenge studies would likely be young, healthy individuals at lowest risk, and so the data generated may not be applicable to elderly and vulnerable populations that need to be protected with a vaccine. There may also be different doses and different viral variants.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Mukherjee</strong>: Peggy, is there something we should be doing while weâ€™re waiting for all these trials?</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Hamburg</strong>: Well, I think we definitely need to be thinking about the scale-up and manufacturing issues, as we said already. Another issue that we need to be thinking about is working with the communities where these large-scale Phase 3 studies will be done. Some will be done in the U.S., but others will be done in other places around the world â€” lower-resourced places that may not have the kind of clinical-research infrastructure that we have here, whether itâ€™s having enough trained researchers or the sophisticated health care services they need, like lab and diagnostic tools and basic things like refrigeration and cold storage.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Mukherjee</strong>: So in speeding up the vaccine-development process, we have three things going for us: We have cleaner and likely safer technologies to create vaccines; we know the viral proteins that are likely to raise a good immune response; and we know how to measure that immune response with much greater accuracy in humans that have been given a test dose of the vaccine. All of these we hope will accelerate the Phase 1 safety trials â€” some of which have already started, between March and May â€” so that they can be done in four to six months. After that, weâ€™re still looking at a roughly 12-month period to test the vaccine in real human populations, so it seems weâ€™re pushing toward the 18-month marker. Dan, whatâ€™s your sense of the time that it will take to actually deploy the vaccine across the population of the world once we have it?</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Barouch</strong>: There are two timelines that matter. One is the infrastructure and timeline needed to manufacture massive numbers of doses of the vaccine, and a separate, potentially different timeline to actually deploy the vaccine.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Hamburg</strong>: On the manufacturing front, youâ€™ve probably heard about Bill Gatesâ€™s decision to begin to invest in a range of different types of manufacturing capabilities, to capture the different categories of vaccines, not knowing which of the different types of vaccine candidates are actually going to make it over the finish line.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Mukherjee</strong>: Right, so that once the â€œwinnerâ€ is identified, that winner can go forward without having to wait for capacity.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Barouch</strong>: The reason to build out this capacity in advance is that different vaccines are made very differently. For example, the manufacturing process for an RNA vaccine is entirely different than for an adenovirus vector-based vaccine. For rapid deployment of a vaccine after clinical efficacy is shown, large-scale manufacturing of multiple vaccine candidates has to begin before there is demonstration of vaccine efficacy.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    <div class="g-ad rad-ad-wrapper">
	<div data-slot-id="mid23" class="place-ad" data-position="mid"></div>
</div>


    <p class="paragraph"><strong>Hamburg</strong>: But even if this initiative moves forward, I think there may be a misunderstanding in the public at large about the challenges of scale-up and manufacturing. Once a vaccine is approved, it is not going be available the next day for whoever wants it.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Mukherjee</strong>: Tell us about that. Thatâ€™s important.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Hamburg</strong>: Manufacturing has to be done in a high-quality and consistent way. There are materials that are needed that can be in limited supply, like the vials and the stoppers that you need for packaging. And then there are chains for distribution, and sometimes vaccines have to be kept frozen at very low temperatures. So you have to have all of those important systems for manufacturing, packaging and delivery and distribution up and running and the supply chains flowing in order to actually get what might now be an approved vaccine actually into the bodies of the individuals who need it.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Mukherjee</strong>: And then this returns to the distribution and inoculation of the vaccine, and epidemiological studies that follow it.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Hamburg</strong>: Yes, I think we need to create systems for assuring fair and equitable and public-health-driven distribution of the vaccine as well. One concern that many have is that thereâ€™s going to be a huge nationalistic push for countries to try to get hold of as much vaccine as they can for use within their own borders, yet ultimately the safety of any country or community depends on addressing and protecting against this virus all over the world.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    
    
    
    
    
    
    
    
<figure class="media photo large" data-id="100000007179784"  data-slug="14mag-roundtable-03">
  <div class="rad-media-wrapper">
    <div class="image" style="height: 0; padding-bottom: 120%">

      <img class="rad-lazy"
        src='data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7'
        data-pattern='https://static01.graylady3jvrrxbe.onion/images/2020/06/14/magazine/14mag-roundtable-03/{{file}}'
        data-widths='{"master":[{"size":495,"filename":"14mag-roundtable-03-master495.jpg"},{"size":675,"filename":"14mag-roundtable-03-master675.jpg"},{"size":854,"filename":"14mag-roundtable-03-jumbo.jpg"},{"size":1707,"filename":"14mag-roundtable-03-superJumbo.jpg"}],"square":[{"size":150,"filename":"14mag-roundtable-03-thumbLarge.jpg"},{"size":320,"filename":"14mag-roundtable-03-square320.jpg"},{"size":640,"filename":"14mag-roundtable-03-square640.jpg"}],"threeTwo":[{"size":190,"filename":"14mag-roundtable-03-thumbWide.jpg"},{"size":225,"filename":"14mag-roundtable-03-mediumThreeByTwo225.jpg"},{"size":768,"filename":"14mag-roundtable-03-videoLarge.jpg"}],"twoThree":[{"size":735,"filename":"14mag-roundtable-03-verticalTwoByThree735.jpg"}]}'
        data-master-ratio='1.2'
        data-mobile-square='false'
        data-mobile-vert='false'
        itemprop="url"/>
    </div>

  </div>

  <div class="rad-caption">
  <div class="rad-caption-wrapper">
    <span class="rad-caption-text"></span>
    <span class="rad-credit" itemprop="copyrightHolder">Photo illustration by Mike McQuade</span>
  </div>
</div>


</figure>

    
    
    
    
    
    
  
    

    
    <h4 class="header">What Will We Have in the Meantime?</h4>

    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Yancopoulos</strong>: As weâ€™ve been saying, with all the challenges regarding developing, testing, manufacturing and distributing a safe and effective vaccine â€” no matter how much effort so many scientists and companies put on the problem â€” it could still take years or even longer. This is why itâ€™s so important to have additional efforts ongoing in parallel to try to fight back against this pandemic. If we donâ€™t have a safe and effective vaccine for one to two years, or even longer, we need to develop other treatments as a bridge to a vaccine â€” to allow society to have a path toward reopening and functioning, while we await a vaccine.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Mukherjee</strong>: So letâ€™s work backward as we work frantically toward the vaccine. What can we do now that will help? How can we move from where we are â€” isolate, quarantine, mask, distance â€” toward a therapy that will bridge us to the vaccine?</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Yancopoulos</strong>: The world has gotten interested in the drug remdesivir, which inhibits the process of RNA replication and has been shown to be active in a lot of viruses that use these mechanisms to replicate themselves.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    <div class="g-ad rad-ad-wrapper">
	<div data-slot-id="mid24" class="place-ad" data-position="mid"></div>
</div>


    <p class="paragraph"><strong>Mukherjee</strong>: An initial study from China, published in the Lancet, showed a rather disappointing effect from remdesivir. There was a hint of clinical improvement in treated patients versus controls, but it was not statistically significant. But there were several problems with that trial. That trial enrolled patients who had the onset of symptoms from one day to 12 days, so the spectrum of disease severity was very broad. And although the study had a placebo control, it did not have a lot of patients: 236 in total, 158 in the treatment and 78 in placebo. In late May there was a study from the National Institutes of Health published in The New England Journal of Medicine that showed remdesivir might have an effect â€” albeit, again, a modest one â€” on hospitalized patients. The number of days that patients spent in hospital was reduced, and the study again hinted that there was a reduction in mortality from 11.9 percent in the placebo group to 7.1 percent in the treated group, though this was not shown to be statistically significant. But again, this was a study that involved a very broad range of patients â€” some with moderate lung damage and some on ventilators.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Hamburg</strong>: Until thereâ€™s a vaccine, I donâ€™t think thereâ€™s going to be one magic bullet for treating this thing, and weâ€™re certainly not going to find that magic-bullet drug treatment in a repurposed drug pulled off the shelf.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Yancopoulos</strong>: History has told us that. Repurposed drugs are usually not panaceas.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Hamburg</strong>: And meanwhile, every day we are learning more about this virus, its life cycle and the complexity of how it causes disease. We initially thought of Covid-19 as a lung disease, and then realized that many of the people who became seriously ill had their disease course worsened by a hyperactive immune response. Now we realize that many other vital organs can be seriously compromised, including the kidneys, the gut and the brain, and that something about this virus is triggering a very dangerous hypercoagulability syndrome, where the blood starts clotting in dangerous ways. And thereâ€™s an apparent association of this novel coronavirus with a very serious hyperimmune syndrome in children, the so-called Kawasaki-like syndrome.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph">I think we need to draw on our best scientific understanding and the work of virologists like Susan to identify where are the targets for intervention, for what will likely be a combination therapy that addresses different points in the life cycle of the virus and the human immune response.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Mukherjee</strong>: What about using antibodies to tide us through this period? As weâ€™ve discussed, the entire purpose of vaccines is to induce the body to make its own â€œprotective antibodiesâ€ that bind and kill the virus. George, you have pioneered ways of making these same type of â€œanti-viral antibodiesâ€ outside the body, manufacturing them and purifying them and then giving them back to individuals â€” so these people now have antibodies against the virus. Itâ€™s like they have already been vaccinated: They now have antibodies but without needing to go through the actual vaccine step.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Yancopoulos</strong>: Right. Earlier I mentioned Ebola. Over the past 10 to 20 years, we have developed a series of technologies that are designed to make antibodies against many disease targets, including viruses. These technologies were used by our scientists to develop a cocktail of three antibodies to bind and block the GP protein of Ebola â€” the GP protein is the Ebola equivalent of the spike protein â€” our so-called REGN-EB3 cocktail, and this treatment was very effective in patients already infected with Ebola, as shown by the World Health Organization in a clinical trial. And now we have used these same technologies to rapidly make an antibody cocktail â€” REGN-COV2 â€” that binds and blocks the spike protein of Covid-19.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Mukherjee</strong>: Explain what that means.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Yancopoulos</strong>: You can almost think of it as a temporary vaccine. Instead of waiting for a vaccine that will make the body make its own antibodies against the virus, we can make exactly those kinds of antibodies and inject them into people.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Mukherjee</strong>: And how long would that take?</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    <div class="g-ad rad-ad-wrapper">
	<div data-slot-id="mid25" class="place-ad" data-position="mid"></div>
</div>


    <p class="paragraph"><strong>Yancopoulos</strong>: For Ebola, we went from starting the project to being in clinical trials in just nine months. With Covid-19, weâ€™ve cut that in almost half: We have already made thousands and thousands of these antibodies and started to grow them up and tested them for blocking the virus. And we plan to start human trials in June. We will conduct three types of trials. First, prophylaxis, in which we give REGN-COV2 to patients not yet infected but at high-risk and hopefully show we can prevent infection â€” much like a vaccine would hope to do but not inducing the â€œpermanent immunityâ€ that a vaccine can confer. Then, we will give REGN-COV2 to patients recently infected, who are asymptomatic and/or who donâ€™t have severe disease, and see if we can rapidly â€œcureâ€ them and eliminate the virus and prevent them from progressing to the severe-and-critical stage that would require hospitalization and ventilation. Then, finally, we would give the REGN-COV2 to severe-and-critical-stage patients, who are in the hospital, many on ventilators, with poor prognosis, and hopefully show we can rescue them, get them off ventilators and save their lives.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Mukherjee</strong>: And how long would the antibodies last in terms of protection?</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Yancopoulos</strong>: We hope each injection should last at least a month, if not several months. Beyond this antibody cocktail, there are quite a few drugs that are being repurposed to see if they have potential in Covid-19. One particularly promising story that came out of China was that blocking the inflammation that seems to be causing the lung problems in Covid-19 â€” in particular by blocking an inflammatory factor called interleukin-6, or IL-6, that is an important driver of the inflammation in rheumatoid arthritis â€” might help patients with lung problems due to Covid-19. This promise was based on a small, uncontrolled but positive experience in China. We are now doing large Phase 3 trials to definitively test whether our IL-6 blocking drug â€” which as I said is already approved for treating the inflammation in rheumatoid arthritis â€” may help with the lung inflammation in Covid-19 patients who are critically ill. But if you look at either repurposed drugs like remdesivir or even the IL-6 blocking approach, those are not the sort of drugs that I think would make Dan happy, because they are just incremental.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Hamburg</strong>: Or me.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Yancopoulos</strong>: Or anybody. But they could provide a benefit. Every life thatâ€™s saved or every disease course thatâ€™s shortened is important.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Mukherjee</strong>: But the incremental effects that you are describing may be because the trials are still being run on patients with moderate to severe disease and in particular on hospitalized patients. In virtually every infectious disease, the use of antibacterials or antivirals or even antibodies against a virus early in the course of disease is better. In terms of remdesivir, itâ€™s possible that the drug is much more likely to be efficacious when used early than late, and in fact, the published trial from the N.I.H. has a hint of that. As we just said, thus far, the trials have generally involved a broad spectrum of patients â€” hospitalized patients and some of the sickest â€” and the benefits have been modest. But experts such as Francisco Marty, an infectious-disease doctor at Brigham and Womenâ€™s Hospital, have argued that this was precisely the wrong population to use the drug. By the time you have lung inflammation and tissue injury, killing the virus is not enough. Itâ€™s too late; the body has turned on itself, and an antiviral drug cannot tackle the inflammation. And so a second fleet of trials is being designed to evaluate whether the drug might be more successful if given as early as possible â€” for instance, as soon as you have detected the virus and the oxygen level has begun to drop, particularly in high-risk patients. It would invert the paradigm: Rather than quarantine and sit at home, you would get the drug sooner rather than later. Infectious-disease doctors, such as Marty, have early evidence that this strategy works: Patients given early remdesivir recover and do not progress to the fulminant lung disease. A group of us, including Marty, are in conversations with the Gates Foundation and others to launch trials of such a strategy.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph">And then thereâ€™s the question of combining drugs: Perhaps an antiviral drug would work even better if used in combination with antibodies. But all of this is logistically complex. All these drugs have to be given intravenously, so you have to go to an infusion center to get them. But I cannot emphasize enough the urgency of doing these early-treatment trials. It would be really a shame to give up a valuable drug in our very limited armamentarium because we couldnâ€™t study the right patients. And the drug itself is in short supply, so every time itâ€™s used on a patient that it would not benefit, we are losing ground. We need political support, financial support and support from Gilead, the manufacturer, to get this urgent early treatment trial done as soon as possible.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph">Susan, what is your sense of combining two targets? Maybe a replication inhibitor along with an antibody. And I know youâ€™ve been involved with other laboratories, testing new drugs. What is your sense of the development of these drugs?</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Weiss</strong>: That might turn out to be useful, but right now drugs are still being evaluated. Quite a few people are testing all kinds of F.D.A.-approved drugs and unapproved drugs against the virus. There are a lot of potential drug targets in the viral-replication cycle â€” that is, the enzymes that are needed to replicate the virus as well as the cellular factors needed for the virus to enter the cell. And I guess I feel like a lot of compounds may inhibit replication of the virus, especially in combination and aimed at multiple targets. But I donâ€™t know how many of them will actually become drugs. In addition, replication inhibitors may not be enough to stop the virus after the early stages of infection, when the individual may be asymptomatic. We may need a combination of an antiviral drug to be effective early in the disease and an anti-inflammatory drug for the later â€œcytokine stormâ€ phase of the disease.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Mukherjee</strong>: Yes, just because a compound inhibits the virus in a petri dish, doesnâ€™t mean that it can immediately become an antiviral drug for human use. The compound might be toxic to humans. It might be degraded into an inactive substance by the body. Its dose might be so high that itâ€™s impossible to administer. But I do think while weâ€™re waiting for the antibodies and the vaccines, it seems reasonable to proceed with testing thousands of drugs against the virus â€” called â€œdrug screeningâ€ â€” so that if something does come up, we might find a drug to combine with remdesivir or with antibodies, making an anti-viral cocktail.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    <div class="g-ad rad-ad-wrapper">
	<div data-slot-id="mid26" class="place-ad" data-position="mid"></div>
</div>


    <p class="paragraph">From what Iâ€™ve been able to see, there is unusual urgency and cooperation among scientists in this effort.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Hamburg</strong>: Itâ€™s remarkable, in terms of the collaboration across disciplines and research institutions and sectors and borders. Thereâ€™s been more openness and sharing than Iâ€™ve seen in past crises like Ebola or Zika or H1N1. Regulatory authorities around the world are coming together in ways that are very, very important to reduce barriers and to make sure that theyâ€™re bringing the best possible science to bear on decision making, trying to identify what are the critical questions that have to be asked and answered, what kind of study designs and preclinical work is going to be necessary, so that you donâ€™t have companies facing different regulatory authorities with different standards and requests and approaches, so that the hard questions can be more effectively addressed through bringing together the best minds, wherever they are.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Weiss</strong>: Iâ€™ve never seen this before, either. Our C.D.C. permit to receive the virus, which is classified as a biosafety Level 3 agent, was approved in less than two days. We received at least two material-transfer agreements, which have to be signed by a number of institutional officials and sometimes lawyers, in a matter of hours. Both of those processes have taken much longer, sometimes weeks, in the past. This is just one sign of administrators and scientists collaborating with each other and acting extra efficiently to facilitate the science.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Barouch</strong>: Iâ€™ll just echo that. From a research perspective, I have never seen such collaborative spirit, such open sharing of materials, data, protocols, thoughts and ideas among academic groups, industry groups, government groups and the clinicians on the front lines.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph"><strong>Yancopoulos</strong>: Iâ€™ve seen unprecedented collaboration from all forces. I can get on the phone and call my counterpart, Mikael Dolsten, at Pfizer, and his first question is, â€œWell, what can we do to help?â€ Whether itâ€™s scientists in academia, whether itâ€™s people at biotech and pharma companies, whether itâ€™s the doctors and health care workers who are at the epicenter at hospitals like Mount Sinai or Columbia in New York City, whether itâ€™s the F.D.A. â€” we are all coming together, and things are happening at unprecedented rates because we realize that we have a common enemy.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    
    <h4 class="header"><a href="https://www.nytimes3xbfgragh.onion/interactive/2020/06/09/magazine/covid-vaccine.html">Developing a Covid-19 Vaccine</a><a href="https://www.nytimes3xbfgragh.onion/interactive/2020/06/09/magazine/remote-work-covid.html">What If Working From Home Goes on â€¦  Forever</a><a href="https://www.nytimes3xbfgragh.onion/interactive/2020/06/09/magazine/architecture-covid.html">The Pandemic and Architecture</a><a href="https://www.nytimes3xbfgragh.onion/interactive/2020/06/10/magazine/covid-data.html">Information Can Be the Best Medicine</a></h4>

    
    
    
    
    
    
    
    
    
    
    
    
  
    

    
    
    
    <hr class="rule--story">

    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph paragraph-detail">This discussion has been edited and condensed for clarity.</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
    

    <p class="paragraph paragraph-detail">Maria Toutoudaki/Getty Images (bottle); Jan Olofsson/EyeEm, via Getty Images (needle); Ilbusca/Getty Images (human figure); Guido Mieth/Getty Images (model); Hannah A. Bullock and Azaibi Tamin/C.D.C. (Covid-19).</p>

    
    
    
    
    
    
    
    
    
    
    
    
    
  
</div>



<div class="rad-article-credits">
  
  
  <p></p>
</div>

  </div>
  <div class="topnav" data-slug="14mag-roundtable">
    <div class="topnav__wrapper">
        <div class="topnav__kicker">
            <a href="https://nytimes3xbfgragh.onion/magazine"><svg class="nyt-logo logo-svg" width="260" height="23" version="1.1" id="Layer_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px"
        viewBox="0 0 260 23" enable-background="new 0 0 260 23" xml:space="preserve">
   <g>
       <defs>
           <rect id="SVGID_1_" y="0.2" width="260" height="21.8"/>
       </defs>
       <clipPath id="SVGID_2_">
           <use xlink:href="#SVGID_1_"  overflow="visible"/>
       </clipPath>
       <path clip-path="url(#SVGID_2_)" class="mag-logo-path" d="M13,2.6c0-1.9-1.9-2.5-3.4-2.4v0.4c0.9,0.1,1.6,0.3,1.6,0.8
           c0,0.4-0.2,0.8-1,0.8c-0.7,0-2-0.4-3-0.7C6,1.1,4.7,0.7,3.8,0.7C2,0.7,0.6,1.9,0.6,3.5c0,1.4,0.9,2,1.4,2.2l0.2-0.3
           C1.9,5.2,1.7,5,1.7,4.5c0-0.4,0.4-1,1.2-1c0.5,0,0.9,0.1,1.5,0.2c0.6,0.1,1.2,0.3,2,0.5c1.2,0.4,2.3,0.7,3.3,0.8v2.6L8.4,8.7v0.3
           l1.3,1.1v3.7c-0.7,0.4-1.4,0.5-2.2,0.5C6.2,14.2,4.9,14,4,13l3.7-1.8V5.1L3,7.1c0.5-1,1.2-1.9,2.2-2.5L5,4.3c-2.6,0.7-5,3-5,6.1
           c0,3.6,3,6.2,6.6,6.2c3.9,0,6.2-2.8,6.2-5.9h-0.4c-0.6,1.1-1.3,2.2-2.3,2.7v-3.5l1.4-1.1V8.7l-1.4-1.1V4.9C11.5,5.1,13,4.3,13,2.6
            M4.9,12.2l-1.2,0.6c-0.7-0.8-1-2-1-3.4c0-0.6,0-1.2,0.2-1.6L5,6.8L4.9,12.2z M23.3,7.4L22.5,8l-2.4-2l-2.6,1.9V0.7h-0.4l-3.4,2.4
           v0.3c0.5,0.2,1,0.3,1,1.1V14l-1.4,0.9l0.3,0.4l0.8-0.5l2.2,1.9l2.6-1.8l-0.3-0.4L18.3,15l-0.8-0.8v-6l0.9-0.6L19.9,9v5
           c0,3.3-0.9,4-2.3,4.5V19c2.7,0.1,5-0.9,5-5.2V8.3l0.9-0.7L23.3,7.4z M32,12.9l-2.3,1.8L27.2,13v-0.9l4.5-2.8V9.2L29.6,6l-5,2.6v5.6
           l-1,0.7l0.3,0.4l1-0.7l3.1,2.3l4.3-3.5L32,12.9z M27.2,11.6V7.7l0.4-0.1l1.8,2.6L27.2,11.6z M49.7,1.9c0-0.3-0.1-0.7-0.2-1h-0.3
           c-0.3,0.8-0.6,1.1-1.3,1.1c-0.8,0-1.2-0.5-1.6-0.9h-0.4l-2.6,3l0.3,0.3l0.8-0.9c0.3,0.2,0.5,0.4,0.9,0.6c0.3,0.2,0.8,0.3,1.2,0.3
           v6.9l-5.2-8.7c-0.4-0.6-1-1.7-2.4-1.7c-1.6,0-2.8,1.2-2.6,3.3l0.4,0.1c0.1-0.6,0.4-1.1,0.9-1.1c0.5,0,0.8,0.3,1,0.7v2.8
           c-1.6,0-2.6,0.9-2.6,2.2c0,0.7,0.4,1.8,1.5,2l0.1-0.3c-0.2-0.2-0.3-0.3-0.3-0.5c0-0.4,0.5-0.7,1-0.7h0.3v3.5c-1.8,0-3.2,1-3.2,2.8
           c0,1.8,1.5,2.7,3.1,2.6l0.1-0.4c-1-0.1-1.4-0.6-1.4-1.1c0-0.7,0.5-1,1.1-1c0.7,0,1.2,0.4,1.7,0.9l2.7-3l-0.3-0.3l-0.7,0.8
           c-0.8-0.7-1.6-1.2-2.6-1.3V4.5l7.2,12.2h0.8V4.4C48.4,4.5,49.7,3.6,49.7,1.9 M56.4,12.9l-2.3,1.8L51.6,13v-0.9l4.5-2.8V9.2L54,6
           l-5,2.6v5.6l-1,0.7l0.3,0.4l1-0.7l3.1,2.3l4.3-3.5L56.4,12.9z M51.6,11.6V7.7L52,7.6l1.8,2.6L51.6,11.6z M71.9,7.1l-0.8,0.5L69.2,6
           l-2,1.8l0.9,0.8v6.2L67.7,15l-1.9-1.1V8.5l0.9-0.6L64.5,6l-2.2,1.8l0.9,0.8v6.2l-0.3,0.1l-2-1.4V8.6c0-1.2-0.6-1.6-1.3-2.1
           c-0.7-0.4-0.9-0.8-0.9-1.4c0-0.7,0.7-0.9,0.9-0.9l-0.1-0.4c-1,0-2.7,0.9-2.7,2.5c0,0.9,0.4,1.2,0.9,1.7c0.5,0.4,0.9,0.9,0.9,1.6
           v4.8l-1,0.8l0.3,0.4l0.9-0.6l2.6,2l2.3-1.5l2.5,1.5L71,14V8.3l1.2-0.9L71.9,7.1z M88.8,2.5l-0.8,0.6l-2.2-1.9l-2.9,2.4V1.4h-0.5
           v14.2c-0.3,0-0.8-0.2-1.4-0.3V3.4c0-0.9-0.7-2.1-2.3-2.1c-1.8,0-2.9,1.4-2.9,2.6h0.5c0.1-0.6,0.5-1,0.9-1c0.6,0,0.9,0.3,0.9,1.5
           v3.3c-1.5,0.1-2.6,1-2.6,2.3c0,0.9,0.4,1.7,1.4,1.9l0.1-0.4c-0.4-0.2-0.5-0.4-0.5-0.6c0-0.5,0.5-0.7,1.1-0.7H78v5.4
           c-1.3,0.5-1.9,1.4-1.9,2.6c0,1.5,1.2,2.6,3,2.6c1.2,0,2.3-0.2,3.4-0.5c0.9-0.2,2.3-0.4,2.8-0.4c0.7,0,1,0.3,1,0.8
           c0,0.6-0.3,0.8-0.7,0.9l0.1,0.4c1.5-0.3,2.4-1.2,2.4-2.6s-1.3-2.1-2.8-2.1c-0.8,0-2.5,0.2-3.6,0.5c-1.2,0.3-2.5,0.4-2.8,0.4
           c-0.7,0-1.4-0.4-1.4-1.2c0-0.8,0.8-1.4,2.3-1.4c0.9,0,1.7,0.2,2.7,0.4c1,0.2,1.9,0.5,2.9,0.5c1.3,0,2.6-0.5,2.6-2.4V3.6l0.9-0.8
           L88.8,2.5z M85.1,7.5C84.8,7.8,84.5,8,84,8c-0.6,0-0.9-0.2-1.1-0.5V4l0.9-0.7l1.3,1V7.5z M85.1,10.2C84.8,10,84.6,9.8,84,9.8
           c-0.6,0-0.9,0.2-1.1,0.4V8.1C83,8.3,83.4,8.5,84,8.5c0.5,0,0.9-0.2,1.1-0.4V10.2z M85.1,14c0,0.8-0.5,1.6-1.4,1.6
           c-0.2,0-0.7,0-0.9-0.1v-4.9c0.2-0.2,0.6-0.4,1.1-0.4c0.5,0,0.9,0.2,1.1,0.4V14z M97.7,8.2l-3-2.3L90,8.6v5.5l-1,0.7l0.3,0.4
           l0.9-0.6l2.9,2.1l4.6-2.8V8.2z M92.7,13.5v-6l2.4,1.6v6L92.7,13.5z M106.5,6c-0.3,0.3-0.5,0.5-0.9,0.5c-0.4,0-0.9-0.2-1-0.5h-0.2
           l-1.5,1.7L101.3,6l-2.8,2l0.3,0.4l0.8-0.5l0.8,0.8V14l-1.4,0.9l0.3,0.4l0.8-0.5l2.3,1.9l3.1-2.1l-0.3-0.4l-0.9,0.6l-1.1-0.9V8
           c0.7,0.7,1.3,0.9,1.9,0.9c1.2,0,1.9-1.5,2-2.9L106.5,6z M117.8,14.3l-0.9,0.6l-4.1-6.1l0.2-0.4c0.4,0.3,0.9,0.7,1.9,0.7
           c1.1,0,2.2-1.2,2.4-3h-0.4c-0.4,0.5-0.7,0.8-1.3,0.8c-0.4,0-1-0.3-1.4-0.8H114l-3.1,4.8l4.1,6l3.2-2.1L117.8,14.3z M112,14.6
           l-0.7,0.5l-0.8-0.8V0.7h-0.4l-3.4,2.4v0.3c0.5,0.2,1,0.3,1,1.1V14l-1.4,0.9l0.3,0.4l0.8-0.5l2.2,1.9l2.6-1.8L112,14.6z M133.8,2.6
           c0-1.9-1.9-2.5-3.4-2.4v0.4c0.9,0.1,1.6,0.3,1.6,0.8c0,0.4-0.2,0.8-1,0.8c-0.7,0-2-0.4-3-0.7c-1.1-0.4-2.4-0.8-3.3-0.8
           c-1.8,0-3.2,1.1-3.2,2.7c0,1.4,0.9,2,1.4,2.2l0.2-0.3c-0.3-0.2-0.5-0.4-0.5-0.9c0-0.4,0.4-1,1.2-1c0.5,0,0.9,0.1,1.5,0.2
           c0.6,0.1,1.2,0.3,2,0.5c1.2,0.4,2.3,0.7,3.3,0.8v2.6l-1.3,1.1v0.3l1.3,1.1v3.7c-0.7,0.4-1.4,0.5-2.2,0.5c-1.3,0-2.6-0.3-3.6-1.2
           l3.7-1.8V5.1l-4.6,2c0.5-1,1.2-1.9,2.2-2.5l-0.2-0.3c-2.6,0.7-5,3-5,6.1c0,3.6,3,6.2,6.6,6.2c3.9,0,6.2-2.8,6.2-5.9h-0.4
           c-0.6,1.1-1.3,2.2-2.3,2.7v-3.5l1.4-1.1V8.7l-1.4-1.1V4.9C132.4,5.1,133.8,4.3,133.8,2.6 M125.7,12.2l-1.2,0.6c-0.7-0.8-1-2-1-3.4
           c0-0.6,0-1.2,0.2-1.6l2.2-0.9L125.7,12.2z M137.1,1.5H137l-1.9,1.7v0.2l1.7,1.8h0.2l1.9-1.7V3.3L137.1,1.5z M140.1,14.3l-0.9,0.6
           l-0.7-0.7V7.9L136.9,6L134,7.9l0.3,0.4l0.8-0.5l0.7,0.9v5.5l-1.3,0.9l0.3,0.4l0.7-0.5l2,1.8l3-2.1L140.1,14.3z M155.9,14.3
           l-0.8,0.6l-0.8-0.8V8.6l0.9-0.7L155,7.5l-0.9,0.6l-2.3-2L149.2,8l-2.2-1.9l-2.7,1.8l-1.6-1.8l-2.9,2l0.3,0.4l0.8-0.5l0.8,0.9v5.5
           l-0.8,0.7l2.4,1.9l2-1.8l-0.9-0.8V8.5l0.9-0.5l1.4,1.3v5.2l-0.8,0.7l2.1,1.8l2.2-1.8l-0.9-0.8V8.6l0.8-0.5l1.5,1.3v5.1l-0.7,0.7
           l2.1,1.9L156,15L155.9,14.3z M164,12.9l-2.3,1.8l-2.5-1.7v-0.9l4.5-2.8V9.2L161.6,6l-5,2.6v5.8l3.3,2.4l4.3-3.5L164,12.9z
            M159.3,11.6V7.7l0.4-0.1l1.8,2.6L159.3,11.6z M172.5,11.3l-1.9-1.4c1.1-1,1.7-2.5,1.7-3.3V6H172c-0.2,0.5-0.6,0.9-1.2,0.9
           c-0.7,0-1.1-0.4-1.5-0.9L165,8.5v3l1.6,1.3c-1.5,1.3-2,2.1-2,3c0,0.9,0.6,1.6,1.3,1.9l0.2-0.3c-0.2-0.2-0.4-0.3-0.4-0.6
           c0-0.3,0.3-0.8,0.9-0.8c0.9,0,1.4,0.6,1.7,0.9l4.1-2.5V11.3z M171.1,8.6c-0.6,1-2,2-2.6,2.4l-0.9-0.9V7.2c0.4,1,1.2,1.7,2.4,1.7
           C170.3,8.9,170.8,8.8,171.1,8.6 M169.8,15.5c-0.5-1.1-1.4-1.8-2.6-1.8c-0.4,0-0.9,0.2-1.4,0.5c0.4-0.7,1.7-1.8,2.8-2.5l1.1,0.9
           L169.8,15.5z M183.1,0.8c-0.3,0.3-0.6,0.6-1,0.6c-0.5,0-0.9-0.1-1.2-0.2c-0.6-0.2-1.1-0.4-1.6-0.4c-0.8,0-2.2,0.5-2.9,2.6l0.4,0.2
           c0.2-0.4,0.5-0.9,1.2-0.9c0.4,0,0.9,0.1,1.2,0.2c0.3,0.1,0.9,0.2,1.2,0.2c1.2,0,2.4-1.3,3.1-2.1L183.1,0.8z M197.2,14.1l-0.8,0.6
           l-1-0.9V4.1l1.1-0.9L196.3,3l-0.9,0.6l-2.8-2.5l-2.3,1.4V1.3h-0.5v1.4l-1.2,0.8l-2.9-2.4l-4.1,2.6C180.8,4.2,179,5.5,179,7v0.2
           c-1.6,0.1-2.5,0.9-2.5,2.3c0,0.6,0.2,0.9,0.3,1.2h0.4v-0.2c0-0.6,0.3-1,1.2-1h0.7V11c0,1-0.1,1.8-1,2l0.1,0.4
           c2.5-0.4,3.6-1.2,3.6-3.1V5.4c0-0.9,0.6-1.5,1.2-2.1v7.8c0,2-0.9,2.5-1.8,2.6c-0.9,0.2-1.7,0.1-2.6,0.5c-0.8,0.3-1.5,0.9-1.5,2.2
           c0,1.7,1.2,2.4,2.5,2.4v-0.5c-0.6,0-1.1-0.2-1.1-0.8c0-0.5,0.3-0.8,1-0.9c0.6-0.1,1.2-0.1,1.9-0.3c0.9-0.2,2.2-1.1,2.2-2.7v-3
           c0.2-0.2,0.6-0.4,1.1-0.4c0.5,0,0.9,0.2,1.1,0.4V14l-1.3,0.9l0.2,0.3l0.7-0.5l2.4,2l3.5-2.6l-0.3-0.3l-0.6,0.4v-3.6
           c0.2-0.2,0.6-0.4,1.1-0.4c0.5,0,0.9,0.2,1.1,0.4v3.3l-1.2,0.9l0.2,0.3l0.7-0.5l2.3,2l3-2.5L197.2,14.1z M192.5,7.5
           c-0.3,0.3-0.7,0.4-1.1,0.4c-0.6,0-0.9-0.2-1.1-0.4V3.2l2.2,1.8L192.5,7.5L192.5,7.5z M192.5,10.2c-0.3-0.2-0.6-0.4-1.1-0.4
           c-0.6,0-0.9,0.2-1.1,0.4V8.1c0.2,0.2,0.6,0.4,1.1,0.4c0.5,0,0.9-0.2,1.1-0.4V10.2z M189.7,14.5l-1.2-0.9V3.9l1.2-0.8V14.5z
            M185.7,7.5c-0.3,0.3-0.7,0.4-1.1,0.4c-0.6,0-0.9-0.2-1.1-0.4V3.3l2.3,1.6V7.5z M185.7,10.2c-0.3-0.2-0.6-0.4-1.1-0.4
           c-0.6,0-0.9,0.2-1.1,0.4V8.1c0.2,0.2,0.6,0.4,1.1,0.4c0.5,0,0.9-0.2,1.1-0.4V10.2z M207.2,14.4l-0.9,0.6l-1-1V8.6l1-0.7l-0.2-0.4
           l-0.9,0.6l-3.1-2l-2.3,1.2c-0.8,0.4-1.3,0.9-1.3,1.8s0.9,1.4,1.8,1.9c-1.2,0.7-2.5,1.6-2.5,3c0,1.7,1.6,2.6,2.8,2.8l2.2-1.6
           l1.6,1.6l2.9-2L207.2,14.4z M202.8,11.2c-1.5-0.4-3.7-1-3.7-2.3c0-0.8,0.6-1.1,1-1.3l2.6,1.6V11.2z M202.8,14.9
           c-0.1,0-0.4,0.1-0.6,0.1c-1,0-1.9-1.2-1.9-2.6c0-0.5,0.1-0.9,0.4-1.3c0.7,0.3,1.7,0.6,2.1,0.7V14.9z M216.3,7.4L215.5,8l-2.8-2.1
           L208,8.6v6l3,2.1l2-1.4c0,1,0.7,1.7,0.7,2.3c0,0.4-0.4,0.8-0.8,0.9c-0.7-0.6-1.5-1.1-2.7-1.1c-1.6,0-2.6,1-3.2,2.3l0.3,0.2
           c0.5-0.3,0.8-0.6,1.3-0.6c0.8,0,1.6,0.4,2.4,1.2c0,0,1.7-1.2,2.8-2c0.6-0.4,1.2-0.8,1.7-1c0.4-0.3,0.8-0.7,0.8-1.1
           c0-0.4-0.1-0.8-0.3-1c-0.1-0.4-0.3-0.8-0.3-1.6V8.4l1-0.7L216.3,7.4z M210.5,13.3V7.4l2.4,1.6v5.8L210.5,13.3z M226.3,14.4
           l-0.9,0.6l-1-1V8.6l1-0.7l-0.2-0.4l-0.9,0.6l-3.1-2L219,7.3c-0.8,0.4-1.3,0.9-1.3,1.8s0.9,1.4,1.8,1.9c-1.2,0.7-2.5,1.6-2.5,3
           c0,1.7,1.6,2.6,2.8,2.8l2.2-1.6l1.6,1.6l2.9-2L226.3,14.4z M221.8,11.2c-1.5-0.4-3.7-1-3.7-2.3c0-0.8,0.6-1.1,1-1.3l2.6,1.6V11.2z
            M221.8,14.9c-0.1,0-0.4,0.1-0.6,0.1c-1,0-1.9-1.2-1.9-2.6c0-0.5,0.1-0.9,0.4-1.3c0.7,0.3,1.7,0.6,2.1,0.7V14.9z M234.6,13.7
           l-0.6,0.7c-0.9-0.5-2.3-0.8-2.9-0.8c-0.9,0-1.9,0.1-2.5,0.3h-0.1c0.4-0.6,1-1.2,1.4-1.7h2.2l1.7-2l-0.3-0.3l-0.6,0.6h-1.9
           c1.5-1.4,2.7-2.6,3.5-4.1l-0.2-0.3c-0.9,0.5-1.6,0.8-2.8,0.8c-1.2,0-2.6-0.5-3.2-0.8h-0.2l-1.6,3l0.4,0.2l0.5-0.8
           c0.6,0.3,1.6,0.6,2.6,0.6c0.6,0,1.4-0.1,2-0.3l-1.5,1.6h-2l-1.7,2l0.3,0.3l0.6-0.6h1.7c-1.6,1.7-2.6,2.8-3,4.4l0.2,0.2
           c0.8-0.7,1.8-0.9,3-0.9c1,0,2.4,0.5,3,0.8h0.1l2.2-2.7L234.6,13.7z M237.8,1.5h-0.2l-1.9,1.7v0.2l1.7,1.8h0.2l1.9-1.7V3.3
           L237.8,1.5z M240.6,14.3l-0.9,0.6l-0.7-0.7V7.9L237.4,6l-2.8,1.9l0.3,0.4l0.8-0.5l0.7,0.9v5.5l-1.3,0.9l0.3,0.4l0.7-0.5l2,1.8
           l3-2.1L240.6,14.3z M251.6,14.3l-0.8,0.6l-0.9-0.8V8.6l0.9-0.7l-0.3-0.4l-0.9,0.6l-2.3-2L245,7.9l-1.6-1.8l-2.9,2l0.3,0.4l0.8-0.5
           l0.8,0.9v5.5l-0.8,0.7l2.4,1.9l2-1.8l-0.9-0.8V8.5l0.9-0.5l1.5,1.3v5.1l-0.7,0.7l2.1,1.9l3.1-2.1L251.6,14.3z M259.8,12.9l-2.3,1.8
           l-2.5-1.7v-0.9l4.5-2.8V9.2L257.4,6l-5,2.6v5.8l3.3,2.4l4.3-3.5L259.8,12.9z M255.1,11.6V7.7l0.4-0.1l1.8,2.6L255.1,11.6z"/>
   </g>
   </svg>
   
</a>
            <span>The Tech & Design Issue</span>
        </div>
        <div class="topnav__contents">
             <ul>
               <li data-slug="14mag-roundtable">
                 <a class="rad-series-link" href="https://www.nytimes3xbfgragh.onion/interactive/2020/06/09/magazine/covid-vaccine.html">Developing a Covid-19 Vaccine
               </li>
               <li data-slug="14mag-remote">
                 <a class="rad-series-link" href="https://www.nytimes3xbfgragh.onion/interactive/2020/06/09/magazine/remote-work-covid.html">What If Working From Home Goes on â€¦ Forever
                 </a>
               </li>
               <li data-slug="14mag-architecture">
                 <a class="rad-series-link" href="https://www.nytimes3xbfgragh.onion/interactive/2020/06/09/magazine/architecture-covid.html">The Pandemic and Architecture
                 </a>
               </li>
               <li data-slug="14mag-epidemiology">
                 <a class="rad-series-link" href="https://www.nytimes3xbfgragh.onion/interactive/2020/06/10/magazine/covid-data.html">Information Can Be the Best Medicine
                 </a>
               </li>


             </ul>
        </div>
    </div>
    <a href="#" class="topnav__control topnav__control--prev">
    </a>
    <a href="#" class="topnav__control topnav__control--next">
    </a>
    <button class="toggler" type="button">
        <img src="https://static01.graylady3jvrrxbe.onion/newsgraphics/2020/06/04/2020-magtechdesign/a4fdae938d97ed501d80d0405d6760d098697e64/caret.svg" />
    </button>
</div>






<script>
  window.NYTG_ASSETS = 'https://static01.graylady3jvrrxbe.onion/newsgraphics/2020/06/04/2020-magtechdesign/a4fdae938d97ed501d80d0405d6760d098697e64/';
  window.NYTG_BIG_ASSETS = 'https://static01.graylady3jvrrxbe.onion/newsgraphics/2020/06/04/2020-magtechdesign/assets/';
  window.NYTG_RAD_CONFIG = {"download_slideshow_images":true,"stack":false,"mobile_square_crops":false,"mobile_vertical_crops":false,"assets_service":"publish","assets_environment":"production","ads":{"frequency":10,"indexes":"[]","beforeBlock":"[]"}}
 </script>

<script src="https://static01.graylady3jvrrxbe.onion/video-static/vhs3/vhs.min.js"></script>
<script id="nytg-rendered-js" src="https://static01.graylady3jvrrxbe.onion/newsgraphics/2020/06/04/2020-magtechdesign/a4fdae938d97ed501d80d0405d6760d098697e64/build.js"></script>

<!-- Pipeline: 2020-06-04-2020-magtechdesign | June 11, 2020, 11:02AM | a4fdae938d97ed501d80d0405d6760d098697e64 -->
</div></section></article></main><div id="standalone-footer"><div><div class=""><div id="interactive-footer-wrapper"><div class="css-i29ckm"><div class="css-1oeie6n"><button type="button" class="css-1dg16hf" aria-label="147 comments. Click to read and post comments." id="comments-speech-bubble-bottom">Read 147 Comments</button></div><div role="toolbar" aria-label="Social Media Share buttons, Save button, and Comments Panel with current comment count" class="interactive-sharetools css-9z2bwm" data-testid="share-tools"><ul class="css-y8aj3r"><li class="fb-share-item css-1iua6j5"><a href="https://www.facebookcorewwwi.onion/dialog/feed?app_id=9869919170&amp;link=https%3A%2F%2Fwww.nytimes3xbfgragh.onion%2Finteractive%2F2020%2F06%2F09%2Fmagazine%2Fcovid-vaccine.html%3Fsmid%3Dfb-share&amp;name=Can%20a%20Vaccine%20for%20Covid-19%20Be%20Developed%20in%20Record%20Time%3F&amp;redirect_uri=https%3A%2F%2Fwww.facebookcorewwwi.onion%2F" target="_blank" rel="noopener noreferrer" aria-label="Share on Facebook"><svg class="css-1acmxgr" viewBox="0 0 7 15" width="7" height="15"><path fill-rule="evenodd" clip-rule="evenodd" d="M4.775 14.163V7.08h1.923l.255-2.441H4.775l.004-1.222c0-.636.06-.977.958-.977H6.94V0H5.016c-2.31 0-3.123 1.184-3.123 3.175V4.64H.453v2.44h1.44v7.083h2.882z" fill="#000"></path></svg></a></li><li class="twitter-share-item css-1iua6j5"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.nytimes3xbfgragh.onion%2Finteractive%2F2020%2F06%2F09%2Fmagazine%2Fcovid-vaccine.html%3Fsmid%3Dtw-share&amp;text=Can%20a%20Vaccine%20for%20Covid-19%20Be%20Developed%20in%20Record%20Time%3F" target="_blank" rel="noopener noreferrer" aria-label="Share on Twitter"><svg viewBox="0 0 13 10" class="css-1acmxgr" width="13" height="10"><path fill-rule="evenodd" clip-rule="evenodd" d="M5.987 2.772l.025.425-.429-.052c-1.562-.2-2.927-.876-4.086-2.011L.93.571.784.987c-.309.927-.111 1.906.533 2.565.343.364.266.416-.327.2-.206-.07-.386-.122-.403-.096-.06.06.146.85.309 1.161.223.434.678.858 1.176 1.11l.42.199-.497.009c-.481 0-.498.008-.447.19.172.564.85 1.162 1.606 1.422l.532.182-.464.277a4.833 4.833 0 0 1-2.3.641c-.387.009-.704.044-.704.07 0 .086 1.047.572 1.657.762 1.828.564 4 .32 5.631-.641 1.159-.685 2.318-2.045 2.859-3.363.292-.702.583-1.984.583-2.6 0-.398.026-.45.507-.927.283-.277.55-.58.6-.667.087-.165.078-.165-.36-.018-.73.26-.832.226-.472-.164.266-.278.584-.78.584-.928 0-.026-.129.018-.275.096a4.79 4.79 0 0 1-.755.294l-.464.148-.42-.286C9.66.467 9.335.293 9.163.24 8.725.12 8.055.137 7.66.276c-1.074.39-1.752 1.395-1.674 2.496z" fill="#000"></path></svg></a></li><li class="email-share-item css-1iua6j5"><a href="mailto:?subject=nytimes3xbfgragh.onion%3A%20Can%20a%20Vaccine%20for%20Covid-19%20Be%20Developed%20in%20Record%20Time%3F&amp;body=From%20The%20New%20York%20Times%3A%0A%0ACan%20a%20Vaccine%20for%20Covid-19%20Be%20Developed%20in%20Record%20Time%3F%0A%0AA%20discussion%20moderated%20by%20Siddhartha%20Mukherjee.%0A%0Ahttps%3A%2F%2Fwww.nytimes3xbfgragh.onion%2Finteractive%2F2020%2F06%2F09%2Fmagazine%2Fcovid-vaccine.html%3Fsmid%3Dem-share" target="_blank" rel="noopener noreferrer" aria-label="Email"><svg viewBox="0 0 15 9" class="css-1acmxgr" width="15" height="9"><path fill-rule="evenodd" clip-rule="evenodd" d="M.906 8.418V0L5.64 4.76.906 8.419zm13 0L9.174 4.761 13.906 0v8.418zM7.407 6.539l-1.13-1.137L.907 9h13l-5.37-3.598-1.13 1.137zM1.297 0h12.22l-6.11 5.095L1.297 0z" fill="#000"></path></svg></a></li><li class="more-share-item css-1iua6j5"><div class="css-6n7j50"><button aria-haspopup="true" aria-expanded="false" aria-label="More sharing options ..." class="css-16ogagc" data-testid="" type="button"><svg class="css-107sgp6" viewBox="0 0 16 13" width="16" height="13"><path fill-rule="evenodd" clip-rule="evenodd" d="M15.406 5.359L8.978 0v3.215C3.82 3.215.406 8.107.406 12.66 1.653 9.133 4.29 7.517 8.978 7.517v3.2l6.428-5.358z" fill="#000"></path></svg></button></div></li></ul></div></div><div></div><div id="bottom-wrapper" class="css-1ede5it"><div id="bottom-slug" class="css-l9onyx"><p>Advertisement</p></div><a href="#after-bottom" style="position:absolute;width:1px;height:1px;margin:-1px;padding:0;border:0;clip:rect(0 0 0 0);overflow:hidden">Continue reading the main story</a><div class="ad bottom-wrapper" id="bottom" style="text-align:center;height:100%;display:block;min-height:90px"></div><div id="after-bottom"></div></div><nav class="css-kdur8l" id="site-index" aria-labelledby="site-index-label" data-testid="site-index"><h2 class="css-1dv1kvn" id="site-index-label">Site Index</h2><div></div></nav><footer class="css-1e1s8k7" role="contentinfo"><nav data-testid="footer" class="css-15uy5yv"><h2 class="css-1dv1kvn">Site Information Navigation</h2><ul class="css-1ho5u4o e5u916q0"><li data-testid="copyright"><a class="css-jq1cx6" href="https://help.nytimes3xbfgragh.onion/hc/en-us/articles/115014792127-Copyright-notice">Â©Â <span>2020</span>Â <span>The New York Times Company</span></a></li></ul><ul class="css-13o0c9t e5u916q1"><li class="css-1yo489b e5u916q2"><a data-testid="footer-link" class="css-jq1cx6" href="https://www.nytco.com/">NYTCo</a></li><li class="css-1yo489b e5u916q2"><a data-testid="footer-link" class="css-jq1cx6" href="https://help.nytimes3xbfgragh.onion/hc/en-us/articles/115015385887-Contact-Us">Contact Us</a></li><li class="css-1yo489b e5u916q2"><a data-testid="footer-link" class="css-jq1cx6" href="https://www.nytco.com/careers/">Work with us</a></li><li class="css-1yo489b e5u916q2"><a data-testid="footer-link" class="css-jq1cx6" href="https://nytmediakit.com/">Advertise</a></li><li class="css-1yo489b e5u916q2"><a data-testid="footer-link" class="css-jq1cx6" href="http://www.tbrandstudio.com/">T Brand Studio</a></li><li class="css-1yo489b e5u916q2"><a data-testid="footer-link" class="css-jq1cx6" href="https://www.nytimes3xbfgragh.onion/privacy/cookie-policy#how-do-i-manage-trackers">Your Ad Choices</a></li><li class="css-1yo489b e5u916q2"><a data-testid="footer-link" class="css-jq1cx6" href="https://www.nytimes3xbfgragh.onion/privacy">Privacy</a></li><li class="css-1yo489b e5u916q2"><a data-testid="footer-link" class="css-jq1cx6" href="https://help.nytimes3xbfgragh.onion/hc/en-us/articles/115014893428-Terms-of-service">Terms of Service</a></li><li class="css-1yo489b e5u916q2"><a data-testid="footer-link" class="css-jq1cx6" href="https://help.nytimes3xbfgragh.onion/hc/en-us/articles/115014893968-Terms-of-sale">Terms of Sale</a></li><li class="css-1yo489b e5u916q2"><a data-testid="footer-link" class="css-jq1cx6" href="https://spiderbites.nytimes3xbfgragh.onion">Site Map</a></li><li class="css-1yo489b e5u916q2"><a data-testid="footer-link" class="css-jq1cx6" href="https://help.nytimes3xbfgragh.onion/hc/en-us">Help</a></li><li class="css-1yo489b e5u916q2"><a data-testid="footer-link" class="css-jq1cx6" href="https://www.nytimes3xbfgragh.onion/subscription?campaignId=37WXW">Subscriptions</a></li></ul></nav></footer></div></div></div></div></div>
    <script>window.__preloadedData = {"config":{"gqlUrlClient":"https:\u002F\u002Fsamizdat-graphql.nytimes3xbfgragh.onion\u002Fgraphql\u002Fv2","gqlRequestHeaders":{"nyt-app-type":"project-vi","nyt-app-version":"0.0.5","nyt-token":"MIIBIjANBgkqhkiG9w0BAQEFAAOCAQ8AMIIBCgKCAQEAs+\u002FoUCTBmD\u002FcLdmcecrnBMHiU\u002FpxQCn2DDyaPKUOXxi4p0uUSZQzsuq1pJ1m5z1i0YGPd1U1OeGHAChWtqoxC7bFMCXcwnE1oyui9G1uobgpm1GdhtwkR7ta7akVTcsF8zxiXx7DNXIPd2nIJFH83rmkZueKrC4JVaNzjvD+Z03piLn5bHWU6+w+rA+kyJtGgZNTXKyPh6EC6o5N+rknNMG5+CdTq35p8f99WjFawSvYgP9V64kgckbTbtdJ6YhVP58TnuYgr12urtwnIqWP9KSJ1e5vmgf3tunMqWNm6+AnsqNj8mCLdCuc5cEB74CwUeQcP2HQQmbCddBy2y0mEwIDAQAB"},"gqlFetchTimeout":4000,"disablePersistedQueries":false,"initialDeviceType":"desktop","fastlyAbraConfig":{},"serviceWorkerFile":"service-worker-test-1599771634256.js"},"interactiveConfig":{"interactive":{"__typename":"Interactive","displayProperties":{"fullBleedDisplayStyle":"","__typename":"CreativeWorkDisplayProperties","displayForPromotionOnly":false,"maxWidth":1050,"minWidth":300,"template":"Standard","displayOverrides":["HIDE_TOP_BANNER_REGION","INCLUDE_TRANSPARENT_MASTHEAD_WITH_WHITE_ICONS"],"displayStyle":"minimal","theme":"standard"},"section":{"id":"U2VjdGlvbjpueXQ6Ly9zZWN0aW9uL2E5MTNkMWZiLTNjZGYtNTU2Yi05YTgxLWYwYjk5NmExYTIwMg==","name":"magazine","__typename":"Section","displayName":"Magazine","url":"https:\u002F\u002Fwww.nytimes3xbfgragh.onion\u002Fsection\u002Fmagazine","taxonomyID":"E57A148E-0CB9-4C02-966D-28B119710151","type":"section","uri":"nyt:\u002F\u002Fsection\u002Fa913d1fb-3cdf-556b-9a81-f0b996a1a202"},"subsection":null,"tone":"FEATURE","collections":[{"id":"TGVnYWN5Q29sbGVjdGlvbjpueXQ6Ly9sZWdhY3ljb2xsZWN0aW9uL2U2ZGRhNzZhLTlmMjMtNWVmNy05MzZmLTFkMmNjNjlmZjVmMA==","name":"The New York Times Magazine","collectionType":"SECTION","__typename":"LegacyCollection","slug":"magazine","url":"https:\u002F\u002Fwww.nytimes3xbfgragh.onion\u002Fsection\u002Fmagazine","uri":"nyt:\u002F\u002Flegacycollection\u002Fe6dda76a-9f23-5ef7-936f-1d2cc69ff5f0","tagline":""},{"id":"TGVnYWN5Q29sbGVjdGlvbjpueXQ6Ly9sZWdhY3ljb2xsZWN0aW9uLzQxZGYzYzA0LWI0ZjEtNWQ4Ni1hYTU1LWE3MDAwNDZiYmI4Ng==","name":"Health","collectionType":"SECTION","__typename":"LegacyCollection","slug":"health","url":"https:\u002F\u002Fwww.nytimes3xbfgragh.onion\u002Fsection\u002Fhealth","uri":"nyt:\u002F\u002Flegacycollection\u002F41df3c04-b4f1-5d86-aa55-a700046bbb86","tagline":""}],"url":"https:\u002F\u002Fwww.nytimes3xbfgragh.onion\u002Finteractive\u002F2020\u002F06\u002F09\u002Fmagazine\u002Fcovid-vaccine.html","sourceId":"100000007180386","dfpTaxonomyException":null,"advertisingProperties":{"sensitivity":"SHOW_ADS","__typename":"CreativeWorkAdvertisingProperties"},"adTargetingParams":[{"key":"als_test","value":"1599799778608","__typename":"AdTargetingParam"},{"key":"prop","value":"nyt","__typename":"AdTargetingParam"},{"key":"plat","value":"web","__typename":"AdTargetingParam"},{"key":"edn","value":"us","__typename":"AdTargetingParam"},{"key":"brandsensitive","value":"true","__typename":"AdTargetingParam"},{"key":"per","value":"","__typename":"AdTargetingParam"},{"key":"org","value":"","__typename":"AdTargetingParam"},{"key":"geo","value":"","__typename":"AdTargetingParam"},{"key":"des","value":"clinicaltrials,vaccinationandimmunization,coronavirus2019ncov,drugspharmaceuticals,coronavirusreopenings","__typename":"AdTargetingParam"},{"key":"spon","value":"","__typename":"AdTargetingParam"},{"key":"auth","value":"","__typename":"AdTargetingParam"},{"key":"col","value":"","__typename":"AdTargetingParam"},{"key":"coll","value":"thenewyorktimesmagazine,health","__typename":"AdTargetingParam"},{"key":"artlen","value":"short","__typename":"AdTargetingParam"},{"key":"ledemedsz","value":"none","__typename":"AdTargetingParam"},{"key":"gui","value":"","__typename":"AdTargetingParam"},{"key":"template","value":"interactive","__typename":"AdTargetingParam"},{"key":"typ","value":"int","__typename":"AdTargetingParam"},{"key":"section","value":"magazine","__typename":"AdTargetingParam"},{"key":"si_section","value":"magazine","__typename":"AdTargetingParam"},{"key":"id","value":"100000007180386","__typename":"AdTargetingParam"},{"key":"trend","value":"","__typename":"AdTargetingParam"},{"key":"pt","value":"nt13,nt17,nt19,nt20,nt5,nt7,pt15","__typename":"AdTargetingParam"},{"key":"gscat","value":"neg_citi_aa,neg_ibmtest,neg_capitalone,neg_chanel,neg_virus,gs_health,neg_bofa,neg_ibm,neg_fcli,gs_health_misc,gs_covid19,neg_mastercard,gs_science,neg_hearts,gs_science_misc,gv_safe,gs_t","__typename":"AdTargetingParam"},{"key":"tt","value":"","__typename":"AdTargetingParam"},{"key":"mt","value":"MT5","__typename":"AdTargetingParam"}],"headline":{"default":"Can a Vaccine for Covid-19 Be Developed in Record Time?","seo":"","__typename":"CreativeWorkHeadline"},"summary":"A discussion moderated by Siddhartha Mukherjee.","shortUrl":"https:\u002F\u002Fnyti.ms\u002F3f8BOqm","commentStatus":undefined,"commentProperties":{"status":"ACCEPT_AND_DISPLAY_COMMENTS","__typename":"CreativeWorkCommentProperties","prompt":"","approvedCommentsCount":147},"uri":"nyt:\u002F\u002Finteractive\u002F51d8474a-dd75-5fe6-b848-ee8b8dbe0393","associatedAssets":[],"storylines":[]}},"statusCode":200,"externalAssets":undefined};</script>
    <script>!function(e){function t(t){for(var r,i,c=t[0],d=t[1],u=t[2],f=0,l=[];f<c.length;f++)i=c[f],Object.prototype.hasOwnProperty.call(n,i)&&n[i]&&l.push(n[i][0]),n[i]=0;for(r in d)Object.prototype.hasOwnProperty.call(d,r)&&(e[r]=d[r]);for(s&&s(t);l.length;)l.shift()();return a.push.apply(a,u||[]),o()}function o(){for(var e,t=0;t<a.length;t++){for(var o=a[t],r=!0,c=1;c<o.length;c++){var d=o[c];0!==n[d]&&(r=!1)}r&&(a.splice(t--,1),e=i(i.s=o[0]))}return e}var r={},n={55:0},a=[];function i(t){if(r[t])return r[t].exports;var o=r[t]={i:t,l:!1,exports:{}};return e[t].call(o.exports,o,o.exports,i),o.l=!0,o.exports}i.e=function(e){var t=[],o=n[e];if(0!==o)if(o)t.push(o[2]);else{var r=new Promise((function(t,r){o=n[e]=[t,r]}));t.push(o[2]=r);var a,c=document.createElement("script");c.charset="utf-8",c.timeout=120,i.nc&&c.setAttribute("nonce",i.nc),c.src=function(e){return i.p+""+({0:"vendor",1:"vendors~audio~byline~capsule~cityguides~collections~home~liveblog~paidpost~regionCapsule~slideshow~s~77b336c9",3:"vendors~audio~capsule~cityguides~collections~home~liveblog~paidpost~regionCapsule~story~trending~video",4:"vendors~audio~capsule~cityguides~collections~home~liveblog~paidpost~regionCapsule~story~video",7:"embeddedGetStarted~getstarted~postLoginInterrupter",9:"embeddedGetStarted~getstarted",11:"recirculation~weekender",12:"vendors~commentsForm~weddings",18:"audioblock",26:"comments",27:"commentsForm",28:"desktopNav",29:"embeddedGetStarted",42:"phone-number-input",43:"postLoginInterrupter",48:"recirculation",51:"regionCapsule",58:"siteIndexContent",66:"vendors~audioblock",70:"vendors~phone-number-input",73:"vendors~videoblock",75:"videoblock"}[e]||e)+"-"+{0:"f24a1d1913b6a0b603ea",1:"0fadd28c51b9fdd0b92e",3:"ee663b6aabbba19d8dce",4:"08c9f97f43c9a4cfbaf7",7:"9a39c098e5198719e054",9:"777a751d8f16b9a1eb41",11:"84a5471a9ff2eb28d811",12:"9260a8b280867368d477",18:"fe1345b840479e8e773b",26:"8485af7dc98a4eae78ed",27:"925905479613e4061ef1",28:"34dfcb1624a576f9f526",29:"068e2205118e19f1534c",42:"9cc10e165c7478eb5c4d",43:"83cc0b4caa859082a874",48:"8e05387ddff14f14121a",51:"79a2acf0ac2ff6d21721",58:"22d0f795eddecee45534",66:"2b7fbea35f180d4eb4c1",70:"046660e9f6b04af4c09d",73:"3a2c43868990ebb5bd0f",75:"5c0044ee95f872d1c12c"}[e]+".js"}(e);var d=new Error;a=function(t){c.onerror=c.onload=null,clearTimeout(u);var o=n[e];if(0!==o){if(o){var r=t&&("load"===t.type?"missing":t.type),a=t&&t.target&&t.target.src;d.message="Loading chunk "+e+" failed.\n("+r+": "+a+")",d.name="ChunkLoadError",d.type=r,d.request=a,o[1](d)}n[e]=void 0}};var u=setTimeout((function(){a({type:"timeout",target:c})}),12e4);c.onerror=c.onload=a,document.head.appendChild(c)}return Promise.all(t)},i.m=e,i.c=r,i.d=function(e,t,o){i.o(e,t)||Object.defineProperty(e,t,{enumerable:!0,get:o})},i.r=function(e){"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.t=function(e,t){if(1&t&&(e=i(e)),8&t)return e;if(4&t&&"object"==typeof e&&e&&e.__esModule)return e;var o=Object.create(null);if(i.r(o),Object.defineProperty(o,"default",{enumerable:!0,value:e}),2&t&&"string"!=typeof e)for(var r in e)i.d(o,r,function(t){return e[t]}.bind(null,r));return o},i.n=function(e){var t=e&&e.__esModule?function(){return e.default}:function(){return e};return i.d(t,"a",t),t},i.o=function(e,t){return Object.prototype.hasOwnProperty.call(e,t)},i.p="/vi-assets/static-assets/",i.oe=function(e){throw console.error(e),e};var c=window.webpackJsonp=window.webpackJsonp||[],d=c.push.bind(c);c.push=t,c=c.slice();for(var u=0;u<c.length;u++)t(c[u]);var s=d;o()}([]);
//# sourceMappingURL=runtime~interactive-0aa0620541dd2fb78731.js.map</script>
    <script defer src="/vi-assets/static-assets/vendor-interactive-c836fb942209e2dd66ac.js"></script>
    <script defer src="/vi-assets/static-assets/comments-8485af7dc98a4eae78ed.js"></script>
<script defer src="/vi-assets/static-assets/recirculation-8e05387ddff14f14121a.js"></script>
<script defer src="/vi-assets/static-assets/story-1882fbab23abd1022b8c.js"></script>
    <script defer src="/vi-assets/static-assets/interactive-31e8437f8adad73184e1.js"></script>
    
    <script>
(function(w, l) {
  w[l] = w[l] || [];
  w[l].push({
    'gtm.start': new Date().getTime(),
    event: 'gtm.js'
  });
})(window, 'dataLayer');
</script>
<script defer src="https://www.googletagmanager.com/gtm.js?id=GTM-P528B3&gtm_auth=tfAzqo1rYDLgYhmTnSjPqw&gtm_preview=env-130&gtm_cookies_win=x"></script>
<noscript>
<iframe src="https://www.googletagmanager.com/ns.html?id=GTM-P528B3&gtm_auth=tfAzqo1rYDLgYhmTnSjPqw&gtm_preview=env-130&gtm_cookies_win=x" height="0" width="0" style="display:none;visibility:hidden"></iframe>
</noscript>
    <script id="native-bridge">
  (function () {
    function isBridgeCommandAvailable(command, supportedBridgeCommands) {
  // The shape of root.navigator.native.bridgeCommands looks like this:
  // {
  //  "ping": {
  //      "enabled": true
  //   },
  //   "resize": {
  //      "enabled": true
  //    }
  // }
  try {
    var commandAvailable = supportedBridgeCommands[command];

    if (!!commandAvailable === false) {
      return false;
    }

    return !!commandAvailable.enabled;
  } catch (e) {
    // if something goes wrong, swallow error and assume unsupported
    return false;
  }
}
    window.NativeBridge = (function initNativeBridge(root) {
  var _root$navigator, _root$navigator$nativ;

  var checkAvailable = arguments.length > 1 && arguments[1] !== undefined ? arguments[1] : true;
  var featureDetectionDictionary = arguments.length > 2 ? arguments[2] : undefined;
  var NativeBridge = root && root.NativeBridge || {}; // default feature list

  var supportedBridgeCommands = featureDetectionDictionary || (root === null || root === void 0 ? void 0 : (_root$navigator = root.navigator) === null || _root$navigator === void 0 ? void 0 : (_root$navigator$nativ = _root$navigator["native"]) === null || _root$navigator$nativ === void 0 ? void 0 : _root$navigator$nativ.bridgeCommands);

  if (typeof root !== 'undefined') {
    root.NYTG = root.NYTG || {};
    root.NYTG.currentAsyncID = 0;
    root.NYTG.storedCallbacks = {}; // Private
    // Do not call this command, for internal use only.

    var dispatchNativeBridgeCommandAsync = function dispatchNativeBridgeCommandAsync(type, options) {
      var asyncID = root.NYTG.currentAsyncID;
      root.NYTG.currentAsyncID += 1;
      var promise = new Promise(function (fulfill, reject) {
        if (checkAvailable && !NativeBridge.isBridgeCommandAvailable(type, supportedBridgeCommands)) {
          throw new Error("[NativeBridge] command ".concat(type, " not supported"));
        }

        try {
          root.NYTG.storedCallbacks[asyncID] = function (result) {
            if (!result.success) {
              var error = new Error(result.error);
              error.details = result.error.details;
              return reject(error);
            }

            return fulfill(result);
          };
        } catch (error) {
          var newError = new Error("Something went wrong creating the callback with ID ".concat(asyncID, ". Error: ").concat(JSON.stringify(error)));
          reject(newError);
        }
      });

      try {
        root.NYTG.enqueue(JSON.stringify({
          id: asyncID,
          type: type,
          options: options,
          senderURI: root.asset.uri
        }));
      } catch (error) {
        // swallow enqueing error
        // eslint-disable-next-line no-console
        console.log("[NativeBridge]: Caught error while enqueing: ".concat(error));
      }

      return promise;
    };

    var checkIsInVariantAsync = function checkIsInVariantAsync(variant) {
      return new Promise(function (fulfill, reject) {
        try {
          var _root$navigator2, _root$navigator2$nati;

          var variantsAvailable = root === null || root === void 0 ? void 0 : (_root$navigator2 = root.navigator) === null || _root$navigator2 === void 0 ? void 0 : (_root$navigator2$nati = _root$navigator2["native"]) === null || _root$navigator2$nati === void 0 ? void 0 : _root$navigator2$nati.activeABTestVariants;

          if (variantsAvailable === undefined) {
            return reject(new Error('root.navigator.native.activeABTestVariants is undefined'));
          }

          if (Array.isArray(variantsAvailable)) {
            return fulfill(variantsAvailable.indexOf(variant) > -1);
          }

          return reject(new Error('Variant Array is not an array'));
        } catch (error) {
          var newError = new Error("Something went wrong checking if user is in variant. Error: ".concat(JSON.stringify(error)));
          return reject(newError);
        }
      });
    }; // Do not call this command, for internal use only.
    // Note â€” if NYTG.onCommandResult is already set, don't overwrite it
    // This is to preserve backwards compatibility w/ interactives that use the AR interface


    if (!root.NYTG.onCommandResult) {
      root.NYTG.onCommandResult = function (result) {
        var callback = root.NYTG.storedCallbacks[result.id];

        if (!callback) {
          // eslint-disable-next-line no-console
          console.log("Callback with ID ".concat(result.id, " not found."));
          return;
        }

        callback(result);
        delete root.NYTG.storedCallbacks[result.id];
      };
    } // Public
    // Hybrid Config


    NativeBridge.isBridgeCommandAvailable = function (type) {
      return isBridgeCommandAvailable(type, supportedBridgeCommands);
    };

    NativeBridge.hybridConfig = function () {
      return new Promise(function (fulfill, reject) {
        document.addEventListener('DOMContentLoaded', function () {
          if (typeof root.config !== 'undefined') {
            fulfill(root.config);
          } else {
            var error = new Error('No root config found.');
            reject(error);
          }
        });
      });
    }; // Programming Commands.
    // NB could be extended to be "global" if we want! Most of these
    // loosely map to existing hybridConfig values.

    /**
     * Returns the read/unread status for a series of assets, by URI.
     * @param   {Array<string>} uris
     * @returns {Promise<Object<String,Boolean>>}
     */


    NativeBridge.getReadStatusForAssets = function (uris) {
      return dispatchNativeBridgeCommandAsync('getReadStatusForAssets', {
        uris: uris
      });
    }; // Interactive Commands
    // Note: Ping is defined for both Articles and Interactives


    NativeBridge.ping = function () {
      return dispatchNativeBridgeCommandAsync('ping');
    };

    NativeBridge.resize = function (height) {
      return dispatchNativeBridgeCommandAsync('resize', {
        height: height
      });
    }; // Generic command for easier debugging


    NativeBridge.sendCommand = function () {
      return dispatchNativeBridgeCommandAsync.apply(void 0, arguments);
    };

    NativeBridge.share = function (_ref) {
      var url = _ref.url,
          text = _ref.text,
          title = _ref.title;
      return dispatchNativeBridgeCommandAsync('share', {
        url: url,
        text: text,
        title: title
      });
    };

    NativeBridge.getAutoPlay = function () {
      return dispatchNativeBridgeCommandAsync('getAutoPlay');
    };

    NativeBridge.setPullToRefreshEnabled = function (value) {
      return dispatchNativeBridgeCommandAsync('setPullToRefreshEnabled', {
        value: value
      });
    }; // Article Commands


    NativeBridge.sendAnalytic = function (eventName, options) {
      return dispatchNativeBridgeCommandAsync('sendAnalytic', {
        eventName: eventName,
        options: options || {}
      });
    };

    NativeBridge.followChannel = function (uri) {
      return dispatchNativeBridgeCommandAsync('followChannel', {
        uri: uri
      });
    };

    NativeBridge.unfollowChannel = function (uri) {
      return dispatchNativeBridgeCommandAsync('unfollowChannel', {
        uri: uri
      });
    };

    NativeBridge.isInVariant = function (variant) {
      return checkIsInVariantAsync(variant);
    };

    NativeBridge.getBlockData = function () {
      return dispatchNativeBridgeCommandAsync('getBlockData');
    };
  }

  return NativeBridge;
})(window, false)
  })()
</script>
    <!-- RELEASE 325664c040d31f0f280d1c32af7ee1264ac506d3 -->
  </body>
</html>